Description of Related Art The extracellular matrix (ECM) is the major component of connective tissue which provides structural integrity, and promotes cell migration and differentiation. As part of these functions, extracellular matrix molecules such as fibronectin, collagen, laminin, von Willebrand factor, thrombospondin, fibrinogen, and tenascin have been shown to support adhesion of cells in vitro. This adhesive interaction is critical for a number of biological processes including hemostasis, thrombosis, wound healing, tumor metastasis, immunity and inflammation.

Fibronectin (FN) is the prototype ECM molecule. The major cell attachment site in the fibronectin molecule has been reproduced synthetically with the amino acid sequence arginine-glycine-aspartic acid, or RGD using single letter nomenclature. Peptides containing the RGD sequence which either inhibit or promote cell adhesion have been described (US Patent Nos. 4,589,881; 4,661,111; 4,683,291; 4,578,079; and 4,792,525). Changes in the peptide

as small as the exchange of alanine for glycine or glu. amic acid for aspartic acid, which constitute the addition of a single methyl or methylene group to the tripeptide, eliminates these activities (Pierschbacher et al., Proc. Natl. Acad. Sci. <BR> <BR> <BR> <BR> <P> USA 81: 5985 (1984)). Recently, a second FN cell binding domain has been identified within the alternatively spliced regicn of the A chain of the molecule, known as the connecting segment 1 (CS-1). The most active cell-binding site within this alternatively spliced region is composed of 25 amino acids where the carboxy terminus contains the sequence EILDVPST. The amino acid sequence EILDVPST forms a recognition motif on FN for cell surface receptors. (Wayner et al., J. Cell Biol.

109: 1321 (1989); Guan et al., Cell 60: 53 (1990)).

The receptors which recognize these sites on FN belor. g to a gene superfamily called integrins which consist of heterodimeric complexes of non-covalently associated alpha and <BR> <BR> <BR> beta subunits. A common ß subunit combines with unique a subunits to form an adhesion receptor of defined specificity.

To date, 8 ß subunits have been identified which can dimerize with 16 distinct a subunits forming 22 distinct integrins. The Pi subfamily, also known as the VLA family (Very Late Activation Antigens), binds to ECM molecules such as FN, collagen and laminin. For reviews, see, Hynes, Cell 48: 549 (1987); Hemler, Annu. Rev. Immunol. 8 : 365 (1990). Leukocyte interaction with FN at the two spatially separate binding domains is mediated by two distinct integrins. The RGD site is recognized by the <BR> <BR> <BR> integrin ai, while, EILDV is recognized by U-4PI (Pytela et al., Cell 40: 191 (1985); Wayner et al., J. Cell Biol. 109: 1321 (1989); Guan et al, Cell 60: 53 (1990)).

Vascular endothelial cells form the interface between blood and tissues and control the passage of leukocytes as well as plasma fluid into tissues. A variety of signals generated at the site of inflammation can activate both endothelial cells

as well as circulating leukocytes so that they become more adhesive to one another. Following this initial adhesion the leukocytes migrate into the tissues to perform host defense functions. Several adhesion molecules have been identified which are involved in leukocyte-endothelial interactions.

In the pi subfamily, in addition to binding to fibronectin, 041 interacts with a cytokine inducible protein on endothelial cells termed vascular cell adhesion molecule (VCAM). Further <BR> <BR> <BR> <BR> involved in the leukocyte-endothelial adhesion process is the ß2<BR> <BR> <BR> <BR> <BR> integrin subfamily. ß2 integrins include CDlla/CD18,<BR> <BR> <BR> <BR> <BR> CDllb/CD18, and CDllc/CD18. In addition, the ß7 subunit associates with a4 to form a unique a4P7 heterodimer which binds to FN, to VCAM, and to Mucosal Addressin Cell Adhesion Molecule-1 (MAdCAM) (Ruegg et al, J. Cell. Biol. 117: 179 (1992); <BR> <BR> <BR> Andrew et al., J. Immunol. 153: 3847 (1994); Briskin et al.,<BR> <BR> <BR> <BR> Nature 363: 461 (1993); Shyjan et al, J. Immunol. 156: 2851 (1996)). a4 integrins are widely expressed on different cell types including hematopoietic progenitors, lymphocytes, natural killer cells, monocytes, eosinophils, basophils, and mast cells (Helmer, M. E., Annu. Rev. Immunol. 8: 365 (1990)). Other molecules on endothelial cells which bind to the leukocytes include ICAM-1, ICAM-2, E-selectin and P-selectin (Carlos and Harlan, Immunol. Rev. 114: 1 (1990); Osborn, L., Cell 62: 3 (1990); Springer T., Nature 346: 425 (1990); Geng et al., Nature 347: 757 (1990); Stoolman, Cell 56 : 907 (1989)).

A number of in vitro and in vivo studies indicate that oPi plays a critical role in the pathogenesis of a variety of diseases. Monoclonal antibodies directed against a4 have been tested in a variety of disease models. Anti-α4 antibodies block adhesion of lymphocytes to synovial endothelial cells; this adhesion plays a potential role in rheumatoid arthritis (van <BR> <BR> <BR> Dinther-Janssen et al, J. Immunol. 147: 4207 (1991)). a4 has

also been implicated with respect to rheumatoid arthritis in separate studies (Laffon et al, J. Clin. Invest. 88: 546 (1991); <BR> <BR> <BR> <BR> Morales-Ducret et al, J. Immunol. 149: 1424 (1992)). A significant number of studies have evaluated the role of a4 in allergy and asthma. For example, monoclonal antibodies to a4 block adhesion of basophils and eosinophils to cytokine <BR> <BR> <BR> <BR> activated endothelial cells (Walsh et al, J. Immunol. 146: 3419 (1991); Bochner et al, J. Exp. Med. 173: 1553 (1991)).

Monoclonal antibodies to a4 were also effective in several lung antigen challenge models (Abraham et al, J. Clin. Invest. <BR> <BR> <BR> <BR> <P>93: 776 (1994); Weg et al, J. Exp. Med. 177: 561 (1993)). The cotton-top tamarin, which experiences spontaneous chronic colitis, showed a significant attenuation of their colitis when <BR> <BR> <BR> <BR> anti- antibody was administered (Podolsky et al, J. Clin.<BR> <BR> <BR> <BR> <BR> <BR> <P>Invest. 92: 372 (1993); Bell et al, J. Immunol. 151: 4790 (1993)). In a rat and mouse model, autoimmune encephalomyelitis was blocked by anti-a4 antibody (Yednock et al, Nature 356: 63 (1992); Baron et al, J. Exp. Med. 177: 57 (1993)). Anti- monoclonal antibodies also inhibit insulitis and delay the onset of diabetes in the non-obese diabetic mouse (Baron et al, J. Clin. Invest. 93: 1700 (1994); Yang et al, Proc. Natl. Acad. Sci. USA 90: 10494 (1993); Burkly et al, Diabetes 43: 529 (1994)). a4 is also implicated in atherosclerosis due to its endothelial expression during atherogenesis (Cybulsky et al, Science 251: 788 (1991)). The migration of leukocytes to an inflammatory site can also be blocked by anti-a4 antibodies. In addition to the blocking of migration, inhibitors of leukocyte endothelial adhesion may block the costimulatory signals mediated by integrins and thus inhibit overproduction of inflammatory cytokines. In a separate set of experiments not using anti-a4 antibodies, the peptides GRDGSP or EILDV were tested against contact

hypersensitivity response. The contact hypersensitivity response was found to be blocked by GRDGSP or EILDV suggesting that both a9 (31 and CC5P, are involved in this inflammatory response.

Other ailments which may involve a4ßl-mediated conditions include the inflammatory disorders rheumatoid arthritis, allergic disorders, asthma, spontaneous chronic colitis, insulitis, contact hypersensitivity response, atherosclerosis and autoimmune encephalomyelitis. These studies illustrate that small molecules that are potent inhibitors of a9 (31 mediated adhesion to either VCAM-1 or CS-1 may be used as a form of treatment in numerous inflammatory diseases. However, these inflammatory conditions could be expanded to include adult respiratory distress syndrome, AIDS, cardiovascular diseases, thrombosis or harmful platelet aggregation, reocclusion following thrombolysis, allograft rejection, reperfusion injury, psoriasis, eczema, contact dermatitis and other skin inflammatory diseases, osteoporosis, osteoarthritis, atherosclerosis, neoplastic diseases including metastasis of neoplastic or cancerous growth, wound healing enhancement, treatment of certain eye diseases such as detaching retina, Type I diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), inflammatory and immunoinflammatory conditions including ophthalmic inflammatory conditions and inflammatory bowel diseases, ulcerative colitis, regional enteritis and other autoimmune diseases. Accordingly, a compound which could inhibit these conditions is desirable.

SUMMARY OF THE INVENTION The present invention is directed to a compound of the following formula:

In the above formula, X is selected from the group consisting of halogen, CF3, N02, OH, Cl3 alkoxy, NH2 and C1-4 alkyl, both Z1 and Z2 are CH or N, n is 1,2 or 3, Y is-OCH2- or-NHC (=O)-, Rx is OH or C1-6 alkoxy and Ra is selected from the group consisting of: HO-C lu--\ and and (C 6 alkylene) N O

In the above formula, represents a single or a double bond. Also, in the above formula, W1 is selected from the group consisting of-CO-,-OCH2CO-,-OCH (CH3) CO-,

-OC (CH3) 2CO-,-SCH2CO-,-SCH (CH3) CO-,-SC (CH3) 2CO-,-CH=CHCO-, -OCH (C6H5) CO-and-SCH (C6H5) CO-, w2 is O or S, q is 5 or 6, m is 0 or 1, Xl is O, S or a bond, yl is C1-3 alkylene or-CH (C6H5), Rc is a bond,-CH2-or =CH-, and Q is a ring of C3-10 cycloalkane or C3-10 cycloalkene, which ring is substituted by the group of Rl and may further be substituted by 1 to 3 methyl groups with the proviso that Q is other than a ring of cyclopentane which is substituted by three methyl groups.

In the above formula, Ru ils selected from the group consisting of -H, -CORx, -CH (OH) CH3,- (C2-7 alkenylene) COR", -NHCO (C1-6 alkylene) COR", =CHCOR", alkyl),-NHCO(C2-7alkenylene)CORx,-NHCO(C1-6alkylene)O(C1-6 alkyl),-NHCONH(C1-6alkylene)CORx,-NHCO(C1-6alyylene)CO(C1-6 =CHCN,-(C1-6alkylene)CORx,-C2-7alkanoyl, C 1 _ 6 allcoxy -NHCO < I ' C 1 _6 alkoxy In the above formula, R2 is selected from the group consisting of-CH2COR",-NHCO (C1-6 alkylene) COR", -NHCO(C1-6alkylene)O(C1-6alkyl),-NHCO(C2-7alkenylene)CORx, -NHCONH(C1-6alkylene)CORx, C)-6 afkoxy -NHCO/ I I I C I _ 6 alkoay

In the above formula, R3 is selected from the group consisting of -OH, -CORx, -(C2-7 alkenylene) COR\ -NHCO(C1-6alkylene)O(C1-6alkyl),-NHCO(C1-6alkylene)CORx, -NHCO(C1-6alkylene)CO(C1-6alkyl),-NHCO(C2-7alkenylene)CORx, -C2-7alkanoyl,-NHCONH(C1-6alkylene)CORx,

-NHCO.-NHCONH.<BR> <P> /\<BR> <BR> I!f-LcoRX-!-COR'<BR> <BR> \/ C1-6akoxy -NHCO < / I C1_6 alkoxy Lastly, in the above formula, R 4 is selected from the group consisting of-COOH,-CH=CHCOOH and methylenedioxy, R 5 is =CHCORX or =CHCN, and R6 is selected from the group consisting of In another embodiment, the compound of the present invention is represented by the following formula:

In a preferred embodiment of the present invention, X is halogen, Y is-OCH2-or-NHC (=O)-, both Z1 and Z2 are CH or N, Rx is OH or C1-6 alkoxy, and Ra is selected from the group consisting of: HO- y-Wl- and /and(C 1 _6 alkylene)- In the above preferred embodiment of the present invention, R6 is selected from the group consisting of:

Also, in the preferred embodiment of the present invention, R7 is -CORx, R8 is selected from the group consisting of hydrogen,-CORX,-COCH3 and-CH (OH) CH3, R9 is hydrogen or methyl, R10 is -CORx or -(C1-6 alkylene) COR", and R is selected from the group consisting of-CORX, -NHCO(C1-6alkylene)CORx,-(C2-7alkenylene)CORx, alkyl),-NHCO(C2-7alkenylene)CORx,-NHCO(C1-6alkylene)O(C1-6 alkyl),-NHCONH(C1-6alkylene)CORx,-NHCO(C1-6alkylene)CO(C1-6 -¬2-7 alkanoyl, Cl6akoxy -NHCO I C 1-6 alkoxy -(Cl6akylene)-N O In the preferred embodiment of the present invention, R12 is -CORx or -CN, W1 is selected from the group consisting of -CO-,-OCH2CO-,-OCH (CH3) CO-,-OC (CH3) 2CO-, -SCH2CO-, -SCH (CH3) CO-,-SC (CH3) 2CO-,-CH=CHCO-,-OCH (C6H5) CO-and -SCH (C6H5) CO-, W2 is O or S, n is 1 or 2, and m is 0 or 1.

In another embodiment of the present invention, Y is -NHC(=O)-.

In another embodiment, the compound of the present invention is represented by the following formula:

In another preferred embodiment of the present invention, Ra is selected from the group consisting of: In another preferred embodiment of the present invention, Ra is selected from the group consisting of:

R6 is selected from the group consisting of: Rll is selected from the group consisting of-NHCO (C2-7 alkenylene)CORx,alkyl),alkylene)CO(C1-6

In a more preferred embodiment of the present invention, Ra is and R8 is CORx or COCH3.

In another more preferred embodiment of the present invention, Ra is and Riz is selected from the group consisting of alkyl),-NHCO(C1-6alkylene)CO(C1-6

In another more preferred embodiment of the present invention, Ra is and R1l is selected from the group consisting of

In another more preferred embodiment of the present invention, Ra is In another more preferred embodiment of the present invention, Ra is and R6 is selected from the group consisting of:

With respect to the present invention, alkyl, alkylene and alkoxy groups are intended to encompass both straigh and branched chain moieties. For example, a C1_6 alkyl group would encompass moieties including, but not limited to, methyl, ethyl, propyl, butyl, pentyl, hexyl, iso-propyl, and t-butyl.

The desired compounds of the present invention may exist in the form of optical isomers based on asymmetric carbon atoms thereof, and the present invention also includes these optical isomers and mixtures thereof.

In an embodiment of the present invention, the steric configuration of a bond need not be fixed. A bond may be of any acceptable configuration. Further, a compound may be a mixture with several different configurations of the same bond.

The desired compound of the present invention may be clinically used either in a free form or in the form of pharmaceutically acceptable salts thereof. Pharmaceutically acceptable salts include acid-addition salts with inorganic acid or organic acid (e. g., hydrochloride, sulfate, nitrate, hydrobromide, methanesulfonate, p-toluenesulfonate, acetate), salt with inorganic base, organic base or amino acid (e. g., triethylamine salt, a salt with lysine, an alkali metal salt, an alkali earth metal salt and the like).

The compound may also be formulated into a pharmaceutical composition comprising a therapeutically effective amount of the compound as defined above and a pharmaceutically acceptable

carrier or diluent.

The compound can also be used for treating or preventing (Appl adhesion mediated conditions in a mammal such as a human.

This method may comprise administering to a mammal or a human patient an effective amount of the compound or composition as explained above.

This method can be used to treat such inflammatory conditions as rheumatoid arthritis, asthma, allergy conditions, adult respiratory distress syndrome, AIDS, cardiovascular diseases, thrombosis or harmful platelet aggregation, reocclusion following thrombolysis, allograft rejection, reperfusion injury, psoriasis, eczema, contact dermatitis and other skin inflammatory diseases, osteoporosis, osteoarthritis, atherosclerosis, neoplastic diseases including metastasis of neoplastic or cancerous growth, wound healing enhancement, treatment of certain eye diseases such as detaching retina, Type I diabetes, multiple sclerosis, systemic lupus erythematosus (SLE), inflammatory and immunoinflammatory conditions including ophthalmic inflammatory conditions and inflammatory bowel diseases, ulcerative colitis, atherosclerosis, regional enteritis and other autoimmune diseases.

The desired compound of the present invention or pharmaceutically acceptable salts thereof may be administered either orally or parenterally, and it may be used as a suitable pharmaceutical preparation, for example, a tablet, a granule, a capsule, a powder, an injection, and an inhalation by a conventional process.

The dose of the desired compound of the present invention or a pharmaceutically acceptable salt thereof varies depending on an administration method, age, body weight, and state of a patient, but, in general, the daily dose is preferably about 0.1 to 100 mg/kg/day, particularly preferably 1 to 100 mg/kg/day.

Preferred routes of administration for asthma: It is preferred that the compound of the present invention be administered in the form of an Aerosol. However, other routes of administration include intravenous, oral, intramuscular, and subcutaneous.

In the case of aerosol administration, compositions containing the compounds of the present invention can be prepared to provide for an excellent means for administering in aerosol form for inhalation therapy. Accordingly, the present invention will provide for self-propelling compositions containing the compounds of the present invention.

Propellants employed should be non-toxic and have a vapor pressure suitable for the conditions under which administration occurs. These propellants can be fluorinated or fluorochlorinated lower saturated aliphatic hydrocarbons. The preferred propellants of this type are the halogenated alkanes containing not more than two carbon atoms and at least one fluorine atom. Illustrative of these are trichloromonofluoromethane, dichlorodifluoromethane, monochlorotrifluoromethane, dichloromonofluoromethane and 1,2- dichloro-1,1,2,2-tetrafluoroethane. These compounds are available from E. I. duPont de Nemours and Company under the trade name"Freon". These propellants may be employed singularly or in admixture.

In addition to the propellant, an organic solvent may also be employed. The organic solvent must be non-toxic and without undesirable effects on inhalation in the amount present in the aerosol produced. In addition, the solvent should be substantially anhydrous, completely miscible with the propellant or mixture of propellants employed and have a suitable boiling point. Examples of such solvents included non-toxic aliphatic alcohols such as ethanol ; ethers such as ethyl ether and vinyl ether; ketones such as acetone; and

suitable halogenated lower alkanes.

In addition to the organic solvent, the composition may also optionally contain a non-toxic hygroscopic glycol. The glycol must be substantially miscible with the organic solvent and the propellant employed. Satisfactory glycols include propylene glycol, triethylene glycol, glycerol, butylene glycol and hexylene glycol.

The above indicated methods of administration and formulation of aerosol compositions should not be viewed as limiting. The compounds of the present invention can be formulated in anyway deemed suitable to one of ordinary skill in the art so as to obtain the desired effects.

Pharmaceutical Compositions As indicated previously, the compounds of formula (I) can be formulated into pharmaceutical compositions. In determining when a compound of formula (I) is indicated for the treatment of a given disease, the particular disease in question, its severity, as well as the age, sex, weight, and condition of the subject to be treated, must be taken into consideration and this perusal is to be determined by the skill of the attendant physician.

For medical use, the amount of a compound of Formula (I) required to achieve a therapeutic effect will, of course, vary both with the particular compound, the route of administration, the patient under treatment, and the particular disorder or disease being treated. A suitable daily dose of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, for a mammalian subject suffering from, or likely to suffer from, any condition as described hereinbefore is 0.1 mg to 100 mg of the compound of formula I, per kilogram body weight of the mammalian subject. In the case of systematic administration, the dose may be in the range of 0.5 to 500 mg of the compound per kilogram body weight, the most preferred dosage being 0.5

to 50 mg/kg of mammal body weight administered two to three times daily. In the case of topical administration, e. g., to the skin or eye, a suitable dose may be in the range of 0.1 ug to 100 ug of the compound per kilogram, typically about 0.1 ug/kg. In the case of oral dosing, a suitable dose of a compound of Formula (I), or a physiologically acceptable salt thereof, may be as specified in the preceding paragraph, but most preferably is from 1 mg to 10 mg of the compound per kilogram, the most preferred dosage being from 1 mg to 5 mg/kg of mammal body weight, for example, from 1 to 2 mg/kg. Most preferably, a unit dosage of an orally administrable composition encompassed by the present invention contains less than about 1.0 g of a formula (I) compound.

It is understood that formulation, both for human and veterinary use, of the present invention may be presented to the mammal by inhalation. To achieve therapeutic effect, the dose may be in the range of 0.5 to 500 mg of the compound, per kg body weight. The most preferred dosage being 0.5 to 50 mg/kg of mammal body weight administered two to three times daily.

It is understood that the ordinarily skilled physician or veterinarian will readily determine and prescribe the effective amount of a compound of Formula I to prevent or arrest the progress of the condition for which treatment is administered.

In so proceeding, the physician or veterinarian could employ relatively low doses at first, subsequently increasing the dose until a maximum response is obtained.

The compounds and compositions of the present invention can be administered to patients suffering from a condition listed herein in an amount which is effective to fully or partially alleviate undesired symptoms of the condition. The symptoms may be caused by inappropriate cell adhesion mediated by a3i integrins. Such inappropriate cell adhesion would typically be expected to occur as a result of increased VCAM-1

and/or CS-1 expression on the surface of endothelial cells.

Increased VCAM-1 and/or CS-1 expression can be due to a normal inflammation response or due to abnormal inflammatory states.

In either case, an effective dose of a compound of the invention may reduce the increased cell adhesion due to increased VCAM-1 expression by endothelial cells. Reducing the adhesion observed in the disease state by 50% can be considered an effective reduction in adhesion. More preferably, a reduction in adhesion by 90%, is achieved. Most preferably adhesion mediated by VCAM-1/a41 and/or CS-1 interaction is abolished by an effective dose. Clinically, in some instances, effect of the compound can be observed or a decrease in white cell infiltration into tissues or a site of injury. To achieve a therapeutic effect, then, the compounds or compositions of the present invention are administered to provide a dose effective to reduce or eliminate inappropriate cell adhesion or to alleviate undesired symptoms.

While it is possible for an active ingredient to be administered alone, it is preferable to present it as a pharmaceutical formulation comprising a compound of Formula (I) and a pharmaceutically acceptable carrier thereof. Such formulations constitute a further feature of the present invention.

The formulations, both for human and veterinary medical use, of the present invention comprise an active ingredient of Formula (I), in association with a pharmaceutically acceptable carrier thereof and optionally other therapeutic ingredient (s), which are generally known to be effective in treating the disease or condition encountered. The carrier (s) must be "acceptable"in the sense of being compatible with the other ingredients of the formulations and not deleterious to the recipient thereof.

The formulations include those in a form suitable for oral, pulmonary, ophthalmic, rectal, parenteral (including

subcutaneous, intramuscular, and intravenous), intra-articular, topical, nasal inhalation (e. g., with an aerosol) or buccal administration. Such formulation are understood to include long-acting formulations known in the art.

The formulations may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. All methods may include the step of bringing the active ingredient into association with the carrier which constitutes one or more accessory ingredients.

In general, the formulations are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired form.

Formulations of the present invention suitable for oral administration may be in the form of discrete units such as capsules, cachets, tablets, or lozenges, each containing a predetermined amount of the active ingredient in the form of a powder or granules; in the form of a solution or suspension in an aqueous liquid. Formulations for other uses could involve a nonaqueous liquid; in the form of an oil-in-water emulsion or a water-in-oil emulsion; in the form of an aerosol; or in the form of a cream or ointment or impregnated into a transdermal patch for use in administering the active ingredient transdermally, to a patient in need thereof. The active ingredient of the present inventive compositions may also be administered to a patient in need thereof in the form of a bolus, electuary, or paste.

The practitioner is referred to"Remington: The Science and Practice of Pharmacy,"l9th Edition, c. 1995 by the Philadelphia College of Pharmacy and Science, as a comprehensive tome on pharmaceutical preparations.

Abbreviations DMF: Dimethylformamide TFA: Trifluoroacetic Acid HBTU: O-Benzotriazol-1-yl-N, N, N', N'-tetramethyluronium hexahydrophosphate HOBT: 1-Hydroxybenzotriazole DIEA: Diisopropylethylamine THF: Tetrahydrofuran BOC: tert-Butoxycarbonyl

Examples The compounds of Examples 1-87 were prepared by the following Methods A, B, C, D, E, F, G, H, or I and could be purified by conventional chromatography on silica gel using a proper eluent such as CHC13, AcOEt, etc.

RB-CI= MerrifieEresin<BR> Reference Compomd A<BR> <BR> #=polymer Method A 0 RA N 1. TFA (Deprotection) RA OH R Cornpod A p 2. N-protected amino acid 1 0 ci 3. TFA (Deprotection) I/ 4. LiOH (Hydrolysis) H Cl Method B 0 H RA N 1. TFA (Deprotection) RA"r OH R Compound A p 2. Carboxylic acid (O Cl 3. LiOH (Hydrolysis) N I H ci Method C 0 H RA N 1. TFA (Deprotection) j OH R Compound A p 2. Acid anhydride 1 0 ci 3. LiOH (Hydrolysis) \+ N J H H I Cl Method D 0 H RA N 1. TFA (Deprotection) R Compound A p 2. p-N02PhOCOCI I 3. Amine 1. 1 4. LiOH (Hydrolysis) N Cl

Method E R% ? XB N v'OH 1. TFA (Deprotection) XB$ Jl\OH R Compound A p 2. BrC (RlORl I) COOH l ci 3.ArXBNa/ 4. LiOH (Hydrolysis) XB = O, S Ar= aryl R 10, RI I = H, alk-yl aryl

Method F 0 H vA D 1. TFA (Deprotection)" R. Compound A D n 2.N-tert-butoxycarbonyl-I O CI aminoacid I I (Boc-XA-Coofi) N H I Ci R. Compound B Method G 0 Y H XAN v'OH 1. TFA (Deprotection) R-Compound B- 2. Carbolic acid I 3. LiOH (Hydrolysis)/ N H title ci Method H 0 H yA, N XAN v OH 1. TFA (Deprotection) R-Compomd B 2. Acid anhydride I ci 3. LiOH (Hydrolysis)/ H H Cl Method I 0 H ! ! yA M XAN v'OH 1. TFA (Deprotection) XA OH R Compound B 2. Isocyanate \ O Cl 3. LiOH (Hydrolysis)/ N H Cl

Example 1: 4- [ (2,6-Dichlorobenzoyl) amino]-N- [ [ (3S)-7-hydroxy- 1,2,3,4-tetrahydro-3-isoquinolyl] carbonyl]-L-phenylalanine The above-titled compound was prepared by Method A (RA: (3S)-2- (tert-butoxycarbonyl)-7-hydroxy-1,2,3,4-tetrahydro- 3-isoquinolyl). Reference Compound A (300 mg) was placed in a 8.0 mL, polypropylene filter column fitted with a 2-way polypropylene stopcock. The resin was pretreated with CH2C12 (2 x 3 mL). The swollen resin was then deprotected with 50% TFA/CH2C12 (3mL, 30min). The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL). The resin was swollen with DMF (2 x 3 mL). (3S)- 2- (tert-butoxycarbonyl)-7-hydroxy-1, 2, 3,4-tetrahydro-3- isoquinolinecarboxylic acid (258 mg) in DMF (1.0 mL) was activated with 0.5 M HBTU/HOBT in DMF (1.6 mL) and DIEA (0.34 mL), and then added to the swollen resin. The mixture was stirred for 2 hr at room temperature. The resin was filtered

and washed in the following order: DMF (2 x 3 mL), CH2Cl2 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL), respectively. If a Kaiser test (Kaiser et al., Anal. Biochem. 1970,34,594- 598) on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. After pretreating the resin with CH2C12 (2 x 3 mL), the swollen resin was then deprotected with 50% TFA/CH2Cl2 (3mL, 30min) to remove tert-butoxycarbonyl group. The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL). The resulting resin was then dried in vacuum to constant weight. The cleavage of the resin (saponification) was achieved with LiOH/CH30H/THF (1: 6: 20). The resin bound material was placed in the polypropylene column and pretreated with THF (3 mL). Then THF (4 mL), CH30H (1.0 mL) and 2N LiOH (0.390 mL) were added. The mixture was stirred for 15 min and filtered to a clean and pre weighed test tube. The resin was next washed with THF/5% CH30H (2mL) and the combined filtrates were evaporated. The resulting gum was dissolved in H20 (1 mL). The solution was then acidified with 1N HC1 to pH 2.0. The precipitate was centrifuged, washed with water (2 x 5 mL) and dried in vacuum to furnish the compound of Example 1: ESMS (m/z) 526 (M-H).

Example 2: N- [ (5-Carboxy-3-pyridinyl) carbonyl]-4- [ (2, 6- dichlorobenzoyl) amino]-L-phenylalanine The above titled compound was prepared by Method B (RA :

5-carboxy-3-piridinyl). R. Compound A (200 mg) was placed in a 8.0 mL, polypropylene filter column fitted with a 2-way polypropylene stopcock. The resin was pretreated with CH2C12 (2 x 3 mL). The swollen resin was then deprotected with 50% TFA/CH2C12 (3mL, 30min). The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL). The resin was swollen with DMF (2 x 3 mL). 3,5- Pyridine dicarboxylic acid (138 mg) in DMF (1.0 mL) was activated with 0.5 M HBTU/HOBT in DMF (1.6 mL) and DIEA (0.34 mL). The preactivated 3,5-pyridine dicarboxylic acid was then added to the swollen resin and the mixture was stirred for 2 hr at room temperature. The resin was filtered and washed in the following order: DMF (2 x 3 mL), CH2Cl2 (2 x 3 mL), CH30H (2 x 3 mL), CH2Cl2 (2 x 3 mL), respectively. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. The resulting resin was then dried in vacuum to constant weight. The cleavage of the resin (saponification) was achieved with LiOH/CH30H/THF (1: 6: 20). The resin bound material was placed in the polypropylene column and pretreated with THF (3 mL). Then THF (4 mL), CH30H (1.0 mL) and 2N LiOH (0.390 mL) were added. The mixture was stirred for 15 min and filtered to a clean and pre weighed test tube. The resin was next washed with THF/5% CH30H (2mL) and the combined filtrates were evaporated. The resulting gum was dissolved in H20 (1 mL). The solution was then acidified with 1N HC1 to pH 2.0.

The precipitate was centrifuged, washed with water (2 x 5 mL) and dried in vacuum to furnish the compound of Example 2: ESMS (m/z) 501 (M-H).

Examples 3,4 The following compounds were prepared in a manner similar to the compound of Example 2:

Ex. # R"MS m/z 529 3 mu+ °49 MH+ 1 ! : :

Example 5: N- (2-Carboxybenzoyl)-4- [ (2,6-dichlorobenzoyl)- amino]-L-phenylalanine

The above titled compound was prepared by the Method C (RA: 2-carboxyphenyl). R. Compound A (150 mg) was placed in a 8.0 mL, polypropylene filter column fitted with a 2-way polypropylene stopcock. The resin was pretreated with CH2C12 (2 x 3 mL). The swollen resin was then deprotected with 50% TFA/CH2C12 (3mL, 30min). The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL). Phthalic anhydride (80 mg, 0.54 mmol) in DMF (2.0

mL)/DIEA (0.15 mL) was added. The mixture was stirred for 3 days at room temperature. The resin was filtered and washed in the following order: DMF (2 x 3 mL), CH2Cl2 (2 x 3 mL), CH30H (2 x 3 mL), CH2Cl2 (2 x 3 mL), respectively. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. The resulting resin was then dried in vacuum to constant weight. The cleavage of the resin (saponification) was achieved with LiOH/CH30H/THF (1: 6: 20).

The resin bound material was placed in the polypropylene column and pretreated with THF (3 mL). Then THF (4 mL), CH30H (1.0 mL) and 2N LiOH (0.390 mL) were added. The mixture was stirred for 15 min and filtered to a clean and pre weighed test tube. The resin was next washed with THF/5% CH30H (2mL) and the combined filtrates were evaporated. The resulting gum was dissolved in H20 (1 mL). The solution was then acidified with 1N HC1 to pH 2.0. The precipitate was centrifuged, washed with water (2 x 5 mL) and dried in vacuum to furnish the compound of Example 5: ESMS (m/z) 499 (M-H).

Examples 6-9 The compounds of the following Examples were prepared in the same way as the compound of Example 5: Ex. # RA MS m/z 6 < 463 COOH (M-H) Ex. # R MS m/z H 7 505 v= COOH COOH (M-H) H 8 13 505 wCOOH (M-H) H 9 491 H COOH (M-H) Example 10: N-[[(2S)-2-Carboxy-1-pyrrolidinyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine

The above titled compound was prepared by the Method D <BR> <BR> <BR> (RA: (2S)-2-carboxy-1-pyrrolodinyl). R. Compound A (100 mg) was placed in a 8.0 mL, polypropylene filter column fitted with a 2-way polypropylene stopcock. The resin was pretreated with CH2C12 (2 x 3 mL). The swollen resin was then deprotected with 50% TFA/CH2C12 (3mL, 30min). The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL). The resin was then treated with p- nitrophenylchloroformate (130 mg) in THF/CH2C12 (1.5 mL) and DIEA (100 µL). This was shaken for 2 hr at room temperature.

The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL). The resulting resin was then treated with L-proline methyl ester (60 mg) in DMF (2 mL) and Et3N (100 J. L) and the mixture was stirred for 3 days

at room temperature. The resin was filtered and washed in the following order: DMF (2 x 3 mL), CH2Cl2 (2 x 3 mL), CH30H (2 x 3 mL), CH2Cl2 (2 x 3 mL), respectively. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained.

The resulting resin was then dried in vacuum to constant weight. The cleavage of the resin (saponification) was achieved with LiOH/CH30H/THF (1: 6: 20). The resin bound material was placed in the polypropylene column and pretreated with THF (3 mL). Then THF (4 mL), CH30H (1.0 mL) and 2N LiOH (0.390 mL) were added. The mixture was stirred for 15 min and filtered to a clean and pre weighed test tube. The resin was next washed with THF/5% CH30H (2mL) and the combined filtrates were evaporated. The resulting gum was dissolved in H20 (1 mL). The solution was then acidified with 1N HC1 to pH 2.0.

The precipitate was centrifuged, washed with water (2 x 5 mL) and dried in vacuum to furnish the compound of Example 10: ESMS (m/z) 492 (M-H).

Example 11. N-[[(2S)-2-Carboxy-1-piperidyl] carbonyl]-4-[2,6- dichlorobenzoyl) amino]-L-phenylalanine The above titled compound was prepared in a similar way as the compound of Example 10. ESMS (m/z): 506 (M-H)-.

Example 12: N- [ (4-carboxyphenoxy) acetyl]-4- [ (2,6-dichloro- benzoyl) amino]-L-phenylalanine

The above titled compound was prepared by the Method E (ArXBC (R10Rll): (4-carboxyphenoxy) methyl). R. Compound A (100 mg) was placed in a 8.0 mL, polypropylene filter column fitted with a 2-way polypropylene stopcock. The resin was pretreated with CH2C12 (2 x 3 mL). The swollen resin was then deprotected with 50% TFA/CH2C12 (3mL, 30min). The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL). Bromoacetic acid (85 mg) and diisopropyl-carbodiimide (80 mg) in DMF (2.0 mL) was added and the mixture was stirred for 1 hr at room temperature. The resin was filtered and washed in the following order: DMF (2 x 3 mL), CH2Cl2 (2 x 3 mL), DMF (2 x 3 mL), respectively. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. Methyl p-hydroxybenzoate (91 mg) was pretreated with NaH (20 mg) in THF (0.5 mL) and DMF (2 mL) for 1.5 hr. The resulting phenoxide was added to the resin and the mixture was stirred for 2 hr at room temperature. The resin was then filtered and washed in the following order: DMF (2 x 3 mL), CH2C12 (2 x 3 mL), THF (2 x 3 mL), respectively. The resulting resin was then dried in vacuum to constant weight. The cleavage of the resin (saponification) was achieved with LiOH/CH30H/THF (1: 6: 20).

The resin bound material was placed in the polypropylene column and pretreated with THF (3 mL). Then THF (4 mL), CH30H (1.0 mL) and 2N LiOH (0.390 mL) were added. The mixture was stirred for 15 min and filtered to a clean and pre weighed

test tube. The resin was next washed with THF/5% CH30H (2mL) and the combined filtrates were evaporated. The resulting gum was dissolved in H20 (1 mL). The solution was then acidified with IN HC1 to pH 2.0. The precipitate was centrifuged, washed with water (2 x 5 mL) and dried in vacuum to furnish the compound of Example 12: ESMS (m/z) 529 (M-H).

Examples 13-30: The compounds of the following Examples were prepared in a similar way as Example 12: Ex RA MS Ex RA MS m/z m/z 1359ifr/ HOOC 4 O- (M-H) Ho2c4+29<<0t (M-H 14 543 23 631 HOOC""0" (M-H)'f) Y (M-H)' HO2C O 15 at 557 24 n l 559 w HOOC ° (M-H) < S (M-H COOH 16 n 605 25 573 I w I (M_H) _ I i S (M_H) _ HOOC O COOH 17n527 26n62117527 26 621 HOOCO 0" O (I"1-H) w 0'Y vs COOH Ex R MS Ex R MS | m/z m/z 18 541 27 529 (M-H) I i p (M-H) O COOH 19 555 28 543 ya oy" (M-H) (M-H) O COOH 20 603 29 605 n 9 (M-H) n 9 (M-H) AfvoK (M-H) (M-H) O COOH 0COOH I Ho, c o M_H-N. N (M-H) Example 31: 4- [ (2,6-Dichlorobenzoyl) amino]-N- [3- [N- (3-methoxy- 1-oxopropyl) amino] benzoyl]-L-phenylalanine

The above titled compound was prepared by the Method G (YA-XA: 3- [N- (3-methoxy-l-oxopropyl) amino] benzoyl). R. Compound B-1 (0.2 g) was pretreated with CH2C12 (2 x 3 mL). The swollen resin was then deprotected with 50% TFA/CH2C12 (3mL, 30min). The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL). The resin was swollen with DMF (2 x 3 mL). 3-methoxypropionic acid (81 mg) in DMF (1.0 mL) was activated with 0.5 M HBTU/HOBT in DMF (1.6 mL) and DIEA (0.34 mL). The preactivated 3-methoxy propionic acid was then added to the swollen resin and the mixture was stirred for 2 hr at room temperature. The resin was filtered and washed in the following order: DMF (2 x 3

mL), CH2Cl2 (2 x 3 mL), CH30H (2 x 3 mL), CH2Cl2 (2 x 3 mL), respectively. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. The resulting resin was then dried in vacuum to constant weight. The cleavage of the resin (saponification) was achieved with LiOH/CH30H/THF (1: 6: 20). The resin bound material was placed in the polypropylene column and pretreated with THF (3 mL). Then THF (4 mL), CH30H (1.0 mL) and 2N LiOH (0.390 mL) were added. The mixture was stirred for 15 min and filtered to a clean and pre weighed test tube. The resin was next washed with THF/5% CH30H (2mL) and the combined filtrates were evaporated. The resulting gum was dissolved in H20 (1 mL). The solution was then acidified with 1N HCl to pH 2.0. The precipitate was centrifuged, washed with water (2 x 5 mL) and dried in vacuum to furnish the compound of Example 31: ESMS (m/z) 556 (M-H).

Example 32: N-[3-[N-[[(1- Carboxymethyl) cyclopentyl] acetyl] amino] benzoyl]-4-[(2, 6- dichlorobenzoyl) amino]-L-phenylalanine The above titled compound was prepared by the Method H (YA-XA: (3-[N-[[(1-carboxymethyl)cyclopentyl]acetyl]amino)- benzoyl). R. Compound B-1 (0.2 g) was pretreated with CH2C12 (2 x 3 mL). The swollen resin was then deprotected with 50% TFA/CH2C12 (3mL. 30min). The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12

(2 x 3 mL). The resin was then swollen with DMF (3mL). 3,3- Tetramethyleneglutaric anhydride (130 mg) dissolved in DMF (4 mL) was added to the swollen resin and stirred at 50 °C for 2hr. The resin was filtered and washed in the following order: DMF (2 x 3 mL), CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2Cl2 (2 x 3 mL), respectively. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained. The resulting resin was then dried in vacuum to constant weight.

The cleavage of the resin (saponification) was achieved with LiOH/CH30H/THF (1: 6: 20). The resin bound material was placed in the polypropylene column and pretreated with THF (3 mL).

Then to the swollen resin THF (3.9 mL), CH30H (1.0 mL) and 2N LiOH (0.39 mL) were added. The mixture was stirred for 15 min and filtered to a clean and pre weighed test tube. The resin was next washed with THF/5% CH30H (2 x 2 mL) and the combined filtrates were evaporated. The resulting gum was dissolved in H20 (1 mL). The solution was then acidified with 1N HC1 to pH 2.0. The precipitate was centrifuged, washed with H20 (2 x 5 mL) and dried in vacuum to furnish the compound of Example 32: ESMS (m/z) 638 (M-H).

Example 33: N- [3- [ (NI-Carboxymethyl) ureido] benzoyl]-4- [ (2, 6- dichlorobenzoyl) amino]-L-phenylalanine The above titled compound was prepared by the Method I <BR> <BR> (YA-XA: 3- [N'- (carboxymethyl) ureido] benzoyl). R. Compound B-1

was pretreated with CH2C12 (2 x 3 mL). The swollen resin was then deprotected with 50% TFA/CH2C12 (3mL, 30min). The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL). The resin was then swollen with DMF (3mL). Ethyl isocyanatoacetate (101 mg) dissolved in DMF (3 mL) and DIEA (340 L) were added to the swollen resin.

This reaction mixture was stirred for 6-8 hr at room temperature. The resin was filtered and washed in the following order: DMF (2 x 3 mL), CH2Cl2 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL), respectively. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained.

The resulting resin was then dried in vacuum to constant weight. The cleavage of the resin (saponification) was achieved with LiOH/CH30H/THF (1: 6: 20). The resin bound material was placed in the polypropylene column and pretreated with THF (3 mL). Then to the swollen resin THF (3.9 mL), CH30H (1.0 mL) and 2N LiOH (0.39 mL) were added respectively.

The mixture was stirred for 15 min and filtered to a clean and pre weighed test tube. The resin was next washed with THF/5% CH30H (2mL) and the combined filtrates were evaporated.

The resulting gum was dissolved in H20 (1 mL). The solution was then acidified with 1N HCI to pH 2.0. The precipitate was centrifuged, washed with H20 (2 x 5 mL) and dried in vacuum to furnish the compound of Example 33: ESMS (m/z) 571, (M-H) Examples 34-87: The compounds of the following Examples were prepared in a similar manner as described above. Ex. # Method yA MS m/z o 34 H HOOC^Ijk' 0 570 _ (M-H) 35 H HOOC H o 612 (M-H)- 0 36 H 0 568 N (M-H) 37 G ( 568 oN o _ COOH 38 G 0 624 N _ o H (M-H) O 39 G 0 568 O H (M-H) o 40 G F6co 0 634 O H (MH) H 41 G o NJ ag 618 COOH H _ (M-H) O 42 G 0 618 i H (M_H) _ COOH 0 43 G ° NJ ar 668 _ HOOC Ex. # Method yA XA MS m/z o 619 4 4 G Hoo I i o- H N hou 45 I I, II 0 635 N N u _ (M-H) o 46 H HOOC" NH 578 (M-H) 47 H \NH 644 HOBT- (M-H) k o (M-H) HOOC (M-H) _ \. _ 49 H 574 lu (M-H) 50 G NH 574 (M-H) 50 GHOOCNt<NH574o (M-H 51 G NH 5 6 2 51(M-H) COOH 52 G NH 630 o (M-H) 0 53 G NH 574 O- (M-H) HOOC,, NH l O (M_H) _ .-o 64 0 F+,CO NH H3co, o, 1-l3Co -. _ O \ _ 56 G I 624 COOL Ex. # Method YA MS m/z o 57 G nu/624 i _ (M-H) COOH 0\ 58 G OOCJL Nu 674 (M-H _ HOOC 0 59 G HOO 625 (M-H) HOU O 60 I I/II N 639 N H (M_H) _ N)'/639 "U,- N (M-H) .- 62 G nu/625 ZANZI HOOC HOOC p \ __ 63 G NH 625 HOOC N- OH OH 64 G NH 649 (M-H) HOBT HOOC NH \ 65 G N NH 614 (M-H) 0 HOOC 66 G 0 NH NIH 637 o MH+ 0 67 G 0 NH 616 o (M-H) Ex. # Method Y MS m/z 68 G o NH 574 o (M-H 69 G NH 574 o o (M-H) _-_ _-_ ___ _ _. __ 70 G o o (M5-9H3 4&NH (M-H) CH2 71 G 637 HOOC HOOC O O 72 G 637 HOOC N NH (MH) Hooc (M-H) / OU O 73 G O X ;/NH (MH) HOBT 0 HOOC 74 G 626 N '-'626- OH (M-H) HOOC HOOC O 75 G HOOC 0 602 Ho- 0 ON0 76 G/ 628- tOL-t 0 4VNH (M-H) 77 G 586 0 ( 0 0 78 G o 586 o _- 78 G> e586o 2r (M-H)- Ex. # Method Y XF'MS m/z NH O 79 G I clos NH O 80 G i cis 625 HOOC 0 NH 0 81 G cis 625 HOOCv N - HOOC 0 nu 0 82 G I w w cis 647- /N 11 (M_H) 0 ooc 83 G t cil 647 N cri o HOOC s NH O 8 4 G HS cis 6 3 5 (M-H) 02N NH O (MH) 85 G 0 ci 617 (M-H) nu 0 86 G > cis X 574 LJ (M-H) /\ NH 0 (M-H) o-NH 0 87 G cis 574 (M-H)

Reference Compound Examples: Reference Compound A: RBCl = Merrifield resin<BR> <BR> <BR> Reference Compound A<BR> <BR> O-polymer Attachment of N-tert-butoxycarbonyl- [4- [ (2,6-dichloro- benzoyl) amino]-L-phenylalanine to Merrifield resin was done using Horiki's method (Horiki et al., Chem. Lett. 1978 (2) 165- 168). In a 250 mL round bottom flask fitted with a drying tube, Merrifield resin (Biorad, 10.0 g, 13.5 mmol/g) and anhydrous potassium fluoride (1.57g) were added to a solution of N-tert-butoxycarbonyl- [4- [ (2,6-dichlorobenzoyl) amino]-L- phenylalanine (Compound 10,6.13 g) in dry DMF (100 mL). The reaction mixture was stirred at 80 °C in an oil bath for 24 hr. The cooled resin was then filtered and washed thoroughly with DMF (2 x 250 mL), 50% aqueous DMF (3 x 250 mL), methanol (3 x 250 mL), dichloromethane (3 x 250 mL), and finally methanol (3 x 250 mL). The resin was then dried under reduced pressure to constant weight to give R. Compound A.

Incorporation of N-tert-butoxycarbonyl- [4- [ (2,6-dichloro- benzoyl) amino]-L-phenylalanine onto the resin was estimated to be 1.3 mmol/g from the increase in resin mass.

Reference Compounds B-1, B-2, B-3 and B-4: Reference Compound A Reference Compound B R. Compound R. Compound R. Compound R. Compound B-1 B-2 B-3 B-4 -NHCO x-JUx-LJ A XA= NH XA-L/ H O O NH

R. Compound A (200 mg) was placed in a 8.0 mL, polypropylene filter column fitted with a 2-way polypropylene stopcock. The resin was pretreated with CH2C12 (2 x 3 mL).

The swollen resin was then deprotected with 50% TFA/CH2C12 (3- 4 mL, 30min) with shaking. The resin was rinsed in the following order: CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL). The resin was swollen with DMF (2 x 3 mL). 3- (tert-butoxycarbonylamino) benzoic acid (180 mg) in DMF (1.0 mL) was activated with 0.5 M HBTU/HOBT in DMF (1.6 mL) and DIEA (0.34 mL). The preactivated 3- (tert-butoxycarbonyl- amino) benzoic acid was then added to the swollen resin and the mixture was stirred for 2 hr at room temperature. The resin was then washed in the following order: DMF (2 x 3 mL), CH2C12 (2 x 3 mL), CH30H (2 x 3 mL), CH2C12 (2 x 3 mL) and dried to give R. Compound B-1. If a Kaiser test on a small quantity of the resin is positive (blue) then repeat the coupling procedure until a negative result is obtained.

Reference Compounds B-2, B-3 and B-4 were prepared in a similar manner as R. Compound B-1.

Reference Compound C: 3- (tert-Butoxycarbonylamino) benzoic acid 3-Aminobenzoic acid (10.0 g) was dissolved in IN NaOH (160 mL) and cooled to 0 °C. To this solution was added drop wise, with stirring, t-butyl dicarbonate (17.5 g) in dioxane (100 mL). After complete addition of t-butyl dicarbonate the reaction mixture was warmed to room temperature and stirred vigorously for 14 hours. The dioxane was evaporated and the aqueous phase was extracted with Et20 (2 X 100 mL). The aqueous layer was then acidified to pH = 2.0 with IN HC1. The precipitate was filtered and washed with H2O, and dried under high vacuum to provide 3- (tert-butoxycarbonylamino) benzoic <BR> <BR> <BR> acid (9.25 g): 1H NMR (400 MHz, DMSO-d6), 8 9.56 (1H), 8.16 (1H), 7.63 (1H), 7.55 (1H), 7.37 (1H), 1.49 (9H); ESMS (m/z) 238 MH.

Examples 88-137 The synthesis of the compounds of Examples 88-137 are as follows:

Scheme 1 Scheme 2 Scheme 3 Scheme A Example 88 Scheme B Example 89 Scheme C Example 90 Scheme D Example 91 Scheme E Example92 Scheme F Example 93 Scheme G Me G-1 Z 1 0 ME OH G-2 ci z cri cri O O G-3 me N OMe H CI/CI/ Ci cri o + o OH O O N OH Me N OH tv041 O p/ \ o vHXOHO ci °N voWl -if" Example 94 Example 95 Scheme H g N°2 o s o H-1 Me N OMe H 0 O s O \ I TOME H-2 Me N OMe \/0 rif XI o N H-3 N orme Me M WL O 0 cicl V H o o o + 0 0 N OH N OH Mu H Me o Me-rr Example 96 Example 97 ci H) tu N t Cl O N OU H Ho-tir HO 0e °0Example 98 Scheme I Example 99 Scheme J Me 0 O O O J-2 Me OH cul H L J N t CI OM e J-3 3/0 Cl O CI CI/ ci cri N \ I N \ I xi o ci 0 ci 0 0 0 Me H OH + H Me-, Example 100, Example i0) o CI/Ci/ ci cri XI 4 ci Cl ci 0 0 0 N OU HO H OH HA O O Example 102 Example 103 O' Scheme K NH2 Compound 5 ocH3 BocHN Cul CI N N K-1 zozo BocHN 0 CI N K-2 I 0 K-2 j (y " OCH3 HCI o ! H 3 N \ N 0 O O K-3 Me N OCH3 H CI N HCI N ( N \ I N \ H N u p O OU + mye Me H p U O o Example 104 Example 105 Scheme L FUT" Compound 5 ex c BocHN OCH3 0 cl Cl Cl N L-1 0 EOCH.. OCH3 BocH X o Cl N CI H L-2 0 /nu OCH3. HCI han CI N CI N v \ OH3 L-3 Me 0 CI N CI CI N CI N \ I N \ // \ O \ O _ 'OH OH N Me H Mey H O o Example 106 Example 107 Scheme M Example109 Scheme N Example110 Scheme O Example 111 Scheme P Example 112

Scheme1 One method for the preparation of this general structure 1-F, having an N-substituted cycloalkanoyl segment, is given in Scheme 1. Condensation of an R-substituted cycloalkanoic acid 1-A with aminoester 1-B gives amidoester 1-C. The nitro substituent of amidoester 1-C is reduced by standard methods to give the amine- substituted amidoester 1-D. Acylation of 1-D provides 1-E (Y=NHCO).

The functionality of R may be changed (such as by oxidation, reduction, substitution, epimerization, and/or degradation) by standard synthetic methods. Hydrolysis of 1-E gives the amidoacid 1-F.

Example 88 (TR-9712): Teaching Scheme A Teaching Scheme A exemplifies the practice of Scheme 1 by teaching the synthesis of Example 88 where (with reference to structure 1-F) R4 is 3-acetyl, m and n equal 1, Zx and Zy are CH, Y is-NHC (O)-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment <BR> <BR> <BR> <BR> is (1S-cis), and the stereochemistry of the amidoacid is L.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> (lS-cis)-3-Acetyl-2, 2-dimethylcyclobutaneacetic acid [64396-97-0] (C1oHl6o3 A-2). This material was prepared as described by Wolk et al. (Wolk, J. L.; Goldschmidt, Z.; Dunkelblum, E. Synthesis 1986, 347-398) from (+)-a-pinene A-1: mp 67-69 °C ; TLC Rf = 0.19 <BR> <BR> <BR> <BR> (800: 200: 1 hexanes/EtOAc/HCO2H); [a] 25D +93 (c 1.0, CHC13); 13C NMR<BR> <BR> <BR> <BR> <BR> <BR> <BR> (CDC13,75 MHz) 8 207.87,178. 94, 54.20,43.29,37.71,34.87,30.18, 30.

(1S-cis)-N- [ (3-Acetyl-2, 2-dimethylcyclobutyl) acetyl]-4-nitro-L- phenylalanine methyl ester (C20H26N2O6, A-3). To a mixture of acid A- 2 (1.82 g, 9.88 mmol), EDC (2.00 g, 10.22 mmol), HOBt (1.40 g,

10.33 mmol), DMAP (0.362 g, 2.96 mmol) and amine Compound 3 (10.22 mmol) in CH2C12 at 0 °C is added Et3N (1.67 mL, 11.89 mmol). The reaction mixture is stirred at room temperature for 40 h. It is diluted with CH2C12. The CH2Cl2 mixture is extracted with H20, aq 0.5 M HC1, H20, aq satd NaHC03 and H20, and then is dried and concentrated to a yellow oil. The oil is purified by silica chromatography to give A-3: TLC Rf = 0.40 (3: 1 EtOAC/hexanes); 1H NMR (CDCl3, 300 MHz) 5 8.14 (m, 2H), 7.28 (m, 2H), 6.02 (s, 1H), 4.90 (m, 1H), 3.73 (s, 3H), 3.27 (m, 1H), 3.13 (m, 1H), 2.88 (m, <BR> <BR> <BR> <BR> 1H), 2.39-1.72 (m, 5H), 2.02 (s, 3H), 1.28 (s, 3H), 0.82 (s, 3H) ;<BR> <BR> <BR> <BR> <BR> 3C NMR (CDCl3, 75 MHz) 8 207.53,171.57,171.53,147.19,143.88, 72,54.13,52.76,52.64,43.25,38.27,37.94,37.23, 93, 17.50.

(1S-cis)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) acetyl]-4-amino-L- phenylalanine methyl ester (C2oH2EN204, A-4). A mixture of A-3 (0.80 g, 2.05 mmol) and 10% Pd/C (0.036 g) in MeOH is hydrogenated (38 psi H2,2 h). The mixture is filtered and concentrated to give A-4: TLC Rf = 0.33 (3: 1 EtOAC/hexanes); 1H NMR (CDC13,300 MHz) 8 6.86 (m, 2H), 6.61 (m, 2H), 5.77 (m, 1H), 4.82-4.75 (m, 1H), 3.72 (s, 3H), 3.62 (s, 1H), 2.99 (m, 2H), 2.86 (m, 1H), 2.39-2.00 (m, 2H), 2.03 (s, 3H), 1.99-1.82 (m, 2H), 1.59 (m, 2H), 1.29 (s, 3H), 0.84 (s, 3H); MS (FAB) m/z 361 (M+H), 203, 177,132,106.

(IS-eis)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) acetyl]-4-[(2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C27H30Cl2N2O5, A- 5). To a solution of 2,6-dichlorobenzoyl chloride (0.28 mL, 1.98 mmol) in THF at room temperature under Ar is added dropwise over 15 min a solution of 17 (0.70 g, 1.94 mmol) in THF. The reaction mixture is stirred overnight at rt. It is diluted with EtOAc. The reaction mixture is extracted with aq 1 M HC1, aq 1 M NaOH and brine. The combined aqueous extracts are back-extracted with EtOAc.

The combined EtOAc extracts are dried and concentrated to give A-5

as a beige-colored solid: TLC Rf = 0.14 (1: 1 EtOAc/hexanes); 1H NMR (CDCl3, 300 MHz) 8 9.57 (s, 1H), 7. 57 (m, 2H), 7.28-7.17 (m, 3H), 6.99 (m, 2H), 6.37 (m, 1H), 4.77 (m, 1H), 3.63 (s, 3H), 3.05-2.91 (m, 2H), 2.76 (m, 1H), 2.28-1.72 (m, 5H), 2.02 (s, 3H), 1.18 (s, <BR> <BR> <BR> 3H), 0. 75 (s, 3H); 13C NMR (CDCl3, 75 MHz) 8 207.63,172.05,171.67, 162.60,137.18,136.75,132.38,132.18,130.40,129.63,127.87, 120.38,54.12,53.06,52.20,43.36,38.34, 37. 10,36.94,30.12, 30.05,23.05,17.34; MS (FAB) m/z 533 (M+H) +.

(lS-cis)-N-[(3-Acetyl-2t2-dimethylcyclobutyl) acetyl]-4-t (2t6- dichlorobenzoyl) amino]-L-phenylalanine (C26H2eCl2N205, Example 88). To a solution of ester A-5 (0.483 g, 0.90 mmol) in 5: 1 THF/MeOH (23 mL) at room temperature under Ar is added a solution of LiOH-H2O (0.088 g, 2.08 mmol) in H2O (4.6 mL). The reaction mixture is stirred for 2 h. It is acidified with aq 1 M HC1, diluted with H20, and extracted with EtOAc. The combined EtOAc extracts are washed with brine. They are dried and concentrated to an off-white solid.

The solid is dissolved in MeCN (15 mL), and the solution is diluted with H20 (15 mL). This solution is frozen and lyophilized to give <BR> <BR> <BR> Example 88 as a cotton-like solid: mp 129-133 °C; TLC Rf = 0.21<BR> <BR> <BR> <BR> <BR> (500: 500: 5 EtOAc/hexanes/HC02H); 1H NMR (CDCl3, 300 MHz) 8.97 (s, 1H), 7.58 (m, 2H), (m, 4H), 7. 11 (m, 2H), 6.11 (m, 1H), 4.74 (m, 1H), 3.21-3. 04 (m, 2H), 2.93-2.76 (m, 1H), 2.48-1.74 (m, 5H), 1.97 (s, 3H), 1.24 (s, 3H), 0.79 (s, 3H); MS (FAB) m/z 519 (M+H) + ; Anal. C 59.41, H 5.57, Cl 13.20, N 5.31 (calcd corrected for 1.02% H2O : C 60.12, H 5.43, Cl 13.65, N 5.39).

Example 89: Teaching Scheme B Teaching Scheme B exemplifies the practice of Scheme 1 by teaching the synthesis of Example 89 where (with reference to structure 1-F) R4 is 3 hydroxyethyl), m and n equal 1, Zx and Zy are CH, Y is- NHC (O)-, X is 2,6-dichlorc, the stereochemistry of the

cycloalkanoyl segment is [1S- (la, 3a)], and the stereochemistry of the amidoacid is L. Example 89 exemplifies a change in the functionality of R9 where the acetyl substituent (1-E, R is acetyl) is reduced (1-E, R4 is 1-hydroxyethyl) prior to the preparation of <BR> <BR> <BR> <BR> <BR> 1-F.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> [1S-(1α,3α)]-4-[(2,6-Dichlorobenzoyl)amino]-N-[[3-(1-hydro xyethyl)- 2,2-dimethylcyclobutyl] acetyl]-L-phenylalanine methyl ester (C27H3oCl2N205, B-1). To a solution of A-5 (0.503 g, 0.94 mmol) in THF at 0 °C under Ar is added solid NaBH4 (0.242 g, 6.47 mmol). The reaction mixture is stirred for 4 h at 0 °C. It is stored overnight at-20 °C, and then stirred for 1 h additional at 0 °C. The reaction mixture is poured into a cold mixture of aq 1 M HC1 and brine, and extracted with CH2Cl2. The combined CH2C12 extracts are washed with brine, dried, filtered and concentrated to give a white foam. This foam is purified by silica flash chromatography to give <BR> <BR> <BR> B-1: TLC Rf = 0.33 (95: 5 CH2CI2/MeOH); 1H NMR (CDCl3, 300 MHz) 8 9.26 (s, 1H), 7.59 (m, 2H), 7.33-7.21 (m, 1H), 7.25 (m, 2H), 7.03 (m, 2H), 6.07 (m, 1H), 4.85-4.74 (m, 1H), 3.68 (s, 3H), 3.66-3.52 (m, 1H), 3.12-2.94 (m, 2H), (m, 5H), 1.94-1.83 (m, 1H), 1.76- 1.57 (m, 1H), 1.06 (s, 3H), 0.97 (m, 3H), 0.95 (s, 3H); 13C NMR (CDCl3, 75 MHz) 8 162. 61, 64,132.47, 132.18,130.51,129.75,127.96,120.39,68.94,52.98,52.30,50.26, MS (FAB) m/z 535 (M + H) +. <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> [1S-(1α,3α)]-4-[(2,6-Dichlorobenzoyl)amino]-N-[[3-(1-hydro xyethyl)- 2, 2-dimethylcyclobutyl] acetyl]-L-phenylalanine (C26H30Cl2N2O5, Example 89). Example 89 is prepared from B-1 as described for Example 88: mp 145-149 °C; TLC Rf = 0.49 (750: 250: 5 EtOAc/hexanes/HCO2H); 1H NMR (CDCl3, 300 MHz) 8 9.21 (s, 1H), 7.60 (m, 2H), 7.27 (m, 3H), 7.09 (m, 2H), 6.06 (m, 1H), 4.72 (m, 1H), 3.61 (m, 1H), 3.09 (m, 2H),

(m, 2H), 1.99 (s, 3H), 1. 87 (m, 1H), 1.68 (m, 1H), 1.20 (m, 1H), 1. 05 (s, 3H), 0.97 (m, 3H), 0.94 (s, 3H); MS (FAB) m/z 523,52i (M+H) ; Anal. C 59.03, H 5.96, Cl 13.20, N 5.27 (calcd for 1.0% H20: C 59.28, H 5.85, Cl 13.46, N 5.32).

Scheme 2 Another method for the synthesis of general structure 1-F is given in Scheme 2, whereby the change of the R may be accomplished at the point of structure 1-B. The R 4functionality of 1-B is changed (such as by oxidation, reduction, substitution, epimerization, and/or degradation) to give 2-C. The nitro substituent of structure 2-C is reduced to the amine 2-D, that may be substituted to give 2- E, that is hydrolyzed to structure 1-F.

Example 90: Teaching Scheme C Teaching Scheme C exemplifies the practice of Scheme 2 by teaching the synthesis of Example 90 where (with reference to structure 1-F) R4 is 3-carboxy, m and n equal 1, Zx and Zy are CH, Y is-NHC (O)-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment <BR> <BR> <BR> is (15-cis), and the stereochemistry of the amidoacid isL.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> (lS-cis)-N- [ [ [3- (1-Methoxy-1-oxomethyl)]-2,2-dimethylcyclobutyl]- acetyl]-4-nitro-L-phenylalanine methyl ester (C2oH26N20, C-1). The haloform degradation of the methyl ketone is carried out as described by Fernandez et al. (Fernandez, F.; Lopez, C.; Hergueta, A. R. Tetrahedron To a solution of 1 M aq NaOH (18.4 mL) at 0 °C under Ar is added dropwise Br2 (0.22 mL, 4.2 mmol). This mixture is stirred for 30 min beyond the time that all of the Br2 has dissolved. At this time a solution of A-3 (0.405 g, 1.04 mmol) in dioxane (2 mL) is added slowly. The reaction mixture

is stirred for 1 h at 0 °C and at room temperature for 2 h. It is cooled to 0 °C and quenched with aq 1 M NaHS03. The solution is extracted with Et20, and the Et20 extracts are discarded. The alkaline aqueous solution is acidified with conc aq HC1, and extracted with EtOAc. The combined EtOAc extracts are dried, filtered and concentrated to an off-white solid. To this solid, dissolved in 3: 1 EtOAc/THF, is added excess ethereal CH2N2. The yellow solution is stirred for 30 min at 0 °C. The excess CH2N2 is removed by an N2 stream. The resulting solution is concentrated to give a pale-yellow colored oil that is purified by silica flash to give C-1: TLC Rf = 0.36 (1: 1 EtOAc/hexanes); 1H NMR (CDCl3, 300 MHz) <BR> <BR> <BR> b 8.15 (m, 2H), 7.28 (m, 2H), 5.94 (m, 1H), 4.91 (m, 1H), 3.74 (s, 3H), 3.65 (s, 3H), 3.28 (m, 1H), 3.15 (m, 1H), 2.73 (m, 1H), 2.37- 1.84 (m, 5H), 1.19 (s, 3H), 0.89 (s, 3H); 1'C NMR (CDC13,75 MHz)# 173.26,171.52,147.22,143.82,130.15,123.74,60.21,52.77, 29.96,24.50, 17.87; MS (EI) m/z 406 (M+).

(lS-cis)-N-[[3-(1-Methoxy-l-oxomethyl)-2, 2-dimethylcyclobutyl]- acetyl]-4-amino-L-phenylalanine methyl ester (C20H28N2O5, C-2). <BR> <BR> <BR> <P>Hydrogenation of C-1 as described for A-4 provides C-2: TLC Rf =<BR> <BR> <BR> <BR> 0.17 (1: 1 EtOAc/hexanes); 1H NMR (CDC1 ;, 300 MHz) 8 6.87 (m, 2H), 6.65 (m, 2H), 5.85 (m, 1H), 4.79 (m, 1H), 3.71 (s, 3H), 3.65 (s, 3H), 3.47 (s, 1H), 3.07-2.89 (m, 4H), 2.72 (m, 1H), 2.38-1.83 (m, 4H), 1.18 (s, 3H), 0.88 (s, 3H); 13C NMR (CDC13,75 MHz) 8 173.39, 172.29,171.40,144.70,130.12,125.99,115.74,53.15,52.28, 51.23,46.15,42.73,38.62,37.51,37.06,29.88,24.61,17.89; MS (EI) m/z 376 (Mt).

(1S-cis)-N-[[3-(1-Methoxy-1-oxomethyl)-2,2-dimethylcyclobuty l)- acetyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C27H30C12N2O6, C-3). Amine C-2 is acylated, as described for A-5, to provide C-3 as a beige-colored solid: TLC Rf = 0.32 (1: 1

EtOAc/hexanes); H NMR (CDCl3, 300 MHz) 6 9.92 (s, 1H), 7.59 (m, 2H), 7.27 (m, 2H), 7.35-7.11 (m, 1H), 7.02 (m, 2H), 6.70 (m, 2H), 4.70 (m, 1H), 3.64 (s, 3H), 3.55 (s, 3H), 3.06-2.89 (m, 2H), 2.62 (m, 1H), 2.13-2.04 (m, 3H), (m, 2H), 1.09 (s, 3H), 0.82 (s, 3H) i l3C NMR (CDC13,75 MHz) 5 172.82,171.70,171.34,162.23, 136.87,136.45,131.97,131.87,130.01,129.23,127.49,119.97, 52.75,51.78,50.69,45.66,42.35,38.31, 36.71, 29.44,24.11, 17.33; MS (FAB) m/z 549 (M+H) +.

(lS-cis)-N- [ (3-Carboxy-2,2-dimethylcyclobutyl) acetyl]-4-[(2,6- dichlorobenzoyl) amino]-L-phenylalanine (C25H26Cl2N206, Example 90).

Ester C-3 is saponified (as described for Example 88) to give Example 90 as an off-white solid: mp 143-146 °C; TLC Rf = 0.32 (750: 250: 5 EtOAc/hexanes/HCO2H); [a] 25D +4 (c 0.8, MeOH); IH NMR (CDCl3, 300 MHz) 8 8.96 (s, 1H), 7.57 (m, 2H), 7.32-7.21 (m, 3H), 7.12 (m, 2H), 6.16 (m, 2H), 4.84-4.72 (m, 1H), 3. 14-3. 06 (m, 2H), 2.72-2.61 (m, 1H), 2.42-1.78 (m, 5H), 1.16 (s, 3H), 0.93 (s, 3H); MS (FAB) m/z 521 (M+H) + ; Anal. C 56.55, H 5.09, Cl 13.27, N 5.03 (calcd for 1.49% H20: C 57.59, H 5.03, Cl 13.60, N 5.37).

Example 91: Teaching Scheme D Teaching Scheme D exemplifies the practice of Scheme 1 by teaching the synthesis of Example 91 where (with reference to structure 1-F) R4 is 3-acetyl, m and n equal 1, Zx and Zy are CH, Y is-NHC (O)-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment is (lR-cis), and the stereochemistry of the amidoacid is L. <BR> <BR> <P>(lR-cis)-3-Acetyl-2,2-dimethylcyclobutane acetic acid [52305-34-7] (CioHi603, D-2). This material was prepared as described by Wolk et al. (Wolk, J. L.; Goldschmidt, Z.; Dunkelblum, E. Synthesis 1986, 347-348) from (-)-a-pinene D-1.

(lR-cis)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) acetyl]-4-nitro-L- phenylalanine methyl ester (C20H26N2O6, D-3). This compound is prepared from D-2 and Compound 3 by the procedure taught for A-3: TLC Rf = 0.32 (1: 1 MHz) 5 8.15 (m, 2H), 7.29 (m, 2H), 5.95 (m, 1H), 4.90 (m, 1H), 3.74 (s, 3H), 3.28 (m, 1H), 3.15 (m, 1H), 2.86 (m, 1H), 2.39-1.83 (m, 5H), 2.06 (s, 3H), 1.27 (s, 3H), 0.80 (s, MHz) 8 207.50, 171.56,175.48,147.21,143.89,130.19,123.73,54.16,52.73, 20,22.98,17.43.

(lR-cis)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) acetyl]-4-amino-L- phenylalanine methyl ester (C2oHz8N204, D-4). This compound is prepared by the procedure taught for A-4: TLC Rf = 0.11 (1: 1 EtOAc/hexanes); 1H NMR (CDC13,300 MHz) 5 6.86 (m, 2H), 6.62 (m, 2H), 5.80 (m, 1H), 4.78 (m, 1H), 3.71 (s, 3H), 3.95-3.17 (m, 2H), 3.05-2.91 (m, 2H), 2.85 (m, 1H), 2.27 (m, 1H), 2.24-1.82 (m, 4H), 2.07 (s, 3H), 1.28 (s, 3H), 0.82 (s, 3H); MS (FAB) m/z 361 (M+H) +.

(lR-cis)-N-[(3-Acetyl-2, 2-dimethylcyclobutyl) acetyl]-4-[(2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C27H30Cl2N2O5, D- 5). This compound is prepared by the procedure taught for D-5: TLC Rf = 0.16 (1: 1 EtOAc/hexanes); 1H NMR (CDCl3, 300 MHz) 8 9.32 (s, 1H), 7.59 (d, 2H, J = 8.5), 7.32-7.20 (m, 1H), 7.26 (d, 2H, J = 8.4), 7.03 (d, 2H, J = 8.4), 6.24 (d, 1H, J = 7.9), 4.77 (m, 1H), 3.67 (s, 3H), 3.10-2.93 (m, 2H), 2.79 (dd, 1H, J = 4), 2.28-1.74 (m, 5H), 1.98 (s, 3H), 1.21 (s, 3H), 0.75 (s, 3H); MS (FAB) m/z 533 (M+H) +.

(1R-cis)-N-[(3-Acetyl-2,2-dimethylcyclobutyl)acetyl]-4-[( 2,6- dichlorobenzoyl) amino]-L-phenylalanine (C26H28C12N205, Example 91).

This compound is prepared by the procedure taught for Example 88:

mp 127-130 °C ; TLC Rf = 0.21 (500: 500: 5 EtOAc/hexanes/HCO2H); 1H NMR (CDCl3, 300 MHz) 8 8.84 (s, 1H), 7.58 (m, 2H), 7.33-7.22 (m, 1H), 7.27 (m, 2H), 7.12 (m, 2H), 6.10 (m, 1H), 4.76 (m, 1H), 3.19-3.02 (m, 2H), 2.81 (m, 1H), 2.30-1.78 (m, 5H), 1.98 (s, 3H), 1.22 (s, 3H), 0.77 (s, 3H); MS (FAB) m/z 519 (M+H) + ; Anal. C 59.65, H 5.45, Cl 13.78, N 5.23 (calcd for 0.75% H20: C 59.67, H 5.48, Cl 13.78, N 5.35).

Example 92: Teaching Scheme E Teaching Scheme E exemplifies the practice of Scheme 1 by teaching the synthesis of Example 92 where (with reference to structure 1-F) R4 is 3- ('-hydroxyethyl),('-hydroxyethyl), m and n equal I-, Zx and Zy are CH, Y is- NHC (O)-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment is [lR- (la, 3a) ;, and the stereochemistry of the amidoacid is L. Example 92 exemplifies a change in the functionality of R where the acetyl substituent (1-E, R4 is acetyl) is reduced (1-E, R4 is 1-hydroxyethyl) prior to the preparation of <BR> <BR> <BR> <BR> 1-F.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> [1R-(1α,3α)]-4-[(2,6-Dichlorobenzoyl)amino]-N-[[3-(1-hydro xyethyl)- 2,2-dimethylcyclobutyl] acetyl]-L-phenylalanine methyl ester (C2nH32Cl2N2O5 E-1). This compound is prepared from compound D-5 by the procedure taught for B-1: TLC If = 0. 34 (97: 3 CH2Cl2/MeOH); 1H NMR (CDC13,300 MHz) 8 7.57 (m, 2H), 7.52 (s, 1H), 7.39-7. 23 (m, 4H), 7.10 (m, 2H), 5.83 (m, 1H), 4.89-4.82 (m, 1H), 3.78-3.63 (m, 1H), 3.75 (s, 3H), 3.18-3.06 (m, 2H), 2.24-1.86 (m, 4H), 1.78-1.68 (m, 1H), 1.20-1.05 (m, 1H), 1.13 (s, 3H), 1.02 (m, 3H), 0.97 (s, 3H); MS (FAB) m/z 535 (M+H) +. <BR> <BR> <BR> <BR> <BR> <BR> <P>[1R-(1α,3α)]-4-[(2,6-Dichlorobenzoyl)amino]-N-[[3 -(1-hydroxyethyl)- Example2,2-dimethylcyclobutyl]acetyl]-L-phenylalanine(C26H30 Cl2N2O5,

92). This compound is prepared from compound E-1 by the procedure taught for Example 88: TLC Rf = 0.50 (750: 250: 5 EtOAc/hexanes/HCO2H); IH NMR (CDCl3, 300 MHz) 6 8.87 (s, 1H), 7.57 (m, 2H), 7.34-7.22 (m, 4H), 7.13 (m, 2H), 6.02 (m, 1H), 4. 76 (m, 1H), 3.63 (m, 1H), 3.15-3.07 (m, 2H), 2.25-1.83 (m, 4H), 1.77-1. 54 (m, 1H), 1.17-1.03 (m, 1H), 1.07 (s, 3H), 0.98 (m, 3H), 0.94 (s, 3H); MS (FAB) m/z 521 (M+H) + ; Anal. C 59.16, H 5.95, Cl 13.25, N 5.36 (calcd for 1.48% H2O : C 59.00, H 5.88, Cl 13.40, N 5.29).

Example 93: Teaching Scheme F Teaching Scheme F exemplifies the practice of Scheme 2 by teaching the synthesis of Example 93 where (with reference to structure 1-F) R4 is 3-carboxy, m and n equal 1, Zx and Zy are CH, Y is-NHC (O)-, X is 2,6-dichloro, the stereochemistry of the cycioalkanoyl segment is (lR-cis), and the stereochemistry of the amidoacid is L.

(1R-cis)-N-[[[3-(1-Methoxy-1-oxomethyl)]-2,2-dimethylcyclobu tyl]- acetyl]-4-nitro-L-phenylalanine methyl ester (C20H26N2O7, F-1). This compound is prepared from compound D-3 by the procedure taught for C-1: TLC Rf = 0.36 (1: 1 EtOAc/hexanes);'H NMR (CDC13,300 MHz) 8 8.15 (m, 2H), 7.28 (m, 2H), 5.91 (m, 1H), 4.91 (m, 1H), 3.74 (s, 3H),. 3.65 (s, 3H), 3.29 (m, 1H), 3.16 (m, 1H), 2. 73 (m, 1H), 2.37- 2.03 (m, 4H), 1.92 (m, 1H), 1.18 (s, 3H), 0.83 (s, 3H); MS (FAB) m/z 407 (M+H) +.

(lR-cis)-N- [ [3- (1-Methoxy-1-oxomethyl)-2,2-dimethylcyclobutyl]- acetyl]-4-amino-L-phenylalanine methyl ester (C20H28N205, F-2). This compound is prepared from compound F-1 by the procedure taught for A-4: TLC Rf = 0.31 (3: 1 MHz) 6 6.87 (m, 2H), 6.64 (m, 2H), 5.81 (m, 1H), 4.79 (m, 1H), 3.78-3.28 (m, 2H), 3.71 (s, 3H), 3.65 (s, 3H), 2.99 (t, 2H, J = 5.6), 2.71

(dd, 1H@ J = 10.3,2.3), 2.33-2.02 (m, 4H), 1.91 (dd, 1H, J = 11.2, 10.3), 1.18 (s, 3H), 0.88 (s, 3H); MS (FAB) m/z 377 (M+H) +, 345, 316,195,177,135,106,95. <BR> <BR> <BR> <BR> <BR> <P> (lR-cis)-N-[[3-(1-Methoxy-1-oxomethyl)-2,2-<BR> <BR> <BR> <BR> <BR> dimethylcyclobutyl) acetyl]-4- [(2, 6-dichlorobenzoyl) amino]-L- phenylalanine methyl ester (C27H30C12N2o6, F-3). This compound is <BR> <BR> <BR> prepared from compound F-2 by the procedure taught for A-5: TLC Rf<BR> <BR> <BR> <BR> = 0.34 (1: 1 EtOAc/hexanes); 1H NMR (CDCl3, 300 MHz) 8 7.57 (m, 2H), 7.29-7.17 (m, 3H), 7.01 (m, 2H), 6.36 (s, 1H), 4.71 (m, 1H), 3.63 (s, 3H), 3.54 (s, 3H), 2.93 (m, 2H), 2.61 (m, 1H), 2.24-1.78 (m, 5H), 1.16 (s, 3H), 0.77 (s, 3H).

(lR-cis)-N- [ [3- (l-Methoxy-l-oxomethyl)-2,2- dimethylcyclobutyl) acetyl]-4- [ (2, 6-dichlorobenzoyl) amino]-L- phenylalanine (C27H30Cl2N2O4, F-4). To a solution of diester F-3 (0.603 g, 1.10 mmol) in 4: 1 THF/MeOH (28 mL) at room temperature under Ar is added a solution of LiOH-H20 (0.120 g, 2.86 mmol) in H20 (5.6 mL), followed by 30% aq H202 (1.2 mL). The reaction is stirred for 20 h. It is concentrated in vacuo, and the residue is taken up in H20 (45 mL). The aqueous solution is acidified with aq 1 M HC1 (12 mL), and extracted with EtOAc. The combined EtOAc extracts are washed with brine, dried, and concentrated to give F-4 as an off- white foam: TLC Rf = 0.46 (750: 250: 5 EtOAc/hexanes/HCO2H); 1H NMR (CDC13,300 MHz) 8 8.90 (s, 1H), 7.58 (m, 2H), 7.34-7.21 (m, 4H), 7.12 (m, 2H), 6.09 (m, 1H), 4.75 (m, 1H), 3.60 (s, 3H), 3.22-2.98 (m, 2H), 2.67 (m, 1H), 2.37-1.78 (m, 6H), 1.15 (s, 3H), 0.83 (s, 3H).

(lR-cis)-N- [ (3-Carboxy-2,2-dimethylcyclobutyl) acetyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine (C2oH26C12N206, Example 93). To a solution of ester F-4 (0.569 g, 1.10 mmol) in 4: 1 THF/MeOH (28.3 mL) at room temperature under Ar is added a solution of LiOH#H2O

(0.120 g, 2.86 mmol) followed by 30% aq H202 (1.2 mL). The reaction is stirred for 90 h, at which time additional portions of LiOH-H20 (0.120 g, 2.86 mmol) and 30% aq H202 (1.2 mL) are added. The reaction mixture is stirred for 18 h. It is concentrated in vacuo, and the residue is taken up in ice water (90 g). The solution is acidified with aq 1 M HC1 and is extracted with EtOAc. The combined EtOAc extracts are washed with brine, dried, and concentrated to give a cream-colored solid. The solid is dissolved in MeCN (15 mL), and the solution is diluted with H20 (15 mL). The solution is frozen and lyophilized to give Example 93: mp 138-141 °C; TLC Rf = <BR> <BR> <BR> 0.29 (750: 250: 5 EtOAc/hexanes/HCO2H); 1H NMR (CDC13,300 MHz) 5 9.24 (s, 1H), 7.56 (m, 2H), 7.31-7.19 (m, 4H), 7.09 (m, 2H), 6.13 (m, 1H), 4.73 (m, 1H), 3.17-2.96 (m, 2H), 2.64 (m, 1H), 3.17-2.96 (m, 2H), 2.64 (m, 1H), 2.34-2.03 (m, 5H), 1.83 (m, 1H), 1.13 (s, 3H), 0.90 (s, 1H); MS (FAB) m/z 523,521 (M+H) +; Anal. C 56.38, H 5.14, Cl 13.20, N 5.07 (calcd for 1.27% H20: C 58.86, H 5.11, Cl 13.43, N 5.30).

Scheme 3 Another method for the preparation of general structure 1-F is given in Scheme 3. In this general scheme a heteroatom-substituted (W equals OH or NH2) arylamidoester (or heteroarylamidoester) 3-A, by standard synthetic methods is alkylated (W equals OH) or acylated (W equals NH2) to give 3-B. The N-terminus of 3-B is deprotected to 3-C, that is acylated with 1-A to provide 3-D. The functionality of R4 may be changed (such as by oxidation, reduction, substitution, epimerization, and/or degradation) by standard synthetic methods. Hydrolysis of 3-D gives the amidoacid 1-F.

Examples 94 & 95: Teaching Scheme G Teaching Scheme G exemplifies the practice of Scheme 3 by teaching the synthesis of Examples 94 and 95 where (with reference to structure 1-F) for Example 94 R4 is 3-carboxy, m equals 1, n equals 0, Zx and Zy are CH, Y is-OCH2-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment is (lS-trans), and the stereochemistry of the amidoacid is L; and for Example 95 R4 is 3- carboxy, m equals 1, n equals 0, Zx and Zy are CH, Y is-OCH2-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment is (1S-cis), and the stereochemistry of the amidoacid is L. Examples 94 and 95 exemplify changes in the functionality R4.

(1S-cis)-3-Acetyl-2, 2-dimethylcyclobutanecarboxylic acid CgH14O3.

G-2). Compound G-2 is prepared from commercial (-)-verbenone G-1 as taught by Carlson et al. (Carlsen, P. H. J.; Katsuki, T.; Martin, V. S.; Sharpless, K. B. J. Org. Chem. ; Carlsen, P. H. J.; Odden, W. Acta Chem. Scand. 1984,38B, 501-504) and Webster et al. (Webster, F. X.; Rivas-Enterrios, J.; Silverstein, R. M. J. Org. Chem. 1987,52,689-691). Compound G-2, obtained by these procedures, is purified by silica chromatography and crystallized from 4: 1 hexanes/EtOAc to give G-2 in excellent enantiomeric purity: mp 133-i34 °C; TLC (750: 250: 2.5 EtOAc/hexanes/HC02H) Rf = 0.25; [«] D25-73.7 (c 1.0, CHC13); 13C NMR (75 MHz, CDC13) 8 99,44.94,30.29,29.99, 18.81,18.02; MS (FAB) m/z 171 [M + H]+ ; Anal. C 63.68, H 8.32 (calcd C 63.51, H 8.29).

(lS-cis)-N- [ (3-Acetyl-2, 2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorophenyl) methoxy]-L-phenylalanine methyl ester (C26H29Cl2NO5, G-3): Compound G-3 is obtained from compound G-2 and Compound 7 as taught by the preparation of compound A-3: TLC (3: 1 EtOAc/hexanes)

Rf = 0.50; 1H NMR (300 MHz, CDC13) 8 7.37 (m, 2H), 7.23 (m, 1H), 7.05 (m, 2H), 6.96 (m, 2H), 5.79 (m, 1H), 5.25 (s, 2H), 4.87 (m, 1H), 3.73 (s, 3H), 3.09 (m, 2H), 2.85 (m, 1H), 2.64 (m, 1H), 2.52 (m, 1H), 2.05 (s, 3H), 1.89 (m, 1H), 1.42 (s, 3H), 0.82 (s, 3H); MS (FAB) m/z 506 [M + H] +.

(lS-trans)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorophenyl) methoxy]-L-phenylalanine (C25H27C12NO5, G-4) and (1S- cis)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4-[(2,6- dichlorophenyl) methoxy]-L-phenylalanine (C25H27Cl2NO5, G-5): To a solution of G-3 (1.23 mmol) in 4: 1 THF/MeOH (32 mL), under Ar at room temperature, is added a solution of LiOH-H2O (0.121 g, 2.87 mmol) in H20 (6.3 mL). The reaction mixture is stirred at room temperature for 120 min. It is diluted with ice-cold H20 (55 mL) and acidified with aq HC1 to a pH of 2-3. The resulting mixture is extracted with EtOAc. The combined EtOAc portions are washed with brine, and are dried and concentrated to give a beige-colored foam.

This material is purified by silica chromatography to separate G-4 and G-5.

G-4: mp 84-86 °C; TLC (750: 250: 5 EtOAc/hexanes/HC02H) Rf = 0.43 ; 3C NMR (75 MHz, 10: 1 CDC13/CD3SOCD3) 8 C: 207.00,173.01,170.52, 162.38,136.48,136.26,132.60,132.23,44.66; CH: 130.40,129.86, 127.80,120.21,52.78,52.62,46.18; CH2: 37.05,18.76; CH3: 30.44, 29.81,17.48; MS (FAB) m/z 492 [M + H] +; Anal. C 60.79, H 5.56, Cl 13.94, N 2.81 (calcd for 0.57% H20: C 60.64, H 5.56, Cl 14.32, N 2.83).

G-5: mp 86-88 °C; TLC (750: 250: 5 EtOAc/hexanes/HCO2H) Rf = 0.30 ; 3C NMR (75 MHz, 10: 1 CDC13/CD3SOCD3) C: 171.84, 162.19,136.64,136.41,132.22,131.95,42.42; CH: 131.87,129.50, 128.60,119.89,53.13,52.59,46.45; CH2: 36.69,18.25; CH3: 30.21, 24.93,24.68; MS (FAB) m/z 492 [M + H] + ; Anal. C 60.15, H 5.76, Cl 14.40, N 2.85 (calcd for 0.84% H20: C 60.47, H 5.58, Cl 14.28, N 2.82).

(lS-trans)-N-[(3-Carboxy-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorophenyl) methoxy]-L-phenylalanine (C24H25Cl2NO6, Example 94): Example 94 is prepared by haloform degradation of G-4 as taught for compound C-1: mp 94-96 °C; TLC (500: 500: 2.5 EtOAc/hexanes/HCO2H) Rf = 0.33; [a] D25 +14 (c 0.96, MeOH); 1H NMR (300 MHz, CDC13) 8 7.34 (m, 2H), 7.26-7.19 (m, 2H), 7.09 (m, 2H), 6.93 (m, 2H), 5.81 (m, 1H), 5.22 (s, 2H), 4.93 (m, 1H), 3.13 (m, 2H), 2.93 (m, 1H), 2.71 (m, 1H), 2.32 (m, 2H), 1.19 (s, 3H), 1.14 (s, 3H); MS (EI) m/z 493 (M+); Anal. C 54.85, H 5.20, Cl 13.39, N 2.65 (calcd for 2.65% H20: C 55.76, H 5.26, Cl 13.96, N 2.76).

(lS-cis)-N-[(3-Carboxy-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorophenyl) methoxy]-L-phenylalanine (C24H25Cl2NO6, Example 95): Example 95 is prepared by haloform degradation of G-5 as taught for compound C-1: mp 116-118 °C; TLC (120: 40: 1 EtOAc/hexanes/HC02H) Rf = 0.27; 1H NMR (300 MHz, CDC13) 8 7.31 (m, 2H), 7.22 (m, 3H), 7.09 (m, 2H), 6.89 (m, 2H), 6.00 (s, 1H), 5.18 (s, 2H), 4.71 (m, 1H), 3.07 (m, 2H), 2.58 (m, 3H), 2.08 (m, 3H), 1.28 (s, 3H), 0.93 (s, 3H); 13C NMR (75 MHz, CDC13) 5 179.00,178.09,175.79,162.48,141.63,136.84, 11, 48.62,41.62,35.11,24.88,22.71.

Examples 96,97 and 98: Teaching Scheme H Teaching Scheme H exemplifies the practice of Scheme 1 by teaching the synthesis of Examples 96,97 and 98 where (with reference to structure 1-F) for Example 96 R4 is 3-acetyl, m equals 1, n equals 0, Zx and Zy are CH, Y is-NHC (O)-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment is (lS-trans), and the stereochemistry of the amidoacid is L; for Example 97 R4 is 3- acetyl, m equals 1, n equals 0, Zx and Zy are CH, Y is-NHC (O)-, X

is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment <BR> <BR> <BR> <BR> is (lS-cis), and the stereochemistry of the amidoacid is L; and for Example 98 R is 3-carboxy, m equals 1, n equals 0, Zx and Zy are CH, Y is-NHC (O)-, X is 2,6-dichloro, the stereochemistry of the <BR> <BR> <BR> <BR> cycloalkanoyl segment is (lS-trans), and the stereochemistry of the amidoacid is L.

(lS-c. is)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4-nitro-L- phenylalanine methyl ester (ClgH24N2O6, H-1): Compound G-2 and Compound 3 are coupled, as taught for compound A-3, to give compound H-1: 1H NMR (300 MHz, CDC13) 8 8.16 (m, 2H), 7.31 (m, 2H), 5.94 (m, 1H), 4.94 (m, 1H), 3.74 (s, 3H), 3.28 (m, 1H), 3.16 (m, 1H), 2.88 (m, 1H), 2.65 (m, 1H), 2.51 (m, 1H), 2.05 (s, 3H), 1.91 (m, 1H), 1.42 (s, 3H), 0.79 (s, 3H); 13C NMR (75 MHz, CDC13) 8 206.94,171.56,170.91,147.20,143.82,130.13,123.74,52.88, 52.64,52.49,46.47,44.70,38.20,30.74,30.11,18.85,17.71.

(lS-cis)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4-amino-L- phenylalanine methyl ester (ClgH26N2O4 H-2). Compound H-2 is prepared from compound H-1 as taught for the preparation of compound A-4: TLC (3: 1 EtOAc/hexanes) Rf = 0.28; 1H NMR (300 MHz, CDC13) 8 6.89 (m, 2H), 6.64 (m, 2H), 5.75 (m, 1H), 4.81 (m, 1H), 3.71 (s, 3H), 3.50 (m, 2H), 2.99 (m, 2H), 2.83 (m, 1H), 2.62 (m, 1H), 2.48 (m, 1H), 2.05 (s, 3H), 1.88 (m, 1H), 1.41 (s, 3H), 0.85 (s, 3H); 13C NMR (75 MHz, CDC13) 6 207.04,172.26,170.65,145.12, 130.05,125.64,115.55,52.98,52.79,52.23,46.40,44.87,37.31, 30.65,30.03,19.05,17.57; MS (FAB) m/z 347 [M + H] +.

(lS-cis)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C26H28C12N205, H- 3): Compound H-3 is prepared from compound H-2 as taught for the preparation of compound A-5: TLC (3: 1 EtOAc/hexanes) Rf = 0.36; 1H

NMR (300 MHz, CDCl3) 8 7.58 (m, 2H), 7.50 (s, 1H), 7.32 (m, 3H), 7.13 (m, 2H), 5.81 (m, 1H), 4.88 (m, 1H), 3.74 (s, 3H), 3.11 (m, 2H), 2.85 (m, 1H), 2. 63 (m, 1H), 2.52 (m, 1H), 2.03 (s, 3H), 1.89 (m, 1H), 1.42 (s, 3H), 0.83 (s, 3H); MS (FAB) m/z 519 [M + H] +.

(lS-trans)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine (C25H26Cl2N205, Example 96) and (lS-cis)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine (C25H26Cl2N2O5, Example 97).

The mixture of Examples 96 and 97, prepared as taught for Examples G-4 and G-5, are separated and purified by silica chromatography.

Example 96: mp 146-148 °C; TLC (750: 250: 5 EtOAc/hexanes/HCO2H) Rf = 0.28; [a] D25 +43 (c 0.86, MeOH); 13C NMR (75 MHz, CDC13) 8 208.12, 172.83,171.84,162.20,136.64,136.41,132.22,131.96,129.98, 129.50,127.48,120.92,119.89,53.13,52.59,46.45,42.42,36.87, 30.21,24.93,24.68,18.25; Anal. C 58.14, H 5.53, Cl 13.36, N 5.22 (calcd for 1.59% H20: C 58.47, H 5.28, Cl 13.81, N 5.46).

Example 97: mp 158-160 °C ; TLC (750: 250: 5 EtOAc/hexanes/HCO2H) Rf = 0.16; [a] D25-8 (c 0.92, MeOH); 13 C NMR (75 MHz, CDC13) 8 207.00, 173.01,170.52,162.38,136.48,136.26,132.60,132.24,130.40, 129.86,127.80,120.21,115.22,52.78,52.62,46.18,44.66,37.05, 30.44,29.81,18.76,17.48; MS (FAB) m/z 505 [M + H]; Anal. C 58.14, H 5.53, Cl 13.36, N 5.22 (calcd for 1.39% H20: C 58.53, H 5.27, Cl 13.82, N 5.46). <BR> <BR> <BR> <BR> <BR> <BR> <P> (lS-trans)-N- [ (3-Carboxy-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine (C24H24C12N2O6, Example 98).

Example 98 is prepared by haloform degradation of Example 96 as taught for compound C-1: mp 159-161 °C; TLC (750: 250: 5 EtOAc/hexanes/HC02H) Rf = 0.31; [ (x] D 25 +21 (c 0.79, MeOH); 13C NMR (75 MHz, CDCl3) 8 180.42,177.94,176.91,167.31,141.70,141.47, 137.22,137.11,135.16,134.68,132.90,132.63,125.02,57.62,

51.93,50.82,46.81,41.82,30.32,29.59,24.49; MS (FAB) m/z 507 [M + H] +; Anal. C 54.59, H 4.81, Cl 13.21, N 5.30 (calcd for 1.66% H20: C 55.91, H 4.87, Cl 13.75, N 5.43).

Example 35: Teaching Scheme I Teaching Scheme I exemplifies the practice of Scheme 2 by teaching the synthesis of Example 99 where (with reference to structure 1-F) R4 is 3-carboxy, m equals 1, n equals 0, Zx and Zy are CH, Y is- NHC (O)-, X is 2,6-dichloro, the stereochemistry of the <BR> <BR> <BR> <BR> cycloalkanoyl segment is (lS-cis), and the stereochemistry of the amidoacid is L.

(lS-cis)-N- [ [3- (1-Methoxy-1-oxomethyl)-2,2- dimethylcyclobutyl] carbonyl]-4-nitro-L-phenylalanine methyl ester (ClsH24N2O7 I-1): Compound H-1 is subjected to haloform degradation, as taught for compound C-1. To a solution of the resulting diacid in EtOAc at 0 °C is added an ethereal CH2N2 solution. The resulting yellow solution is stirred at 0 °C for 15 min, after which the yellow color is dissipated by the passage of an N2 stream. The solution is concentrated to provide, as a beige-colored foam, compound I-1: TLC (3: 1 EtOAc/hexanes) Rf = 0.36; 1H NMR (300 MHz, CDC13) 5 8.11 (m, 2H), 7.29 (m, 2H), 6.00 (m, 1H), 4.91 (m, 1H), 3.70 (s, 3H), 3.63 (s, 3H), 3.28 (m, 1H), 3.16 (m, 1H), 2.74 (m, 1H), 2.62 (m, 1H), 2.48 (m, 1H), 2.00 (m, 1H), 1.28 (s, 3H), 0.82 (s, 3H); MS (FAB) m/z 393 [M + H] +.

(15-cis)-4-Amino-N- [ [3- (l-methoxy-l-oxomethyl)-2,2- dimethylcyclobutyl]-carbonyl]-L-phenylalanine methyl ester (ClgH26N2O5, I-2): Compound I-2 is prepared from compound I-1 as taught for the preparation of compound A-4: TLC (3: 1 EtOAc/hexanes) <BR> <BR> <BR> Rf = 0.17; 1H NMR (300 MHz, CDC13) 5 6.91 (m, 2H), 6.68 (m, 2H), 5.72

(m, 1H), 4.82 (m, 1H), 3.71 (s, 3H), 3.67 (s, 3H), 3.48 (s, 2H), 3.01 (m, 2H), 2.75 (m, 1H), 2.62 (m, 1H), 2.51 (m, 1H), 2.02 (m, 1H), 1.31 (s, 3H), 0.91 (s, 3H); 13C NMR (75 MHz, CDC13) 8 172.64, 25, 95; MS (FAB) m/z 363 [M + H] +.

(1S-cis)-4-[(Dichlorobenzoyl)amino]-N-[[3-(1-methoxy-1-oxome thyl)- 2,2-dimethylcyclobutyl] carbonyl]-L-phenylalanine methyl ester (C26H28C12N206, I-3): Compound I-3 is prepared from compound I-2 as taught for the preparation of compound A-5: TLC (3: 1 EtOAc/hexanes) Rf = 0.34; 1H NMR (300 MHz, CDC13) 8 8.17 (s, 1H), 7.57 (m, 2H), 7.30 (m, 2H), 7.07 (m, 2H), 5.84 (m, 1H), 4.83 (m, 1H), 3.70 (s, 3H), 3.62 (s, 3H), 3.07 (m, 2H), 2.72 (m, 1H), 2.53 (m, 2H), 1.28 (s, 3H), 0.85 (s, 3H).

(lS-cis)-N- [ (3-Carboxy-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine (C24H24Cl2N2O6, Example 99): Example 99 is prepared by haloform degradation of I-3 as taught for compound C-1: mp 154-156 °C; TLC (750: 250: 5 EtOAc/hexanes/HC02H) Rf = 0.26; [a] D25 +15 (c 0.85, MeOH); 13C NMR (75 MHz, CDC13) 8 174.28, 173.17,171.09,162.56,136.90,136.71,132.65,132.37,130.40, 129.91 (2C), 88, 46.67,45. 39, 43. 84, 37.17,30.41,20.05,18.05; MS (FAB) m/z 507 [M + H] +; Anal. C 55.91, H 5.22, Cl 13.01, N 5.18 (calcd for 1.76% H20: C 55.82, H 4.88, Cl 13.73, N 5.42).

Examples 100-103: Teaching Scheme J Teaching Scheme J exemplifies the practice of Scheme 3 by teaching the synthesis of Examples 100,101,102, and 103 where (with reference to structure 1-F) for Example 100 R4 is 3-acetyl, m

equals 1, n equals 0, Zx and Zy are CH, Y is-NHC (O)-, X is 2,6- <BR> <BR> <BR> <BR> dichloro, the stereochemistry of the cycloalkanoyl segment is (lR- trans), and the stereochemistry of the amidoacid is L; for Example 101 R4 is 3-acetyl, m equals 1, n equals 0, Zx and Zy are CH, Y is- NHC (O)-, X is 2,6-dichloro, the stereochemistry of the <BR> <BR> <BR> <BR> cycloalkanoyl segment is (lR-cis), and the stereochemistry of the<BR> <BR> <BR> <BR> <BR> <BR> amidoacid is L; for Example 102 R is 3-carboxy, m equals 1, n equals 0, Zx and Zy are CH, Y is-NHC (O)-, X is 2,6-dichloro, the <BR> <BR> <BR> <BR> stereochemistry of the cycloalkanoyl segment is (lR-trans), and the<BR> <BR> <BR> <BR> <BR> <BR> stereochemistry of the amidoacid is L; and for Example 103 R4 is 3- carboxy, m equals 1, n equals 0, Zx and Zy are CH, Y is-NHC (O)-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment <BR> <BR> <BR> <BR> is (lR-cis), and the stereochemistry of the amidoacid is L.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> (lR)-(+)-4,6,6-Trimethylbicyclo [3.1.1] hept-3-en-2-one [18309-32-5]<BR> <BR> <BR> <BR> <BR> <BR> <BR> (C1oH140, J-1): (lR)-Verbenone was prepared from (lR)- (+)-a-pinene<BR> <BR> <BR> <BR> <BR> <BR> <BR> (97% ee) as described by Sivik et al. ( Sivik, M. R.; Stanton, K.

J.; Paquette, L. A. Org. Synth. 1993,72,57-61): TLC (10: 1 <BR> <BR> <BR> <BR> hexanes/EtOAc) Rf = 0.23; [a] 25D +243 (c 10.2, EtOH).<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> (lR-cis)-3-Acetyl-2,2-dimethylcyclobutanecarboxylic acid [22571-78- 4] (CgHl4O3, J-2): Compound J-2 is prepared from J-1 by the procedures cited in the preparation of compound G-2: mp 134-135 °C; [a] D25 +73 (c 1.01, CHC13); MS (FAB) m/z 171 [M + H] +; Anal. C 63.59, H 8.26 (calcd C 63.51, H 8.29). <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P>(lR-cis)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6-<BR> <BR> <BR> <BR> <BR> <BR> <BR> dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C26H28Cl2N205, J- 3): Compound J-3 is obtained from compound J-2 and Compound 6 as taught by the preparation of compound A-3: TLC (3: 1 EtOAc/hexanes) <BR> <BR> <BR> <BR> Rf = 0.50; 1H NMR (300 MHz, CDC13) 8 9.37 (s, 1H), 7.59 (m, 2H), 7.26 (m, 3H), 7.05 (m, 2H), 6.08 (m, 1H), 4.79 (m, 1H), 3.67 (s, 3H),

3.06 (m, 1H), 2.96 (m, 1H), 2.78 (m, 1H), 2.51 (m, 2H), 1.98 (s, 3H), 1.79 (m, 1H), 1.32 (s, 3H), 0.71 (s, 3H); MS (EI) m/z 516 <BR> <BR> <BR> <BR> (M).<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> (lR-trans)-N-[(3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine (C25H26Cl2N2O5, Example 100) <BR> <BR> <BR> <BR> and (lR-cis)-N-[(3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorobenzoyl)-amino]-L-phenylalanine (C25H26Cl2N2O5, Example 101): These compounds are prepared and separated as taught for the preparation of compounds G-4 and G-5.

Example 100: mp 194-196 °C; TLC (750: 250: 5 EtOAc/hexanes/HCO2H) Rf = 0.49; [a] D25-18 (c 0.92, MeOH); 1H NMR (300 MHz, CDCl3) 8 9.63 (s, 1H), 7.51 (m, 2H), 7.20 (m, 3H), 7.06 (m, 2H), 6.25 (m, 1H), 4.71 (m, 1H), 3.00 (m, 3H), 2.42 (m, 2H), 2.20 (m, 1H), 2.01 (m, 1H), 1.91 (s, 3H), 0.98 (s, 3H), 0.93 (s, 3H); MS (EI) m/z 504 (M+); Anal. C 58.80, H 5.14, Cl 13.05, N 5.54 (calcd for 1.46% H20: C 58.56, H 5.28, Cl 13.80, N 5.45).

Example 101: mp 208-209 °C; TLC (600: 400: 5 EtOAc/hexanes/HC02H) Rf = 0.35; [a] D25 +59 (c 0.96, MeOH); 1H NMR (300 MHz, CDCl3) 8 8.89 (s, 1H), 7.57 (m, 2H), 7.28 (m, 2H), 7.12 (m, 2H), 6.01 (m, 1H), 4.79 (m, 1H), 3.09 (m, 2H), 2.79 (m, 1H), 2.55 (m, 2H), 1.97 (s, 3H), 1.81 (m, 2H), 1.34 (s, 3H), 0.76 (s, 3H); MS (FAB) m/z 505 [M + H] +; Anal. C 59.17, H 5.56, Cl 12.79, N 6.55 (calcd for 0.50% H20: C 59.28, H 5.50, Cl 12.96, N 6.40).

(1R-trans)-N-[(3-Carboxy-2, 2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine (C24H24C12N206, Example 102): Example 100 is subjected to haloform degradation, as taught for compound C-1, to give Example 102: TLC (750: 250: 5 EtOAc/hexanes/HCO2H) Rf = 0.29; [a] D25 +2 (c 0.91, MeOH); 1H NMR (300 MHz, CDCl3) 8 10.05 (s, 1H), 7.65 (m, 2H), 7.40-7.29 (m, 3H), 7.19 (m, 2H), 6.53 (m, 1H), 4.81 (m, 1H), 4.10 (m, 1H), 3.10 (m, 3H),

2.85 (m, 1H), 2.73 (m, 1H), 2.25 (m, 2H), 1.16 (s, 3H), 1.02 (s, 3H); MS (FAB) m/z 507 [M + H] +; Anal. C 55.74, H 4.91, Cl 13.30, N 5.28 (calcd for 0.94% H2O: C 56.28, H 4.83, Cl 13.84, N 5.45).

(lR-cis)-N-[(3-Carboxy-2,2-dimethylcyclobutyl) carbonyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine (C24H24C12N2O6, Example 103).

Example 101 is subjected to haloform degradation, as taught for compound C-1, to give Example 103: TLC (600: 400: 5 EtOAc/hexanes/HCO2H) Rf = 0.24; [a] (c 0.90, MeOH); 1H NMR (300 MHz, CDC13) 5 9.53 (s, 1H), 7.54 (m, 2H), 7.28-7.17 (m, 3H), 7.07 (m, 2H), 6.13 (m, 1H), 4.72 (m. 1H), 4.02 (m, 1H), 3.02 (m, 2H), 2.66-2.35 (m, 4H), 1.89 (m, 1H), 1.20 (s, 3H), 0.83 (s, 3H); MS (FAB) m/z 507 [M + H] + ; Anal. C 52.81, H 4.59, Cl 12.41, N 4.85 (calcd for 2.1% H20: C 55.62, H 4.91, Cl 13.67, N 5.40).

Examples 104 and 105: Teaching Scheme K Teaching Scheme K exemplifies the practice of Scheme 3 by teaching the synthesis of Examples 104 and 105 where (with reference to structure 1-F) for Example 104 R4 is 3-acetyl, m equals 1, n equals 0, Zx is CH, Zy is 3-NH, Y is-NHC (O)-, X is 2-chloro, the stereochemistry of the cycloalkanoyl segment is (lS-trans), and the stereochemistry of the amidoacid is L; and for Example 105 R4 is 3- acetyl, m equals 1, n equals 0, Zx is CH, Zy is 3-NH, Y is-NHC (O)-, X is 2-chloro, the stereochemistry of the cycloalkanoyl segment is (lS-cis), and the stereochemistry of the amidoacid is L.

N-[(1, 1-Dimethylethoxy) carbonyl]-4-[[(2-chloro-3- pyridinyl) carbonyl] amino]-L-phenylalanine methyl ester (C21H24ClN3O5, K-1). To a mixture of 2-chloro-3-pyridinecarboxylic acid (1.36 g, 8.48 mmol), EDC (1.73 g, 8.85 mmol), HOBT (1.204 g, 8.87 mmol), amine Compound 5 (2.60 g, 8.85 mmol) and DMAP (0.323 g, 2.6 mmol)

in CH2Cl2 (55 mL) under N2 at 0 °C is added Et3N (1.44 mL, 10.22 mmol). The reaction mixture is stirred for 44 h at rt. Additional portions of acid 2-chloro-3-pyridinecarboxylic acid (1.36 g, 8.48 mmol), EDC (1.73 g, 8.85 mmol), HOBT (1.204 g, 8.87 mmol) and DMAP (0.323 g, 2.6 mmol) and Et3N (1.44 mL, 10.22 mmol) are added. The reaction is stirred an additional 15 h. The reaction mixture is diluted with CH2Cl2, and washed with H20,5% aq NaHC03, and H20. The organics are dried and concentrated to give an amber oil, that solidifies upon standing. The solid is purified by silica chromatography to give K-1: TLC Rf = 0.21 (1: 1 EtOAc/hexane); 1H NMR (CDC13,300 MHz) 8 8.51 (s, 1H), 8.18 (m, 2H), 7.58 (m, 2H), 7.41 (m, 1H), 7.14 (m, 2H), 5.07-4.96 (m, 2H), 4.64-4.56 (m, 1H), 3.73 (s, 3H), 3.16-2.97 (m, 2H), 1.42 (s, 9H); MS (FAB) m/z 434 [M+H] +, 436.

4- [ [ (2-Chloro-3-pyridinyl) carbonyl] amino]-L-phenylalanine methyl ester hydrogen chloride salt (C16Hl6ClN3O3 HC1, K-2). A solution of K-1 (3.37 g, 7.77 mmol) in 4 M HC1 in dioxane is stirred at room temperature for 20 h. The reaction mixture is concentrated in vacuo. The solid is taken up in H20 and extracted with Et20. The Et20 is discarded. The aqueous solution is frozen and lyophilized to give K-2 as a solid: 1H NMR (CDC13,300 MHz) 5 10.74 (s, 1H), 8.64 (s, 3H), 8.52 (m, 1H), 8.04 (m, 1H), 7.65 (m, 2H), 7.55 (m, 1H), 7.21 (m, 2H), 4.23 (m, 1H), 3.23-3.05 (m, 2H); MS (EI) m/z 333 <BR> <BR> <BR> <BR> lml+.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> (1S-cis)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4- [ [ (2- chloro-3-pyridinyl) carbonyl] amino]-L-phenylalanine methyl ester (C25H28ClN305, K-3). Compound K-3 is prepared from acid G-2 and K-2 <BR> <BR> <BR> <BR> as taught for A-3: TLC Rf = 0.35 (EtOAc); 1H NMR (CDC13,300 MHz) 6 8.51 (m, 1H), 8.20 (m, 2H), 7.59 (m, 2H), 7.41 (m, 1H), 7.14 (m, 2H), 5.83 (m, 1H), 4.88 (m, 1H), 3.73 (s, 3H), 3.11 (m, 2H), 2.64 (m, 1H), 2.51 (m, 1H), 2.05 (s, 3H), 1.89 (m, 1H), 1.42 (s, 3H),

0.84 (s, 3H); 13C NMR (CDCl3, 75 MHz) 6 207.12,172.01,170.76, 162.55,151.39,146.96,140.04,136.26,132.83,131.36,130.00, 122.99,120.46,52.94,52.72,52.46,46.40,44.84,37.61,30.70, 30.10,18.93,17.68; MS (FAB) m/z 486 [M + H] +.

(1S-trans)-N-[(3-Acetyl-2,2-dimethylcyclobutyl)carbonyl]-4-[ [(2- chloro-3-pyridinyl) carbonyl] amino]-L-phenylalanine (C24H26ClN305, Example 104) and (lS-cis)-N- [ (3-Acetyl-2,2- dimethylcyclobutyl) carbonyl]-4- [ [ (2-chloro-3- pyridinyl) carbonyl] amino]-L-phenylalanine (C24H26ClN3O5, Example 105). Examples 104 and 105 are prepared and separated as taught for Compounds G-4 and G-5.

Example 104: mp 115-117 °C; TLC Rf = 0.41 (1000: 2.5 EtOAc/HCO2H); <BR> <BR> <BR> [a] ZSD = +42 (c = 1.0, MeOH); 1H NMR (CDCl3, 300 MHz) 8 9.47 (s, 1H), 8.41 (m, 1H), 7.90 (m, 1H), 7.55 (m, 2H), 7.28 (m, 1H), 7.09 (m, 2H), 6.00 (m, 1H), 4.77 (m, 1H), 3.07 (m, 2H), 2.46 (m, 1H), 2.28 (m, 1H), 2.07 (m, 1H), 1.98 (s, 3H), 1.14 (s, 3H), 1.01 (s, 3H); 13C NMR (CDC13,75 MHz) 5 208.67,173.25,172.22,163.52,150.49, 147.51,138.58,136.90,132.99,132.79,130.01,122.55,120.22, 42.84,37.12,30.71,25.34,25.14,18.67; MS (ESI-) m/z 470.1 [M-H]'; Anal. C 59.11, H 5.91, Cl 6.68, N 8.32 (calcd for 2.81% H2O and melt solvate: C 59.36, H 5.72, Cl 7.29, N 8.65).

Example 105: mp 129-130 °C; TLC Rf = 0.31 (1000: 2.5 EtOAc/HCO2H); <BR> <BR> <BR> [a] D =-7 (c = 1.0, MeOH); 1H NMR (CDCl3, 300 MHz) 5 9.56 (s, 1H), 8.39 (m, 1H), 7.88 (m, 1H), 7.54 (m, 2H), 7.28 (m, 1H), 7.08 (m, 2H), 4.71 (m, 1H), 3.04 (m, 2H), 2.76 (m, 1H), 2.49 (m, 2H), 1.95 (s, 3H), 1.77 (m, 1H), 1.33 (s, 3H), 0.77 (s, 3H); 13C NMR (CDCl3, 75 MHz) 8 207.18,173.21,170.67,163.56,150.43,147.53,138.50, 136.95,133.06,132.74,129.96,122.53,120.23,52.92,52.80, 46.29,44.81,37.21,30.59,30.02,18.55,17.65; MS (ESI-) m/z 470.0 [M - H]-; Anal. C 57.17, H 5.67, Cl 7.17, N 8.55 (calcd for 2.61% H20 and melt solvate: C 59.19, H 5.70, Cl 7.28, N 8.62).

Examples 106 and 107: Teaching Scheme L Teaching Scheme L exemplifies the practice of Scheme 3 by teaching the synthesis of Examples 106 and 107 where (with reference to structure 1-F) for Example 106 R4 is 3-acetyl, m equals 1, n equals 0, Zx is CH, Zy is 3-NH, Y is-NHC (O)-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment is (1S-trans), and the stereochemistry of the amidoacid is L; and for Example 105 R4 is 3- acetyl, m equals 1, n equals 0, Zx is CH, Zy is 3-NH, Y is-NHC (O)-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment is (lS-cis), and the stereochemistry of the amidoacid is L.

N- [ (1, 1-Dimethylethoxy) carbonyl]-4- [ [ (2, 6-dichloro-3- pyridinyl) carbonyl] amino]-L-phenylalanine methyl ester (C2lH23Cl2N305, L-1). A mixture of 2,6-dichloro-3-pyridinecarboxylic acid and Compound 5 are coupled by the procedure taught for A-5: TLC: Rf= 0.42 (1: 1 EtOAc/hexanes); 1H NMR (CDC13,300 MHz) 5 8.14 (m, 1H), 7.56 (m, 2H), 7.42 (m, 1H), 7.14 (m, 2H), 4.99 (m, 1H), 4.58 (m, 1H), 3.72 (s, 3H), 3.17-2.96 (m, 1H), 1.41 (s, 9H); MS (FAB) m/z 470,468 [M+H] +.

4- [ [ (2,6-Dichloro-3-pyridinyl) carbonyl] amino]-L-phenylalanine methyl ester hydrogen chloride salt (C16Hl5Cl2N303 HC1, L-2). A solution of L-1 is transformed to L-2 by the procedure taught for <BR> <BR> <BR> K-2: 1H NMR (CDC13,300 MHz) b 10.84 (s, 1H), 8.60 (s, 3H), 8.14 (m, 1H), 7.72 (m), 7.63 (m, 2H), 7.22 (m, 2H), 4.29-4.17 (m, 1H), 3.69 (s, 3H), 3.19-3.06 (m, 2H); MS (ESI+) m/z 370,368 [M+H] +.

(lS-cis)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4-[[(2,6- dichloro-3-pyridinyl) carbonyl] amino]-L-phenylalanine methyl ester (C25H27Cl2N3O5, L-3). Compound L-3 is prepared from acid G-2 and L-2 as taught for A-3: TLC Rf = 0.34 (3: 1 EtOAc/hexanes); 1H NMR (CDC13,300 MHz) 8 8.26 (s, 1H), 8.16 (m, 1H), 7.57 (m, 2H), 7.42 (m, 1H), 7.13 (m, 2H), 5.83 (m, 1H), 4.87 (m, 1H), 3.73 (s, 3H), 3.11 (m, 2H), 2.86 (m, 1H), 2.63 (m, 1H), 2.53 (m, 1H), 2.05 (s, 3H), 1.64 (m, 1H), 1.42 (s, 3H), 0.82 (s, 3H). <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> (lS-trans)-N- [ (3-Acetyl-2,2-dimethylcyclobutyl) carbonyl]-4-[[(2,6- dichloro-3-pyridinyl) carbonyl] amino]-L-phenylalanine (C24H25C12N305, Example 106) and (lS-cis)-N-[(3-Acetyl-2,2- dimethylcyclobutyl) carbonyl]-4-[[(2,6-dichloro-3- pyridinyl) carbonyl] amino]-L-phenylalanine (C24H25C12N305, Example 107).

Examples 106 and 107 are prepared and separated as taught for Compounds G-4 and G-5.

Example 106: mp 139-141 °C; TLC Rf = 0.28 (750: 250: 5 <BR> <BR> <BR> <BR> EtOAc/hexanes/HC02H); [a] 25p = +39 (c = 0.7, MeOH); 1H NMR (CD3SOCD3, 300 MHz) 8 12.55 (s, 1H), 10.63 (s, 1H), 8.14 (m, 1H), 8.01 (m, 1H), 7.71 (m, 1H), 7.55 (m, 2H), 7.19 (m, 2H), 4.45 (m, 1H), 3.30 (s, 1H), 3.00 (m, 2H), 2.82 (m, 1H), 2.08 (m, 1H), 1.97 (s, 3H), 1.84 (m, 1H), 1.07 (s, 3H), 1.00 (s, 3H); MS (FAB) m/z 506 [M + H] +; Anal. C 55.88, H 5.26, Cl 13.04, N 7.92 (calcd for 2.26% H20: C 55.64, H 5.12, Cl 13.69, N 8.11).

Example 107: mp 189-191 °C; TLC Rf = 0.21 (750: 250: 5 <BR> <BR> <BR> <BR> EtOAc/hexanes/HCO2H); [a] 25D =-3 (c = 0.8, MeOH); 1H NMR (CDC13,300 MHz) 8 12.56 (s, 1H), 10.63 (s, 1H), 8.14 (m, 1H), 7.78 (m, 1H), 7.70 (m, 1H), 7.54 (m, 2H), 7.20 tm, 2H), 4.42 (m, 1H), 3.01 (m, 1H), 2.87 (m, 2H), 2.61 (m, 1H), 2.36 (m, 1H), 1.95 (s, 3H), 1.54 (m, 1H), 1.34 (s, 3H), 0.64 (s, 3H); MS (FAB) m/z 506 [M + H] +; Anal. C 56.29, H 5.57, Cl 12.77, N 7.93 (calcd for 2.26% H20: C

55.64, H 5.21, Cl 13.69, N 8.11).

Example 108 From Example 107 is prepared Example 108, wherein R4 is 3-carboxy, m equals 1, n equals 0, Zx is CH, Zy is 3-NH, Y is-NHC (O)-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment is <BR> <BR> <BR> <BR> (lS-cis), and the stereochemistry of the amidoacid is L.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> (15-cis) [ (3-Carboxy-2,2-dimethylcyclobutyl) carbonyl]-4- [ [ (2, 6- dichloro-3-pyridinyl) carbonyl] amino]-L-phenylalanine (C23H23Cl2N306, Example 108). Example 108 is made from Example 107 as taught for Compound C-1: mp 154-157 °C; TLC Rf = 0.19 (750: 250: 5 EtOAc/hexanes/HCO2H); [a] 25D = +15 (c = 0.9, MeOH); 1H NMR (CD3SOCD3, 300 MHz) 8 12.27 (s, 1H), 10.56 (s, 1H), 8.14 (m, 1H), 7.81 (m, 1H), 7.71 (m, 1H), 7.55 (m, 2H), 7.21 (m, 2H), 4.43 (m, 1H), 3.01 (m, 1H), 2.84 (m, 1H), 2.68 (m, 1H), 2.34 (m, 1H), 1.68 (m, 1H), 1.23 (s, 3H), 0.76 (s, 3H); MS (FAB) m/z 508 [M + H] +; Anal. C 52.49, H 4.97, Cl 12.49, N 7.62 (calcd for 2.29% H20: C 53.10, H 4.71, Cl 13.63, N 8.08).

Example 109: Teaching Scheme M Teaching Scheme M exemplifies the practice of Scheme 3 by teaching the synthesis of Example 109 where (with reference to structure 1- F) R4 is 3-carboxy, m equals 1, n equals 0, Zx is 2-NH, Zy is CH, Y is-OCH2-, X is 2,6-dichloro, the stereochemistry of the cycloalkanoyl segment is (lS-cis), and the stereochemistry of the amidoacid is L. <BR> <BR> <BR> <BR> <BR> <BR> <P>()-2-Chloro-3- [ (2-tetrahydropyranyl) oxy]-6-iodopyridine<BR> <BR> <BR> <BR> <BR> <BR> (CloHllClIN02, M-2): To a solution of 2-chloro-6-iodo-3-pyridinol (Wishka, D. G.; Graber, D. R.; Seest, E. P.; Dolak, L. A.; Han, F.;

Watt, W.; Morris, J. J. Org. Chem. M-1 (1.00 g, 3.91 mmol) and dihydropyran (1.0 mL, 10.6 mmol) in CH2Cl2 (10 mL) under Ar at room temperature is added pyridinium chloride (0.050 g). The reaction mixture is stirred for 72 h. It is diluted with CH2Cl2 and is washed with satd aq NaHC03 and brine. The CH2Cl2 solution is dried and concentrated to an oil, that is purified by silica chromatography: TLC (19: 1 hexanes/EtOAc) Rf = 0.24; 1H NMR (CDC13,300 MHz) 8 7.55 (m, 1H), 7.17 (m, 1H), 5.50 (m, 1H), 3.77 (m, 1H), 3.61 (m, 1H), 2.07-1.57 (m, 6H); MS (+ESI) m/z 361.9 [M + Na] +, 339.9 [M + H] +.

(S)-2-Chloro-a-[[(1, 1-dimethylethoxy) carbonyl] amino]-3- [ (2- tetrahydropyranyl) oxy]-6-pyridinepropanoic acid methyl ester (ClgH27ClN2O6, M-3): To an amberized flask containing activated Zn dust (0.349 g, 5.51 mmol) under Ar is added THF (2 mL) and 1,2- dibromoethane (0.018 mL, 0.21 mmol). The suspension is brought to reflux for several minutes, cooled to approximately 30 °C, and TMSC1 (0.17 mL of a 1 M solution in THF) is added. The reaction mixture is stirred at 405 °C for 30 min. A degassed solution of Boc-L-iodoalanine methyl ester [93267-04-0] (1.814 g, 5.51 mmol) in 11: 7 dimethylacetamide/THF (9.0 mL) is added to the suspension. The reaction mixture is stirred for 5 h at 455 °C. It is then cooled in an ice bath, and solid PdCl2 (PPh3) 2 (0.192 g) is added, followed by a degassed solution of the iodide M-2 (0.936 g, 2.76 mmol) in 1: 1 THF/dimethylacetamide (9.4 mL). This reaction mixture is stirred for 11 h at 455 °C. It is cooled to 0 °C, quenched with satd aq NH4Cl, and extracted with EtOAc. The combined EtOAc portions are washed with satd aq NH4Cl and brine, dried and concentrated to a green-yellow colored foam that is purified by silica chromatography: TLC (7: 3 hexanes/EtOAc) Rf = 0.21; 1H NMR (CDC13,300 MHz) 8 7.39 (m, 1H), 7.00 (m, 1H), 5.46 (m, 1H), 4.61 (m, 1H), 4.13 (m, 1H), 3.80 (s, 3H), 3.62 (m, 1H), 3.20 (m, 1H), 2.13-1.53 (m, 6H), 1.42 (s, 9H); MS (+ESI) m/z 474.0 [M + H] +.

(S)-a- [ [ (1, l-Dimethylethoxy) carbonyl] amino]-3- [ (2- tetrahydropyranyl) oxy]-6-pyridinepropanoic acid methyl ester (Cl9H28N206, M-4): A suspension of pre-reduced Pd/CaCO3 (3.5 g) and M-3 (1.15 g, 2.77 mmol) in EtOH (40 mL) is hydrogenated (30 psi H2) for 19 h at rt. The mixture is filtered, and the filtrate is evaporated to give a yellow-colored foam, that is purified by silica chromatography: TLC (1: 1 hexanes/EtOAc) Rf = 0.27; 1H NMR (CDC13,300 MHz) b 8.30 (m, 1H), 7.29 (m, 1H), 7.03 (m, 1H), 5.81 (m, 1H), 5.39 (s, 1H), 4.65 (m, 1H), 3.86 (m, 1H), 3.73 (s, 3H), 3.62 (m, 1H), 3.21 (m, 2H), 1.96-1.53 (m, 6H), 1.42 (s, 9H); MS (+ESI) m/z 381.1 [M + H] +.

(S) a- [[(1, 1-Dimethylethoxy) carbonyl] amino]-5-hydroxy-2- pyridinepropanoic acid methyl ester (Cl4H2oN20s, M-5): A solution of M-4 (0.346 g, 0.91 mmol) and pyridinium p-toluenesulfonate (0.031 g, 0.12 mmol) in EtOH (8 mL) is stirred at 555 °C for 20 h. The reaction mixture is cooled to room temperature, and concentrated in vacuo. The residue is taken up in EtOAc. This solution is washed with brine, dried, and concentrated to a pale yellow-colored oil that is purified by silica chromatography: TLC (1: 1 hexanes/EtOAc) Rf = 0.18; 1H NMR (CDC13,300 MHz) 8 8.13 (s, 1H), 7.13 (m, 1H), 7.03 (m, 1H), 5.71 (m, 1H), 4.65 (m, 1H), 3.70 (s, 3H), 3.20 (m, 2H), 1.39 (s, 9H); MS (+ESI) m/z 297.1 [M + H] +.

(S)-5-[(2,6-Dichlorophenyl) methoxy]-a- [ [ (1, 1- dimethylethoxy) carbonyl] amino]-2-pyridinepropanoic acid methyl ester (C2lH24Cl2N205, M-6): To a solution of M-5 (0.126 g, 0.43 mmol), 2,6-dichlorobenzylalcohol (0.075 g, 0.43 mmol) and PPh3 (0.113 g, 0.43 mmol) in dry THF (4 mL) at 0 °C under Ar is added DEAD (0.068 mL). The reaction mixture is permitted to warm to room temperature, and is stirred for 18 h. It is concentrated, and the residue is purified by silica chromatography: TLC (7: 3

hexanes/EtOAc) Rf = 0.34; 1H NMR (CDC13,300 MHz) 8 8.31 (m, 1H), 7.37 (m, 2H), 7.25 (m, 2H), 7.08 (m, 1H), 5.81 (m, 1H), 5.29 (s, 2H), 4.65 (m, 1H), 3.70 (s, 3H), 3.24 (m, 2H), 1.63 (m, 1 H), 1.43 (s, 9H); 13C NMR (CDC13,75 MHz) 8 172.47,155.50,153.82,149.71, 137.33,137.00,131.51,130.72,128.56,123.99,122.78,79.74, 65.64,53.25,52.27,38.43,28.33 (3C); MS (+ESI) m/z 454.9 [M + <BR> <BR> <BR> <BR> H] +.<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <P> (S)-a-Amino-5- [ (2,6-dichlorophenyl) methoxy]-2-pyridinepropanoic acid methyl ester dihydrogen chloride salt (Cl6Hl6Cl2N2O, M-7) : A solution of carbamate M-6 (0.546 g, 1.20 mmol) in 4 M HC1 in dioxane (12 mL) is stirred at room temperature under Ar for 16 h.

The reaction mixture is concentrated in vacuo. The residue is dissolved in H20, and this solution is extracted with Et20. The aqueous solution is frozen and lyophilized to give M-7: 1H NMR <BR> <BR> <BR> <BR> <BR> (CD3SOCD3,300 MHz) 5 8.75 (s, 3H), 8.47 (m, 1H), 7.81 (m, 1H), 7.57 (m, 3H), 7.48 (m, 1H), 5.35 (s, 2H), 4.49 (m, 1H), 3.67 (s, 3H), 3.42 (m, 2H); 13C NMR (CD3SOCD3,75 MHz) 6 169.42,154.95,146.54, 136.57,134.35,132.50,131.30,129.36,126.72,126.52,66.40, 53.32,51.79,34.81.

[1S- [la (R*), 3a]]-a- [ [ (3-Acetyl-2,2- dimethylcyclobutyl) carbonyl] amino]-3- [ (2,6-dichlorophenyl) methoxy]- 6-pyridinepropanoic acid methyl ester (C25H2ôCl2N205, M-8): To a mixture of acid G-2 (0.936 g, 5.50 mmol), HOAt (0.749 g, 5.50 mmol), EDC (1.055 g, 5.50 mmol), and M-7 (2.14 g, 5.00 mmol) in 4: 1 CH2Cl2/DMF (20 mL) at 0 °C is added N-methylmorpholine (NMM) (1.38 mL, 12.5 mmol). The solution is kept at 0 °C for 40 h, and then is concentrated. The residue is taken up in CH2Cl2, and this solution is washed with water, satd aq NaHC03, and H2O. The combined aqueous portions are back-extracted with CH2C12. The combined CH2C12 portions are dried and concentrated to give a green-brown colored foam, that is purified by silica chromatography: TLC Rf = 0.32 (3: 1

EtOAc/hexanes) i lH NMR (CDCl3,300 MHz) 5 8.32 (m, 1H), 7.38 (m, 2H), 7.30-7.25 (m, 3H), 7.08 (m, 1H), 5.31 (s, 2H), 4.87 (m, 1H), 3.67 (s, 3H), 3.28 (m, 1H), 3.20 (m, 1H), 2.85 (m, 1H), 2.05 (s, 3H), 1.91 (m, 1H), 1.46 (s, 3H), 0.86 (s, 3H); MS (+ESI) m/z 509.2, 507.2 [M + H] +.

[1S- [la (R*), 3a]]-a- [ [ (3-Carboxy-2,2- dimethylcyclobutyl) carbonyl] amino]-3-[(2,6- dichlorophenyl) methoxy] 6pyridinepropanoicacid (C23H24Cl2N2o6, Example 109): To a solution of 1 M aq NaOH (21.2 mL) at 0 °C is added portionwise Br2 (0.254 mL, 4.93 mmol). The mixture is stirred for 30 min beyond the point that all of the Br2 is dissolved. At that time a solution of M-7 (0.60 mL, 1.18 mmol) in 1: 1 dioxane/THF (16.0 mL) is added. The reaction mixture is stirred for 1 h at 0 °C and for 2.5 h at rt. It is cooled to 0 °C and quenched with cold 1 M aq NaHS03 (50 mL). The aqueous mixture is extracted with Et20. The aqueous mixture is acidified with concentrated aq HC1, and extracted with EtOAc.

The combined EtOAc portions are dried and concentrated to give a colorless paste, that is purified by silica chromatography.

The solid that is obtained upon concentration of the column fractions is dissolved in 1: 1 MeCN/H2O (40 mL). This solution is lyophilized to give Example 109 as an amorphous solid: mp 121-124 °C; TLC Rf = 0.11 (750: 250: 5 EtOAc/hexanes/HCO2H); 1H NMR (CD3SOCD3,300 MHz) 5 12.27 (s, 2H), 8.27 (m, 1H), 7.82 (m, 1H), 7.56 (m, 2H), 7.48-7.42 (m, 2H), 7.23 (m, 1H), 5.25 (s, 2H), 4.62 (m, 1H), 3.30 (s, 2H), 3.14-2.97 (m, 2H), 2.67-2.55 (m, 2H), 2.29 (m, 1H), 1.71 (m, 1H), 1.21 (s, 3H), 0.72 (s, 3H); 13C NMR (CD30D, 75 MHz) b C: 175.93,174.5,173.72,155.6, 151.23,132.98,45.40; CH: 138.04,132.30,129.79,125.9, 124.31,53.6,47.38,46.40 ; CH2: 66.85,39.02,20.96; CH3: 30.54,18.39 ; MS (+ESI, MeOH) m/z 497.2,495.2 [M + H] + ; Anal.

C 55.77, H 4.88, N 5.39 (calcd for 1.50% H20: C 54.93, H 4.98,

N 5.57).

Example 110: Teaching Scheme N 7,9-Dioxaspiro [4.5] decan-8-one (CgHl2O3, N-1). Anhydride N1 is prepared from 1,1-cyclopentanediacetic acid [16713-66-9] by standard methods (Balo, M. B.; Fernandez, F.; Lens, E.; Lopez, C. Nucleosides Nucleotides 1996,15,1335-1346).

N- [ (l-Carboxymethyl) cyclopentaneacetyl]-O- ( [ (2,6- dichlorophenyl) methyl]-L-tyrosine methyl ester (C26H29Cl2NO6, N- 2). To a mixture of anhydride N-1 (0.84 g, 5.0 mmol), Compound 8 (1.95 g, 5.0 mmol) and iPr2EtN (4.4 mL, 25 mmol) in THF (15 mL) is heated at reflux for 17 h. The reaction mixture is cooled, and is concentrated in vacuo. The residue is taken up in aqueous 1 M HC1 (40 mL), and this mixture is extracted with EtOAc. The combined EtOAc extracts are dried and concentrated, and the residue is purified by silica chromatography. The column fractions are concentrated, and the resulting solid is dissolved in MeCN/H20. This solution is lyophilized to give N-2: 13C NMR (CDC13,75 MHz) 8 175.0, 172.8,171.7,157.9,136.7,131.8,130.3,130.0,128.3,127.9, 115.0,65.0,53.2,52.4,44.2,44.1,43.1,38.2,36.6,23.5; MS (EI) m/z 523,521; Anal. C 59.62, H 5.82, C1 13.44, N 2.57 (calcd C 59.78, H 5.60, C1 13.57, N 2.68).

N- [ (l-Carboxymethyl) cyclopentaneacetyl]-O- ( [ (2,6- dichlorophenyl) methyl]-L-tyrosine (C25H27Cl2NO6, Example 110). A mixture of ester N-2 (1.00 g, 1.90 mmol) and LiOH-H20 (0.84 g, 20.0 mmol) in H20 (12 mL) is stirred at 0 °C for 4 h. The reaction mixture is acidified with aqueous 1 M HC1 (24 mL) to give a white solid. The solid is recovered by filtration. It is dissolved in 1: 1 MeCN/H20 (20 mL), and this solution is

lyophilized to give Example 110: mp, 108 °C (softens); 13C NMR (CD3SOCD3,75 MHz) 8 175.2,174.0,173.0,158.0,132.0,130.5, 130.3,130.1,128.7,128.5,115.0,65.2,53.6,53.5,44.2, 42.0,25.6,21.3; MS (EI) m/z 521; Anal. C 60.37, H 5.84, Cl 14.33, N 2.55 (calcd for 0.73% H20: C 58.59, H 5.33, Cl 14.62, N 2.73).

Example 111: Teaching Scheme O 3-Oxabicyclo [3.2.1] octane-2,4-dione [6054-16-6] (C7H803, 0-1).

Anhydride O-1 is prepared from cis-1,3- cyclopentanedicarboxylic acid [876-05-1] by standard methods (Balo, M. B.; Fernandez, F.; Lens, E.; Lopez, C. Nucleosides Nucleotides 1996,15,1335-1346).

N- [cis- (3-Carboxycyclopentyl) carbonyl]-O- [ (2,6- dichlorophenyl) methyl]-L-tyrosine methyl ester (C25H27C12NO6,0- 2). Compound 0-2 is prepared from anhydride O-1 and Compound 8 as taught for Compound N-2: 13C NMR (CDC13,75 MHz) 8 179.0, 178.9,175.8,175.7,171.9,157.9,136.8,131.9,130.3,130.1, 4,52.3, 9,36.8,36.7,32.5,32.1,31.3,30.8,29.7, 29.6; Anal. C 59.27, H 5.22, Cl 14.26, N 2.78 (calcd for 0.39% H20: C 58.31, H 5.10, Cl 14.34, N 2.83).

N- [cis- (3-Carboxycyclopentyl) carbonyl]-O- [ (2,6- dichlorophenyl) methyl]-L-tyrosine (C23H23Cl2NO6, Example 111).

Example 111 is prepared from ester 0-2 as taught for Example <BR> <BR> <BR> 110: 1H NMR (CDC13,300 MHz) 8 7.40-7.32 (m, 2H), 7.30-7.22 (m, 1H), 7.13 (m, 2H), 6.93 (m, 2H), 6.75-6.60 (m, 1H), 5.23 (s, 2H), 4.85-4.70 (m, 1H), 3.25-3.00 (m, 2H), 2.90-2.60 (m, 2H), 2.22-1.80 (m, 6H); Anal. C 56.56, H 4.76, Cl 14.66, N 2.79

(calcd for 0.90% H2O: C 57.51, H 4.83, Cl 14.76, N 2.92).

Example 112: Teaching Scheme P ()-cis-1,3-Cyclopentanedicarboxylic acid monomethyl ester <BR> <BR> <BR> <BR> [96382-85-3] (C8H1204, P-1). Monoester P-1 is prepared from<BR> <BR> <BR> <BR> <BR> <BR> <BR> cis-l, 3-cyclopentane-dicarboxylic acid by standard methods (Chenevert, R.; Martin, R. Tetrahedron: Asymmetry 1992,3, 199-200).

4- [ (2,6-Dichlorobenzoyl) amino]-N- [cis- [3- (l-methoxy-l- oxomethyl) cyclopentyl] carbonyl]-L-phenylalanine methyl ester (C25H26C12N206, P-2). To a mixture of P-1 (0.5 g, 2.9 mmol), HOBt (0.45 g, 3.3 mmol) DMAP (0.04 g, 0.32 mmol), NEt3 (1.45 mL, 10.4 mmol) in CH2C12 (25 mL) at 0 °C is added Compound 7 (1.15 g, 2.8 mmol). The reaction mixture is stirred at room temperature for 48 h. The CH2C12 is removed from the reaction mixture in vacuo, and the residue is taken up in aqueous 1 M HC1 (50 mL). The aqueous mixture is extracted with CH2Cl2. The combined CH2C12 extracts are washed with satd aq NaHC03, dried, and concentrated. The residue is purified by silica chromatography to provide, as a diastereomeric mixture, P-2: MS (EI) m/z 520,351,350,349,280,278,175,173,155,95, 67; Anal. C 57.55, H 5.03, Cl 13.62, N 5.40 (calcd for 0.11% H20: C 57.59, H 5.03, Cl 13.60, N 5.37).

N- [cis- (3-Carboxycyclopentyl) carbonyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine (C23H22C12N206, Example 112). Example 112 is prepared, as a diastereomeric mixture, from P-2 as taught for Example 110: MS (FAB) m/z 496,495, 494,493,492,476,475,337,335,175,173; Anal. C 55.40, H 4.55, Cl 14.08, N 5.62 (calcd for 1.87% H20: C 56.00, H 4.50, Cl 14.37, N 5.68).

Scheme Q

Scheme Q describes a general method for preparing ureas and thioureas of general structure Q-4. This method is not preferred for preparing ureas containing a carboxyl substituent in the 2 position of the piperidine or pyrrolidine ring of structure Q-2. An amino acid of general structure Q-1 is reacted with carbonyldiimidazole or thiocarbonyldiimidazole followed by the cyclic amino acid of general structure Q-2 to afford the diester intermediate Q-3. Mild base hydrolysis afford the diacid of general structure Q-4.

Example 113

1-[[[(1S)-1-carboxy-2-[4-[(2,6- dichlorobenzoyl) amino] phenyl] ethyl] amino] carbonyl]-4- piperidinecarboxylic acid. To a cooled (0-5°C) solution of Compound 11 (410 mg, 0.74 mmol) in THF (23 mL) and MeOH (7.5 mL) was added an aqueous (5 mL) solution of lithium hydroxide monohydrate (94 mg, 2.24 mmol) via a syringe pump over 1 h.

After an additional 1 h at 0-5°C, the ice bath was removed and the solution stirred 2 h at ambient temperature. The reaction mixture was diluted with ethyl acetate and 0.1 N HC1 and the organic layer separated, washed with water, dried (Na2SO4), filtered and concentrated in vacuo. Lyophilization of the residue from glacial acetic acid afforded the title compound (360 mg) as a white amorphous powder: IR (mull) 3123,3034, 1717,1665,1606,1562,1535,1517,1432,1414,1326,1272, 1213,1195,799 cm-1; 1H NMR (300 MHz, CD30D) 8 7.57 (2 H), 7.43 (3 H), 7.24 (2 H), 4.48 (1 H), 3.85 (2 H), 3.19 (1 H), 3.95 (3 H), 2.47 (1 H), 1.83 (2 H), 1.55 (2 H); 13C NMR (75 MHz, CD30D) 8 178.3,176.2,165.2,159.4,138.1,137.8,133.4,132.4, 131.0,129.4,121.5,56.8,44.6,44.5,42.0,38.1,29.2; MS (FAB) m/z (rel. intensity) 508 (MH+, 99), 511 (19), 510 (64), 509 (36), 508 (99), 391 (34), 356 (16), 173 (20), 149 (29), 128 (17), 57 (16); HRMS (FAB) calcd for C23H23C12N306+H1 508.1042, found 508.1033. Anal. Calcd for C23H23Cl2N3o6 0-25 H20: C, 53.87; H, 4.62; N, 8.19. Found: C, 53.85; H, 4.87; N, 8.04.

Example 114

1-[[[(1S)-1-carboxy-2-[4-[(2,6- dichlorobenzoyl) amino] phenyl] ethyl] amino] carbonyl]-3- piperidinecarboxylic acid. Example 114 was prepared as described in Scheme Q from (R, S)-ethyl nipecotate. Physical properties as follows: IR (mull) 3062,3035,1718,1665, 1628,1606,1562,1536,1517,1432,1414,1326,1268,1216, 1195 cm-1; 1H NMR (300 MHz, CD30D) 6 7.58 (2 H), 7.43 (3 H), 7.25 (2 H), 4.52 (1 H), 4.01 (1 H), 3.73 (1 H), 3.29 (1 H), 3.95 (3 H), 2.38 (1 H), 1.99 (1 H), 1.63 (2 H), 1.37 (1 H); 13C NMR (75 MHz, CD30D) 8 176.4,169.4,165.2,159.4,138.1,137.7, 135.8,133.4,132.4,131.0,129.4,121.5,60.1,56.5,47.4, 45.7,42.4,38.2,28.6,25.5; MS (FAB) m/z (rel. intensity) 508 (MH+, 99), 512 (12), 511 (18), 510 (66), 509 (31), 508 (99), 335 (10), 173 (11), 130 (11), 128 (20), 84 (11). Anal.

Calcd for C23H23C12N306 0.5 H20: C, 53.39; H, 4.67; N, 8.12.

Found: C, 53.56; H, 4.60; N, 7.95.

Example 115

1-[[((lS)-1-carboxy-2-[4-[(2,[[((lS)-1-carboxy-2-[4-[(2, 6- dichlorobenzoyl) amino] phenyl] ethyl) amino] carbonyl]-3- piperidinecarboxylic acid. Example 115 was prepared as described in Scheme Q from (R, S)-ethyl nipecotate. The intermediate diester products of general structure Q-3 were separated by chiral HPLC. The individual diastereomers were saponified as described for Example 113 to provide single stereoisomers of undetermined absolute stereochemistry.

Physical properties of one stereoisomer as follows: 1H NMR (300 MHz, CD30D) 8 7.57 (2 H), 7.45 (3 H), 7.25 (2 H), 4.52 (1 H), 4.02 (1 H), 3.74 (1 H), 3.23 (1 H), 2.93 (3 H), 2.34 (1 H), 2.01 (1 H), 1.65 (2 H), 1.44 (1 H); 13C NMR (75 MHz, CD30D) 8 177.0,176.1,165.2,159.4,138.1,137.7,135.8,133.4, 132.4,131.0,129.4,121.5,62.4,56.7,47.4,45.6,42.4, 38.2,28.6,25.5; MS (FAB) m/z (rel. intensity) 508 (MH+, 99), 510 (69), 509 (32), 508 (99), 173 (18), 130 (21), 128 (29), 84 (19), 57 (16), 55 (18), 43 (17); HRMS (FAB) calcd for C23H23C12N306+H1 508.1042, found 508.1033.

Example 116 1-[[[(1S)-1-carboxy-2-[4-[(2,6- dichlorobenzoyl) amino] phenyl] ethyl] amino] carbonyl]-3- piperidinecarboxylic acid. Example 116 is the other individual stereoisomer related to Example 115. Physical properties as follows: 1H NMR (300 MHz, CD30D) 8 7.58 (2 H), 7.43 (3 H), 7.25

(2 H), 4.53 (1 H), 4.05 (1 H), 3.71 (1 H), 3.23 (1 H), 2.95 (3 H), 3.37 (1 H), 2.01 (2 H), 1.63 (2 H); 13C NMR (75 MHz, CD30D) b 177.1,176.1,165.2,159.4,138.1,137.7,135.8,133.4, 132.4,131.0,129.4,121.5,56.7,47.2,45.7,42.4,38.1, 32.9,28.6,25.5,23.8; MS (FAB) m/z (rel. intensity) 508 (MH+, 99), 511 (19), 510 (69), 509 (34), 508 (99), 335 (15), 173 (21), 130 (21), 128 (32), 123 (18), 84 (20); HRMS (FAB) calcd for C23H23Cl2N306+H1 508.1042, found 508.1038.

Example 117 1-[[[(1S)-1-carboxy-2-[4-[(2,6- dichlorobenzoyl) amino] phenyl] ethyl] amino] thiocarbonyl]-3- piperidinecarboxylic acid. Example 117 was prepared as described in Scheme Q from (R, S)-ethyl nipecotate and thiocarbonyldiimidazole as reagents. Physical properties as follows: IR (mull) 3109,3030, 1274,1234, 1224,1195 cm 1 ; 1H NMR (300 MHz, CD30D) 8 7.57 (2 H), 7.42 (3 H), 7.24 (2 H), 5.34 (1 H), 4.60 (1 H), 4.24 (1 H), 3.23 (4 H), 2.48 (1 H), 2.06 (1 H), 1.64 (3 H); 13C NMR (75 MHz, CD30D) 8 183.1,183.0, 176.9,176.8,175.7,175.6,165.2,138.1,137.7,135.4,133.4, 132.4,131.0,129.4,121.6,121.5,61.1,51.5,51.3,42.3,42.2, 38. 0,28.7,28.5,25.5,25.3,20.9; MS (FAB) m/z (rel. intensity) 524 (MH+, 99), 602 (40), 600 (51), 526 (68), 525 (42), 524 (99), 188 (28), 173 (33), 172 (67), 130 (29), 128 (35); HRMS (FAB) calcd for C23H23C12N305S +H1 524.0814, found 524.0816. Anal. Calcd for C23H23Cl2N30sS'0.25 H20: C, 52.23; H, 4.48; N, 7.94. Found: C,

52.28; H, 4.92; N, 7.81.

Compound Preparations cont.

Compound 3

4-Nitro-L-phenylalanine methyl ester hydrochloride (Compound 3). To a cold (0-5°C) solution of anhydrous methanolic HC1 was added L-4-nitrophenylalanine (Advanced ChemTech, 100 g) portionwise over 15 min. The mechanically stirred mixture was heated to gentle reflux for 48 h. The mixture was allowed to cool and filtered through a sintered glass filter funnel, washing the collected solids with hot MeOH until only insoluble residues remained. The filtrate was concentrated in vacuo to afford the methyl ester as waxy off white solid which was used without further purification.

Compound 4

N-tert-Butoxycarbonyl-4-nitro-L-phenylalanine methyl ester (Compound 4).

To a suspension of methyl ester described above (87 g, 0.33 mole) in CH2C12 (1500 mL) at ambient temperature was added di- t-butyldicarbonate (109 g, 0.50 mole) followed by the dropwise addition of Et3N (51 mL, 0.37 mole). After 15 min additional

Et3N (40 mL, 0.29 mol) was added to maintain a slightly basic mixture (ca. pH 8). The reaction mixture was stirred 18 h and additional CH2C12 (1400 mL) and Et3N (15 mL, 0.11 mol) were added. After an additional 2 h the reaction mixture was quenched by the slow addition of MeOH (100 mL), stirred for 1 h and then partitioned between CH2C12 and cold 10% aqueous KHSO4. The organic layer was washed with saturated NaHC03 and brine, dried (Na2SO4), filtered and concentrated in vacuo.

Purification of the residue by flash chromatography using hexane and a gradient of a 1: 1 mixture of ETOAc/CH2CI2 (25- 33%) afforded the title compound (69 g) as a white solid.

Physical properties as follows: 1H NMR (300 MHz; CDC13) 8 8.16 (2H), 7.31 (2H), 5.04 (1H), 4.63 (1H), 3.73 (3H), 3.18 (2H), 1.41 (9H); MS (ES+) for ClSH2oN206 m/z 325.2 (M+H) +.

Compound 5 N-tert-Butoxycarbonyl-4-amino-L-phenylalanine methyl ester (Compound 5). Palladium on carbon (10% w/w, 1.25 g) was added to a Parr hydrogenation flask under a N2 atmosphere and carefully wetted with 100 mL of MeOH/THF (1: 1). A solution of the Boc-methyl ester described above (25 g, 77 mmol) in 400 mL of MeOH/THF (1: 1) was added and the mixture shaken on a hydrogenation apparatus under a hydrogen atmosphere (20 psi) for 1 h at ambient temperature. The reaction mixture was filtered through a pad of Celite and the solids washed several times with MeOH. The combined filtrates were concentrated in vacuo to afford the title compound which was used without further purification. Physical properties as follows: 1H NMR (300 MHz, CDC13) 8 6.89 (2H), 6.61 (2H), 4.96 (1H), 4.50 (1H), 3.69 (3H), 2.95 (2H), 1.41 (9H); MS (ES+) for C15H22N204 m/z 295.2 (M+H) +.

Compound 6

N-tert-Butoxycarbonyl-4- [ (2,6-dichlorobenzoyl) amino]-L- phenylalanine methyl ester (Compound 6). To a cooled (0-5°C) solution of 2,6-dichlorobenzoyl chloride (11.1 mL, 77.5 mmol) in THF (125 mL) was added a solution of the compound 5 (22.7 g, 77.1 mmol) and Et3N (16 mL, 115 mmol) in THF (125 mL). The reaction mixture was allowed to warm to temperature and stir an additional 18 h. The mixture was diluted with EtOAc (2 L) and washed with 1N aqueous HC1, H20,1N aqueous NaOH and brine. The organic extract was dried (Na2SO4), filtered, and concentrated in vacuo to give the crude product as a pale yellow solid. This material was recrystallized from acetone/hexanes to afford the amide as a crystalline solid.

Physical properties as follows: mp IR (mull) 3305,1747,1736,1690,1665,1609,1548,1512,1433,1414, 1325,1277,1219,1171,781 cm-1; 1H NMR (300 MHz; CDC13) 8 7.57 (2H), 7.34 (4H), 7.14 (2H), 4.98 (1H), 4.60 (1H), 3.74 (3H), 3.11 (2H), 1.42 (9H); MS (ES+) for C22H24Cl2N205 m/z 467.0 (M+H) +.

Compound 7

4- [ (2,6-Dichlorobenzoyl) amino]-L-phenylalanine methyl ester hydrochloride (Compound 7). To 650 mL of anhydrous 4M HC1 in dioxane at ambient temperature was added compound 6 (30.6 g, 65.5 mmol) portionwise and the resulting mixture stirred until all the solids had dissolved (ca. 1 h). Volatiles were removed in vacuo to give a light yellow solid which was partitioned between water (500 mL) and ether (1 L). The water layer was separated and concentrated in vacuo to approximately 200 mL. The aqueous solution was then frozen and lyophilized to afford the title compound as a light yellow solid.

Physical properties as follows: [a] 25D = +5 (c 1, MeOH); IR (mull) 3244,3186,3112,1747,1660,1604,1562,1539,1516, 1431,1416,1327,1273,1243,799 cm 1 ; 1H NMR (300 MHz; CD30D) 5 7.69 (2H), 7.45 (3H), 7.29 (2H), 4.34 (1H), 3.83 (3H), 3.21 (2H); 13C NMR (300 MHz; CD30D) 8 169.0,163.9,137.8,136.08, 131.8,131.0,130.3,129.7,127.9,120.6,53.8,52.3,35.4; MS (ES+) for C17Hl6Cl2N203 m/z 367.1 (M+H) +.

Compound 8 0-2,6-Dichlorobenzyl-L-tyrosine methyl ester hydrochloride (Compound 8). To a cooled (0-5°C) solution of anhydrous methanolic HC1 (200 mL) was added 25 g of N-a-tert-Butoxycarbonyl-0-2,6- dichlorobenzyl-L-tyrosine (Sigma) portionwise over 15 min. After 30 minutes at 0-5°C, the mixture was heated to 50°C for 2 h. The solution was cooled to room temperature and the volatiles removed

in vacuo. The solid was suspended in ethyl ether and collected by filtration to afford the title compound which was used without further purification. Physical properties as follows: [oe] 25D = +16 (c 1.00, ethanol); 1H NMR (300 MHz, CD30D) 8 7.44 (2 H), 7.35 (1 H), 7.21 (2 H), 7.02 (2 H), 5.28 (2 H), 4.29 (1 H), 3.81 (3 H), 3.18 (2 H); MS (ESI+) for Cl7Hl7Cl2NO3 m/z 359.1 (M+H) + ; Anal. Calcd for Cl7Hl7Cl2NO3-HCl: C, 52.26; H, 4.64; N, 3.59. Found: C, 52.17; H, 4.74; N, 3.61.

Compound 9 <BR> <BR> <BR> <BR> <BR> <BR> <BR> 4-AminoN-[(1, 1dimethylethoxy) carbonyl]-L-phenylalanine (Cl4H20N2o4, Compound 9). To a mixture of N- [ (l, l-dimethylethoxy) carbonyl]-4- nitro-L-phenylalanine (12.0 g, 38.7 mmol) and 10% Pd/C (0.8 g) in MeOH (0.15 L) is hydrogenated (35 psi H2) at room temperature for 2 h. The catalyst is removed by filtration, and the MeOH is removed in vacuo to give, after vacuum drying, Compound 9: 1H NMR (CDC13, 300 MHz) d 6.95 (m, 2H), 6.63 (m, 2H), 5.1 (s, 1H), 4.4 (s, 1H), 3.0 (m, 2H), 1.4 (s, 9H).

Compound 10 4- [2,6- (Dichlorobenzoyl) amino]-N- [ (1,1-dimethylethoxy) carbonyl]-L- phenylalanine (C2lH22C12N205, Compound 10). To a mixture of Compound 9 (12.0 g, 42.7 mmol), NaOH (3.4 g, 85.5 mmol) in H20 (80 mL) is added a solution of 2,6-dichlorobenzoylchloride (10.7 g, 51.3 mmol) in dioxane (24 mL). The mixture is stirred for 24 h at rt. It is contentrated partially to remove the dioxane, and is then acidified to precipitate the product. The precipitate is collected by filtration, washed with cold H20, and dried in a vacuum oven at room temperature overnight. The solid is triturated with THF, and the THF is discarded. The solid is dissolved in MeCN (2 L), and the solution is concentrated to a volume of approximately 300 mL. Water

(150 mL) is added. The solution is frozen and lyophilized to give Compound 10: MS (FAB) m/z453,399,398,397,353,307,280,278, 175,173,57; Anal. C 55.48; H 4.74, Cl 15.37, N 6.25 (calcd corrected for 2.68% H20: C 55.64, H 4.89, Cl 15.64, N 6.18).

Compound 11 To a cooled (0-5 °C) solution of Compound 7 (0.75 g, 1.86 mmol) in THF (20 mL) was added NEt3 (520 pL, 3.72 mmol) and CDI (0.30 g, 1.86 mmol). After 60 min, ethyl isonipecotate was added and the mixture stirred for an additional hour at 0-5 °C. The ice bath was removed and the solution stirred overnight at room temperature and diluted with ethyl acetate and 0.25 N aqueous HC1. The organic layer was separated and washed with 0.25 N aqueous HC1, brine, dried (MgSO4) filtered and concentrated in vacuo. Crystallization of the residue from aqueous ethanol afforded the above compound as a colorless solid: 1H NMR (300 MHz, CDC13) 8 7.60 (2 H), 7.32 (3 H), 7.10 (2 H), 4.70 (1 H), 4.13 (2 H), 3.78 (2 H), 3.74 (3 H), 3.12 (2 H), 2.89 (2 H), 2.48 (1 H), 1.88 (2 H), 1.63 (2 H), 1.23 (3 H); 13C NMR (75 MHz, CDC13) 8 174.8,173.4,163.2,156.8,136.8,136.3,132.9, 132.4,130.8,129.9,128.1,120.5,60.8,56.8,54.6,52.4,43.4, 41. 0,37.7,27.8,14.2; MS (ESI+) for C26H29C12N306 mlz 550.0 (M+H) +; MS (ESI-) for C26H29C12N306 m/z 548.0 (M-H)'; Anal. Calcd for C26H29Cl2N306: C, 56.73; H, 5.31; N, 7.63. Found: C, 56.42; H, 5.43; N, 7.58.

Scheme R

Preparation R-1-1 Scheme R, R-1, wherein R = CO2tBu, R'= CH3 3-Carbomethoxy-2,4,4-trimethyl-2-cyclohexen-1-ylideneacetic acid, 1,1-dimethylethyl ester, (E) (C17H2604) R-1 To a stirring solution of 1M potassium t-butoxide in THF (44mL) at 0°C was added a solution of t-butyl diethylphosphonoacetate (12.6g, 49.8mmol) in THF (15mL) dropwise. The solution was allowed to warm to RT and stirred for 30 minutes before being recooled to 0°C. A solution of the known ketone 3-carbomethoxy-2,4,4-trimethyl-2-cyclohexen-1-one (Boulin, B.; Miguel, B. Arreguy-San; D. B. Tetrahedron 1998, 54,2753) (5.75g, 29.3mmol) in THF (lOmL) was added dropwise.

The solution was allowed to slowly warm to RT and was stirred for 16h. The solution was evaporated in vacuo, and the residue was partitioned between H20 (250mL) and EtOAc (250L). The aqueous phase was extracted with EtOAc (250mL). The combined organic phases were washed with H20 (500mL), brine (500mL), filtered, and evaporated in vacuo. The resulting orange oil was chromatographed on silica gel (450g, 230-400 mesh, 70mm OD column, packed and eluted with EtOAc/heptane, 5: 95 (2L), then EtOAc/heptane, 1: 9, collecting 270mL fractions) using the flash technique. Fractions 5-13 were combined and evaporated in vacuo to afford the desired diester R-1 (R = CO2tBu, R'= CH3) 6.41g of clear colorless oil, (74%). 1H-NMR (300 MHz., <BR> <BR> <BR> CDC13): 6 = 5. 8I (1), 3.80 (3), 3.00-3.07 (2), 1.79 (3), 1.56-1.69 (2), 1.50 (9), 1.13 (6). IR (mull) 1723,1702,1610, 1602,1395,1300,1286,1249,1210,1 180,1147,113 (), 1 () 63, 982, and 864cm-1. MS (FAB) m/z (rel. intensity) 295 (MH+, 20),

295 (20), 263 (1 ()), 24 () (15), 239 (99), 237 (8), 221 (39), 207 (40), 133 (9), 91 (8), 57 (29). Anal. Calcd for C17H2604: C, 69.36; H, 8.90. Found: C, 69.02; H, 8.80.

Preparation R-1-2 Scheme R, R-l, wherein R = C02tBu, R'= H 3-Carboxy-2,4,4-trimethyl-2-cyclohexen-1-ylideneacetic acid, 1,1-dimethylethyl ester, (E) (Cl6H2404) R-1 To a stirring solution of the R-1 (R = CO2tBu, R'= CH3) (6.08g, 20.7mmol) in DMF (75mL) was added KOH (1.27g, 22.7mmol) and thiophenol (2.3mL, 22.7mmol), and the mixture was heated at 100°C for 16h. The mixture was allowed to cool to RT, and evaporated in vacuo. The resulting residue was partitioned between Et20 (500mL) and 5% aqueous NaOH (500mL), and the organic phase was discarded. Aqueous 6N HC1 was added to the aqueous phase until the pH was ca. 2-3; and the mixture was extracted with Et2O (2x500mL). The combined extracts were washed with brine (500mL), dried (Na2SO4), filtered, and evaporated in vacuo to afford the carboxylic acid R-1 (R = CO2tBu, R'= H) as a creamcolored solid, 5.55g (96%). MP <BR> <BR> <BR> <BR> 83-87°C; 1H-NMR (300 MHz, DMSO-d6): 6 = 12.91 (1), 5.70-5.77 (2), 2.88-2.97 (2), 1.75 (3), 1.40-1.55 (10), 1.09 (6); IR (mull) 3488,3389,2584,1683,1604,1303,1283,1262,1230, 1218,1150,1132,987,865, and 854cm-1. MS (EI) m/z (rel. intensity): 280 (M+, 1), 224 (71), 207 (54), 206 (95), 179 (99), 178 (62), 161 (48), 133 (52), 119 (49), 111 (50), 57 (97). HRMS (EI) calcd for C16H2404 280.1764. Found 280.1668.

Preparation R-2-1 Scheme R, R-2, wherein R = C02tBu, R"= CH3, X = NH, Y = C=O N-[[(3E)-3-[[(1,1-Dimethylethoxy) carbonyl] methylene]-2,6,6- trimethyl-1-cyclohexen-1-yl] carbonyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C33H38Cl2N206)R-2 To a stirring solution of the carboxylic acid R-1 (R = CO2tBu, <BR> <BR> <BR> <BR> <BR> R'= H) (2.54g, 9.06mmol) in DMF (75mL) was added 4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (11. Og, 27.2mmol), HATU (6.89g, 18.1mmol), and diisopropylethylamine (7.9mL, 45.3mmol). The solution was allowed to stir at RT for 16h and then was evaporated in vacuo. The residue was partitioned between 1M aqueous HCI (500mL) and EtOAc (500mL), and the aqueous phase was extracted with EtOAc (500mL). The combined extracts were washed with brine (500mL), dried (Na, SO4), filtered, and evaporated in vacuo. The resulting yellow oil was chromatographed on silica gel (450g, 230-400 mesh, 70mm OD column, packed and eluted with EtOAc/CH2C12, (1: 9), collecting 270mL fractions) using the flash technique. Fractions 8-16 were combined and evaporated in vacuo. to afford the desired product R-2 (R = C02tBu, R"= CH3, X = NH, Y = C=O) as a white solid, 2.22g (39%). MP 158-160°C; 1H-NMR (300 MHz, CDC13) b = 7.56-7.64 (2), 7.30-7.41 (3), 7.17-7.24 (2), 5.74-5.83 (2), 5.03-5.13 (1), 3.79 (3), 3.07-3.26 (2), 2.95-3.05 (2), 1.73 (3), 1.45-1.59 (12), 1.12 (3), 1.05 (3); IR (mull) 3259,175 (), 1707,169 (), 1671,1639,

1432,1332,1279,1216,1151, and 1135cm-1; MS (FAB) m/z; (rel. intensity): 629 (MH+, 3), 557 (32), 555 (46), 349 (18), 263 (31), 208 (18), 207 (99), 175 (19), 173 (30), 161 (18), 57 (26); HRMS (FAB) calcd for C33H38Cl2N206+Hl 629.2185, found 629.2176.

Preparation R-2-2 Scheme R, R-2, wherein R = CO2H, R"= CH3, X = NH, Y = C=O N- [ [ (3E)-3-Carboxymethylene-2,6,6-trimethyl-l-cyclohexen-l- yl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C29H30C12N206) R-2 The diester R-2-1 (R-2 (R = C02tBu, R"= CH3, X = NH, Y = C=O) (3.95g, 6.27mmol) was dissolved in trifluoroacetic acid (70mL), and the solution stirred at RT for 12h. Evaporation in vacuo gave a viscous, light brown oil which, upon trituration with Et2O/heptane (1: 1,100mL), afforded the target carboxylic acid R-2-2 (R-2 R = CO2H, R"= CH3, X = NH, Y = C=O) as a powdery white solid which was collected by suction filtration and dried (3.45g, 96%). MP 163-168°C; 1H-NMR (300 <BR> <BR> <BR> <BR> MHz, DMSO-d6): 8 = 10.65 (1), 8.39 (1), (5), 7.26 (2), 5.72 (1), 4.59-4.72 (1), 3.66 (3), 3.05-3.18 (1), 2.75-3.02 (3), 0.72-1.83 (12); IR (mull) 3258,1746,1664, 1639,1607,1562,1544,1515,1432,1414,1328,1277,1216, 1194, and 799cm-1; MS (FAB) m/z (rel. intensity): 573 (MH+, 21), 573 (21), 557 (41), 555 (59), 351 (20), 349 (31), 207 (99), 177 (65), 175 (26), 173 (42), 105 (25); HRMS (FAB)

calcd. for C29H3oCl2N206+Hl 573.1559, found 573.1544.

Example 118 Scheme R, R-2, wherein R = CO2H, R"= H, X = NH, Y = C=C <BR> N- [ [ (3E)-3-Carboxymethylene-2,6,6-trimethyl-1-cyclohexen-1- yl]carbonyl]-4-[(2,6-dichlorobenzoyl)amino]-L-phenylalanine (C28H28C12N206) R-2 To a stirring solution R-2-2 (R-2 R = CO2H, R"= CH3, X = NH, Y = C=O) (4.25g, 7.41mmol) in CH30H (50mL) was added a solution of LiOH-H20 (0.62g, 14.8mmol) in H20 (15mL) and 30% H202 (25 drops).

The solution stirred at RT for 16h and was then evaporated in vacuo. The residue was dissolved in H20 (50mL) and acidified to pH ca. 1-2 with 1N aqueous HC1. The resulting gelatinous solid was collected by suction filtration and dried in a vacuum oven at 70°C for 16h. The resulting solid was crushed, washed thoroughly with H20, and dried in a vacuum oven at 70°C for 16h to afford the target diacid R (R = CO2H, R"= H, X = NH, Y = C=O) as an off-white, crystalline solid, 3.98g ('96%). MP: 175-185°C; <BR> <BR> <BR> 1H-NMR (300 MHz, DMSO-d6): 8 = 11.94-12.80 (1), 10.64 (I), 8.23 (1), 7.44-7.66 (5), 7.24 (2), 5.71 (1), 4.53-4.66 (1), 3.06-3.19 (1), 2.76-3.01 (3), 0.61-1.87 (12); IR (mull) 3257,3195,3128, 3067,1712,1663,1606,1563,1540,1517,1432,1415,1329, 1275, and 1194cm-1 ; MS (FAB) m/z (rel. intensity): 559 (MH+, 61), 559 (61), 543 (74), 541 (98), 517 (42), 515 (55), 207 (99,, 175 (46), 173 (69), 161 (54), 135 (65); HRMS (FAB) calcd for C2BH28C12N206+Hl 559.1403, found 559.1387.

Preparation R-2-3 Scheme R, R-2, wherein R = C02tBu, R"= CH3, X = 0, Y = CH2 N-[[(3E)-3-[[(1,1-Dimethylethoxy) carbonyl] methylene]-2,6,6- trimethyl-1-cyclohexen-1-yl] carbonyl]-4-0- (2,6- dichlorophenylmethyl)-L-tyrosine methyl ester (C33H39Cl2NO6) R-2 To a stirring solution of the carboxylic acid R-1 (R = CO2tBu, R'= H) (1. 10g, 3.92mmol) in DMF (30mL) was added 4-0- (2,6- dichlorophenylmethyl)-L-tyrosine methyl ester hydrochloride (2.30g, 5.89mmol), HATU (1.79g, 4.71 mmol), and diisopropylethylamine (2.7mL, 15.7mmol). The solution stirred at RT for 16h and then was evaporated in vacuo. The residue was partitioned between 1M aqueous HC1 (150mL) and CH2C12 (150mL). The organic phase was washed with saturated aqueous NaHC03 (150L), brine (150mL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting amber oil was chromatographed on silica gel (300g, 230-400 mesh, 70mm OD column, packed and eluted with CH2C12 (2L), then EtOAc/CH2Cl2 (5: 95), collecting 270mL fractions) using the flash technique.

Fractions 16-20 were combined and evaporated in vacuo to afford the desired product R-2-3 (R = C02tBu, R"= CH3, X = 0, Y = CH2) as a light yellow solid, 0.87g (36%). 1H-NMR (300 MHz, <BR> <BR> <BR> CDC13) 7.33-7.38 (2), 7.21-7.28 (1), 7.10 (2), 6.95 (2), 5.69-5.73 (2), 5.24 (2), 5.01 (1), 3.76 (3), 3.18 (1), 2.94-3.07 (3), 1.66-1.69 (4), 1.46-1.55 (10), 1.09 (3), 1.00 (3); IR (mull) 1746,1705,1636,1611,1586,1512,1439,1301,

1277,1241,1196,1179,1152,1134, and 1018cm-1; HRMS (EI): calcd for C33H39Cl2NO6 615.2155, Found: 615.2156. Anal. Calcd for C33H39Cl2NO6: C, 64.28; H, 6.38; N, 2.27; Cl, 11.50. Found: C, 63.91; H, 6.38; N, 2.52; Cl, 11.33.

Preparation R-2-4 Scheme R, R-2, wherein R = C02H, R"= CH3, X = O, Y = CH2 N- [ [ (3E)-3-Carboxymethylene-2,6,6-trimethyl-1-cyclohexen-1- yl] carbonyl]-4-O-(2, 6-dichlorophenylmethyl)-L-tyrosine methyl ester (C29H3lCl2NO6) R-2 The diester (0.80g, 1.30mmol) was dissolved in trifluoroacetic acid (15mL), and the solution stirred at RT for 16h.

Evaporation in vacuo gave a viscous, amber oil which, upon trituration with Et2O/hexanes (1: 1,100mL), afforded the target carboxylic acid R-2 (R = C02H, R"= CH3, X = 0, Y = CH2) as a powdery white solid which was collected by suction filtration and dried, 0.63g (86%). MP: 140-143°C; 1H-NMR (300 <BR> <BR> <BR> <BR> MHz, CDCl3) : 8 7.37 (2), 7.26 (2), 7.11 (2), 6.96 (2), 5.82-5.89 (2), 5.24 (2), 5.05 (1), 3.78 (3), 2.90-3.25 (4), 1.70 (3), 1.54 (2), 1.09 (3), 1.00 (3).

Example 119 Scheme R, R-2, wherein R = C02H, R"= H, X = O, Y = CH2 N-[[(3E)-3-Carboxymethylene-2,6,6-trimethyl-1-cyclohexen-1- yl]carbonyl]-4-O-(2,6-dichlorophenylmethyl)-L-tyrosine (C28H29Cl2NO6)R-2

To a stirring solution of the methyl ester R-2 (R = CO2H, R" = H, X = 0, Y = CH2) (0.59g, 1.05mmol) in CH30H (lOmL) was added a solution of LiOH H2O (0.09g, 2.11mmol) in H20 (5mL) and 30% H202 (5 drops). The solution stirred at RT for 16h and was then evaporated in vacuo. The residue was dissolved in H20 (50mL) and acidified to pH ca. 1-2 with 1N aqueous HC1. The resulting gelatinous solid was collected by suction filtration and dried in a vacuum oven at 70°C for 16h. The resulting solid was crushed, washed thoroughly with H20, and dried in a vacuum oven at 70°C for 16h to afford the target diacid R-2 (R = COOH, R"= H, X = O, Y = CH2) as an off-white, crystalline solid, 0.47g (82%). MP: 115-138°Ci 1H-NMR (300 MHz, DMSO-d6): d = 11.67-12.88 (1), 8.15 (1), 7.54 (2), 7.40-7.48 (1), 7.20 (2), 6.93 (2), 5.68 (1), 5.16 (2), 4.47-4.58 (1), 3.04-3.13 (1), 2.73-2.95 (4), 1.33-1.65 (5), 0.68-0.98 (6): IR (mull): 3058,1693,1611,1601,1565,1539,1512,1439,1299,1278, 1244,1196,1179,777, and 769cm~1; HRMS (EI) calcd for C28H29C12NO6545.1372, found 545.1377; % Water (KF): 2.53.

Preparation R-1-4 Scheme R, R-1, wherein R = CN, R'= CH3 3-Carbomethoxy-2,4,4-trimethyl-2-cyclohexen-l- ylindeneacetonitrile, (E) (Cl3Hl7NO2) R-1 Sodium hydride (0.73g of a 60E oil dispersion, 18.3mmol) was washed with hexane (3 x 5 mL) and suspended in THF (lOmL) and cooled to 0°C. To this suspension was added a solution of t-butyl diethylphosphonoacetate (4.60g, 26. Ommol) in THF (lOmL) dropwise. After stirring at 0°C for lh, the ice water bath was removed and a solution of the ketone, 3-carbomethoxy- 2,4,4-trimethyl-2-cyclohexen-1-one (Boulin, B.; Miguel, B.

Arreguy-San; D. B. Tetrahedron 1998,54,2753), (3.00g, 15.3mmol) in THF (lOmL) was added dropwise. The reaction mixture stirred at RT for 16h before being evaporated in vacuo. The residue was partitioned between H20 (lOOmL) and EtOAc (100ml), and the aqueous phase was extracted with EtOAc (50mL). The combined organic phases were washed with H20 (lOOmL), brine (lOOmL), filtered, and evaporated in vacuo. The resulting light brown oil was chromatographed on silica gel (400g, 230-400 mesh, 70mm OD column, packed and eluted with Et20/hexanes, 15: 85, collecting 270mL fractions) using the flash technique. Fractions 11-18 were combined and evaporated in vacuo to afford the vinyl nitrile R-1 (R = CN, R'= CH3) as a mixture of geometric isomers (E: Z = 3.5: 1, as determined by 1H-NMR); 3.20g (95%) of clear, colorless oil. 1H-NMR (300 MHz, <BR> <BR> <BR> <BR> CDC13): 6 = 5.30 (0.78), 5.19 (0.22), 3.79 (3), 2.74-2.80 (1.56), 2.44-2.51 (0.44), 2.14 (0.66), 1.75 (2.34), 1.60-1.67 (2), 1.14 (4.68), 1.13 (1.32); IR (neat) 2966,2954,2871,

2212,1726,1584,1450,1433,1330,1291,1247,1222,1067, 1027, and 802cm-1; MS (EI) m/z (rel. intensity): 219 (M+, 19), 219 (19), 188 (12), 172 (16), 161 (13), 160 (99), 159 (13), 144 (12), 133 (8), 118 (11), 91 (9); Anal. Calcd for Ci3HnN02: C, 71.21; H, 7.81 ; N, 6.39. Found: C, 71.04 ; H, 7.74; N, 6.37.

Preparation R-1-5 Scheme R, R-1, wherein R = CN, R'= H 3-Carboxy-2,4,4-trimethyl-2-cyclohexen-1-ylideneacetonitrile , (E) (CisHisNOz) R-1 To a stirring solution of the nitrile R-1 (R = CN, R'= CH3) (2.05g, 9.35mmol) in DMF (35mL) was added KOH (0.58g, 10.3mmol) and thiophenol (l. lmL, 10.3mmol), and the mixture stirred at 100°C for 16h. After cooling to RT, the reaction mixture was evaporated in vacuo. The residue was partitioned between 5% aqueous NaOH (lOOmL) and Et20 (lOOmL), and the organic phase was discarded. Then, 6N aqueous HC1 was added dropwise to the aqueous phase until the pH reached ca. 1, and it was then extracted with Et20 (2xlOOmL). The combined extracts were washed with H20 (lOOmL), brine (lOOmL), dried (Na2SO4), filtered, and evaporated in vacuo to afford the carboxylic acid R-1 (R = CN, R'= H) as a mixture of geometric isomers (E: Z = 4.7: 1, as determined by 1H NMR); 1.81g (94%) as a white solid. MP: 88-92°Ci 1H-NMR (300 MHz, CDC13): 8 = 8.02-9.24 (1), 5.36 (0.82), 5.24 (0.18), 2.77-2.84 (1.64), 2.48-2.54 (0.36), 2.27 (0.54), 1.88 (2.46), 1.64-1.71 (2), 1.22 (4.92), 1.21 (1.08); MS (ESI-) for C15Hl5N02 m/z 204.2 (M-H).

Preparation R-2-5 Scheme R, R-2, wherein R = CN, R"= CH3, X = NH, Y = C=O <BR> <BR> N- [ [ (3E)-3-Cyanomethylene-2,6,6-trimethyl-1-cyclohexen-1- yl] carbonyl]-4- [(2,[(2, 6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C29H29Cl2N304) R-2 To a stirring solution of the carboxylic acid R-1 (R = CN, R' = H) (1.80g, 8.77mmol) in DMF (35mL) was added 4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (7.08g, 17.5mmol), HATU (4.00g, 1 0.5mmol), and diisopropylethylamine (6. lmL, 35.1 mmol). The solution stirred at RT for 62h and then was evaporated in vacuo. The residue was partitioned between 1N aqueous HCI (250mL) and CH2C12 (250mL), and the aqueous phase was extracted with CH2Cl2 (250mL). The combined extracts were washed with saturated aqueous NaHCO3 (500mL), brine (500mL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting orange oil was chromatographed on silica gel (400g, 230-400 mesh, 70mm OD column, packed and eluted with EtOAc/CH2Cl2 (1: 9), collecting 260mL fractions) using the flash technique. Fractions 12-25 were combined and evaporated in vacuo to afford the desired product R-2 (R = CN, R"= CH3, X = NH, Y = C=O) as a mixture of geometric isomers (E: Z = 4.2: 1, as determined by 1H-NMR), 4.93g (100%) of light yellow solid. MP: 120°C; 1H-NMR (300 <BR> <BR> <BR> <BR> <BR> MHz, DMSO-d6): 5 = 10.65 (1), 8.48 (1), 7.43 7.62 (5), 7.23 (2), 5.55 (0.81), 5.52 (0.19), 4.58-4.69 (1), 3.64 (3), 3.33

(3), 3.10 (1), 2.81-2.92 (1), 2.62 (1.62), 2.37-2.45 (0.38), 1.42-1.69 (2), 0.68-1.05 (6); IR (mull) 3292,1745,1665, 1642,1605,1580,1562,1536,1517,1431,1414,1325,1270, 1217, and 799cm-1; HRMS (EI) calcd for C29H29Cl2N304 553.1535, found 553.1551.

Example 120 Scheme R, R-2, wherein R = CN, R"= H, X = NH, Y = C=O N- [ [ (3E)-3-Cyanomethylene-2,6,6-trimethyl-1-cyclohexen-1- yl] carbonyl]-4- [(2, 6-dichlorobenzoyl)[(2, 6-dichlorobenzoyl) amino]-L-phenylalanine (C28H27C12N304) R-2 To a stirring solution of the methyl ester R-2 (R = CN, R"= CH3, X = NH, Y = C=O) (1.80g, 3.25mmol) in CH30H (40mL) was added a solution of LiOH H20 (0.27g, 6.50mmol) in H20 (lOmL) and 30% H202 (20 drops). The solution was stirred at RT for 16h and was then evaporated in vacuo. The residue was dissolved in H20 (50mL) and acidified to pH ca. 1-2 with 1N aqueous HC1.

The resulting gelatinous solid was collected by suction filtration and dried in a vacuum oven at 70°C for 16h. The resulting solid was crushed, washed thoroughly with H20, and dried in a vacuum oven at 70°C for 16h to afford the target carboxylic acid R-2 (R = CN, R"= H, X = NH, Y = C=O) as an off-white, crystalline solid, 1.43g (81%). MP: 172-180°C; lH- <BR> <BR> <BR> <BR> NMR (300 MHz, DMSO-d6) 12.05-13.42 (1), 10.63 (1), 8.30 (1), 7.42-7.61 (5), 7.23 (2), 5.52 (1), 4.50-4.62 (1), 2.34-3.55 (7), 1.41-1.68 (2), 0.71-1.06 (6); IR (mull) 3291,

1734,1664,1645,1605,1581,1562,1537,1517,1432,1414, 1327,1272,1195, and 799cm-1; MS (FAB) m/z (rel. intensif): 540 (MH+, 80), 543 (20), 542 (57), 541 (32), 540 (8 ()), 335 (17), 189 (18), 188 (99), 175 (19), 173 (30), 161 (41); HRMS (FAB) calcd for C28H27Cl2N304+Hl, 540.1457, found % Water (KF): 3.07.

Scheme S

Preparation S-1 Scheme S, S-1 (3E)-3-Carbomethoxy-2,4,4-trimethyl-2-cyclohexen-1- ylideneacetic acid (C13Hl804) S-1 A solution of 3-carbomethoxy-2,4,4-trimethyl-2-cyclohexen-1- ylideneacetic acid, 1,1-dimethylethyl ester, prepared as described in Scheme R (Preparation R-l-1, Scheme R, R-1, wherein R = CO2tBu, R'= CH3) (1.82g, 6.18mmol) was stirred in TFA (lOmL) at RT for 16h and was then evaporated in vacuo. The resulting black oil was chromatographed on silica gel (150g, 230-400 mesh, 35mmOD column, packed and eluted with MeOH/CH2Cl2,2.5: 97.5, collecting 30mL fractions) using the flash technique. Fractions 24-56 were combined and evaporated in vacuo to afford 0.92g (62%) of the carboxylic acid S-1 as an off-white solid, as an 83: 17 mixture of E/Z geometric isomers. MP 115-120°C (sublimes); TLC: Rf = 0.31 (MeOH/CH2Cl2, 7.5: 92.5); 1H-NMR (300 MHz, CDC13): 8-5. 92 (0.83), 5.73 (0.17), 3.82 (2.4 9), 3.80 (0.51), 3. 06 (1.63), 2. 43 (0.37), 1.89 (0.54), 1.81 (2.46), 1.61 (2), 1.14 (1.02), 1.13 (4.98); IR (mull) 1718,1685,1664,1600,1433,1416,1326,1303, 1288,1258,1227,1210,1060,1027, and 866cm-1 ; MS (EI) m/z (rel. intensity) 238 (M+, 30), 238 (30), 207 (31), 206 (33), 179 (99), 178 (38), 161 (51), 133 (63), 119 (33), 91 (41), 77 (24); Anal. Calcd for C13H18O4 : C, 65.53; H, 7.61. Found: C, 65. 32; H, 7.79.

Preparation S-2-1 Scheme S, S-2, wherein R = R'= CH3 N- [ (lE)-3-Carbomethoxy-2,4,4-trimethyl-2-cyclohexen-1- ylideneacetyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C30H32Cl2N206) S-2 To a stirring solution of the carboxylic acid S-1 (0.88g, 3.69mmol) in CH2C12 (15mL) was 4- [ (2,6-dichlorobenzoyl) amino]- L-phenylalanine methyl ester hydrochloride (1.49g, 3.69mmol), EDC (0.71g, 3.69mmol), DMAP (0.14g, l. lOmmol), HOBT (0.50g, 3.69mmol) and triethylamine (3mL). The solution was allowed to stir at RT for 16h and then was evaporated in vacuo. The residue was partitioned between 1N aqueous HC1 (150mL) and CH2Cl2 (150mL). The organic phase was washed with saturated aqueous NaHC03 (150mL), brine (150mL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting yellow solid was chromatographed on silica gel (400g, 230-400 mesh, 70mm OD column, packed and eluted with MeOH/CH2Cl2,5: 95, collecting 150mL fractions) using the flash technique. Fractions 4-7 were combined and evaporated in vacuo to afford the desired product S-2 (R = R'= CH3) as a yellow solid, 1.31g (60%). An analytical sample was obtained by recrystallization from CH2Cl2/CH30H/Et20. MP: 193°C; TLC: Rf = 0.22 (MeOH/CH2Cl2, <BR> <BR> <BR> <BR> 5: 95); 1H-NMR (300 MHz, DMSO-d6): 5 = 10.66 (1), 8.39 (1), 7.52-7.61 (4), 7.44-7.50 (1), 7.19 (2), 6.00 (1), 4.51 (1), 3.70 (3), 3.62 (3), 3.01 (1), 2.78-2.91 (3), 1.68 (3), 1.42 (2), 1.01 (6); IR (mull) 1749,1723,1669,1643,1612,1562,

MS (FAB) m/z (rel. intensity): 587 (MH+, 13), 589 (8), 587 (13), 557 (8), 555 (12), 222 (15), 221 (99), 175 (14), 173 (23), 161 (21), 133 (14); HRMS (FAB) calcd for C3oH32Cl2N206+H, 587.1715, found 587.1705; Anal. Calcd for C30H32Cl2N206: C, 61.33; H, 5.49; N, 4.77. Found: C, 60.94; H, 5.42; N, 4.80.

Example 121 Scheme S, S-2, wherein R = R'= H N- [ (lE)-3-Carboxy-2,4,4-trimethyl-2-cyclohexen-l- ylideneacetyl]-4- [(2,[(2, 6-dichlorobenzoyl) amino]-L-phenylalanine (C28H28C12N206) S-2 To a stirring solution of the diester S-2 (R = R'= CH3) (1.13g, 1.92mmol) in DMF (15mL) was added KOH (0.24g, 4.23mmol) and thiophenol (0.44mL, 4.23mmol), and the mixture was heated at 100°C for 16h. Evaporation in vacuo afforded a brown residue which was dissolved in H20 (50mL). To this solution was added 1N aqueous HC1 until the pH of the mixture was ca. 3, and it was extracted with MeOH/Et20 (5: 95,50mL).

The extract was washed with brine (50mL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting orange solid was recrystallized from EtOAc/cyclohexane to give the diacid S-2 (R = R'= H) as a light yellow solid. Residual volatiles were removed by heating (100°C) in a vacuum oven for 6h to give 0.90g (84%) of S-2 (R = R'= H). MP: 159°C

(decomposition); 1H-NMR (300 MHz, DMSO-d6): b-12. 70 (1), 10.65 (1), 8.23 (1), (6), 7.20 (2), 5.97 (1), 4.46 (1), 3.03 (1), 2.77-2.88 (3), 1.73 (3), 1.41 (2), 1.05 (6); IR (mull) 3265,3123,3055,3035,1720,1645,1605,1562, 1537,1516,1432,1414,1326,1217, and 1196cm-1; MS (FAB) m/z (rel. intensity): 559 (MH+, 27), 559 (27), 543 (30), 541 (41), 335 (18), 221 (51), 207 (99), 175 (31), 173 (48), 161 (30), 133 (19); HRMS (FAB) calcd for C28H28C12N206+H1 559.1403, found 559.1398; % Water (KF): 1.24.

Scheme T

Preparation T-1-1 Scheme T, T-1, wherein 3-CO2CH3 (E)-3- [3-Hydroxy-3-oxo-l-propenyl] benzoic acid methyl ester<BR> <BR> (CllHl004) A solution of the known diester 3- [3- (l, l-dimethylethoxy)-3- oxo-1-propenyl]benzoic acid methyl ester (Mjalli, A. M. M.; Cao, X.; Moran, E. J. PCT Int. Appl., 89pp. CODEN: PIXXD2. WO 9708934 A2 970313. CAN 126: 277769) (l. OOg, 3.81mmol) in TFA (lOmL) was stirred at RT for 16 hours. Evaporation in vacuo afforded 0.83g (100%) of the T-1 (3-CO2CH3) as a white solid.

MP: 186-187°C; 1H-NMR (300MHz, DMSO-d6): # = 8. 16 (1), 7.94 (2), 7.52-7.67 (2), 6.59 (1), 3.85 (3); IR (mull) 1730,1678,1634, 1438,1346,1329,1297,1227,1201,1079,985,871,757,721, and 670cm-1 ; MS (EI) m/z (rel. intensity) 206 (M+, 54), 206 (54), 175 (99), 174 (14), 147 (24), 130 (14), 129 (19), 102 (16), 91 (33), 65 (16), 51 (19); HRMS (EI) calcd for Clin1004 206.0579, found 206.0586.

Preparation T-1-2 Scheme T, T-1, wherein 4-CO2CH3 (E)-4- [3-Hydroxy-3-oxo-l-propenyl] benzoic acid methyl ester (CiiHioC) A solution of the known diester 4- [3- (l, l-dimethylethoxy)-3- oxo-1-propenyl]benzoic acid methyl ester (Mjalli, A. M. M.; Cao, X.; Moran, E. J. PCT Int. Appl., 89pp. CODEN: PIXXD2. WO 9708934 A2 970313. CAN 126: 277769) (l. OOg, 3.81mmol) in TFA (lOmL) was stirred at RT for 2 hours. Evaporation in vacuo afforded 0.79g (100%) of the title compound T-1 (4-CO2CH3) as

a white solid. lH-NMR (300MHz, DMSO-d6): 8 = 7.94 (2), 7.80 (2), 7.62 (1), 6.62 (1), 3.84 (3); IR (mull): 1715,1685,1634,1569, 1438,1426,1329,1309,1284,1227,1185,1111,992,775, and 72 cm 1; MS (EI): m/z (rel. intensity) 206 (M+, 44), 206 (44), 191 (19), 176 (12), 175 (99), 147 (28), 102 (12), 101 (9), 91 (23), 65 (11), 51 (10); HRMS (EI) calcd for CllHloOe 206.0579, found 206.0583.

Preparation T-3-1 Scheme T, T-3, wherein 3-substituted, R = CH3, R"= CH3 N- [ (E)-3- (3-Carbomethoxyphenyl)-l-oxo-2-propenyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester T-3 (C28H24Cl2N206) To a stirring suspension of the acid T-1 (3-CO2CH3) (0.73g, 3.54mmol) in CH2CL2 (30mL) was added 4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (1.43g, 3.54mmol), EDC (0.69g, 3.54mmol), DMAP (0.13g, 1.06mmol), and HOBT (0.48g, 3. 54mmol). To this mixture was added Et3N dropwise until all solids went into solution.

After stirring for 16h at RT, the resulting precipitate was collected by suction filtration, washed with CH2C12 and Et20, and dried to afford 1.26g (64%) of T-2-1 (3-CO2CH3) as an off- white solid. MP: 216-218°C; 1H-NMR (300MHz, DMSO-d6): # = 10.35 (1), 8.58 (1), 8.13 (1), 7.93 (1), 7.81 (1), 7.43-7.60 (6), 7.21 (2), 6.82 (1), 4.61 (1), 3.86 (3), 3.64 (3), 2.88-3.10 (3); IR (mull): 1746,1741,1728,1670,1655,1624,1611,1562,1552, 1513,1444,1433,1334,1282, and 1207 cm-1; MS (FAB) m/z

(rel. intensity): 555 (MH+, 68), 558 (16), 557 (48), 556 (26), 555 (68), 349 (21), 189 (58), 175 (20), 174 (99), 173 (30), 103 (15); HRMS (FAB) calcd for C28H2CL2N206+H1 555.1089, found 555.1083.

Example 122 Scheme T, T-3, wherein 3-substituted, R = H, R"= H N-[(E)-3-(3-Carboxyphenyl)-l-oxo-2-propenyl]-4-[(2,[(E)-3-(3 -Carboxyphenyl)-l-oxo-2-propenyl]-4-[(2, 6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester T-3 (C26H20Cl2N206) To a stirring solution of the diester T-3 (3-substituted, R = CH3, R"= CH3) (0.83g, 1.50mmol) in MeOH/DMSO (1: 1,20mL) was added a solution of LiOHH20 (0.12g, 3.00mmol) in H20 (5mL).

After stirring for 16h at RT, the reaction mixture was evaporated in vacuo. The residue was dissolved in H20 (25mL) and 6M aq. HCl was added until the pH of the mixture was ca.

1. The resulting gelatinous solid was collected by suction filtration and dried in the vacuum oven at 70°C for 16h. The resulting solid was washed with H20 and dried in the vacuum oven at 70°C for 16h to afford 0.33g (42%) of T-3 (3- substituted, R = H, R"= H) as a light yellow solid. MP: <BR> <BR> <BR> <BR> 165°C; 1H-NMR (300MHz, DMSO-d6): 8 = 10.37 (1), 8.37 (1), 8.12 (1), 7.90 (1), 7.75 (1), (6), 7.21 (2), 6.84 (1), 4.5491), 2.80-3.15 (3); IR (mull) 3280,3062,1709,1661,1606,1584, 1562,1539,1516,1432,1414,1326,1267,1196, and 799 cm-1 ; MS (FAB) m/z (rel. intensity) 527 (MH+, 51), 530 (11), 529 (32), 528 (17), 527 (51), 225 (12), 175 (25), 174 (99), 173

(9), 161 (16), 123 (12); HRMS (FAB) calcd for C26H20CL2N206+H 527.0776, found 527.0770.

Preparation T-3-2 Scheme T, T-3, wherein 4-substituted, R = CH3, R"= CH3 N- [ (E)-3- (4-Carbomethoxyphenyl)-l-oxo-2-propenyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester T-3 (C28H24C12N206) To a stirring suspension of the acid T-1 (4-C02CH3) (0.74g, 3.59mmol) in CH2CL2 (30mL) was added the 4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (1.45g, 3.59mmol), EDC (0.69g, 3.59mmol), DMAP (0.13g, 1.08mmol), and HOBT (0.48g, 3.59mmol). To this mixture was added N, N-diisopropyl ethylamine (3mL). After stirring for 16h at RT, the reaction mixture was evaporated in vacuo.

The residue was partitioned between CH2Cl2 (50mL) and 1N aq. HC1 (50mL), and an insoluble white solid formed. This was collected by suction filtration, washed with H20, washed with Et20, and dried to afford 1.28g (64%) of the title compound T-3 <BR> <BR> <BR> (4-C02CH3, R = CH3, R"= CH3). MP : >250°C; lH-NMR (300MHz, DMSO-d6): 8 = 8.62 (1), 7.96 (2), 7.68 (2), 7.42-7.60 (6), 7.21 (2), 6.81 (1), 4.61 (1), 3.84 (3), 3.64 (3), (2); IR (mull) 3284,3071,1745,1721,1671,1654,1622,1611,1554,1513, 1433,1416,1337,1283, and 121 cm-1; MS (FAB): m/z (rel. intensity) 555 (MH+, 99), 558 (21), 557 (70), 556 (35), 555 (99), 349 (22), 189 (73), 175 (19), 174 (21), 173 (27), 130 (38); HRMS (FAB) calcd for C28H24CL2N206+H1 555.1089, found

555.1093.

Example 123 Scheme T, T-3, wherein 4-substituted, R = H, R"= H N- [(E)-3-(4-Carboxyphenyl)-l-oxo-2-propenyl]-4-[(2,[(E)-3-(4-C arboxyphenyl)-l-oxo-2-propenyl]-4-[(2, 6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester T-3 (C26H2oC12N206) To a stirring solution of the diester (4-CO2CH3, R = CH3, R"= CH3) (0.75g, 1.35mmol) in MeOH/DMSO (3: 1,20mL) was added a solution of LiOHH20 (0.23g, 5.40mmol) in H20 (5mL). After stirring for 16h at RT, the reaction mixture was evaporated in vacuo. The residue was dissolved in H20 (30mL) and 6N aq. HC1 was added until the pH of the mixture was ca. 1. The resulting precipitate was collected by suction filtration, washed with H20, and dried in a vacuum oven at 70°C for 16 hours to afford 0.69g (97%) of the title compound T-3 (4-CO2H) as a white solid. MP: 177-181°C; 1H-NMR (300MHz, DMSO-d6): 6 = 8.46 (1), 7.93 (2), 7.64 (2), 7.40-7.58 (6), 7.21 (2), 6.82 (1), 4.54 (1), 2.86-3.13 (2); IR (mull) 3278,1708,1661,1608,1562, 1325,1270,1230,1196,1179, and 778cm"; MS (FAB): m/z (rel. intensity) 527 (MH, 99), 531 (11), 530 (20), 529 (73), 528 (33), 527 (99), 335 (11), 315 (13), 175 (64), 173 (15), 161 (45); HRMS (FAB) calcd for C26H2oCL2N206+H1 527.0776, found 527.0770.

Preparation T-2-1 Scheme T, T-2, wherein 3-CO2H <BR> <BR> <BR> (E)-3- [3- (1, 1-dimethylethoxy)-3-oxo-1-propenyl] benzoic acid To a stirring solution of the known diester 3- [3- (1,1- dimethylethoxy)-3-oxo-1-propenyl] benzoic acid methyl ester (Mjalli, A. M. M.; Cao, X.; Moran, E. J. PCT Int. Appl., 89pp.

CODEN: PIXXD2. WO 9708934 A2 970313. CAN 126: 277769) (1. OOg, 3.81mmol) in CH30H (lOmL) was added a solution of LiOHH20 (0.32g, 7.62mmol) in H20 (5mL). After stirring at RT for 16 hours, the reaction mixture was evaporated in vacuo. The residue was dissolved in H20 (25mL), and 6N aq. HC1 was added until the pH of the mixture was ca. 4-5. The resulting white precipitate was extracted with EtOAc/THF (1: 1,2X25mL). The combined extracts were washed with sat'd. aq. NaCl (50mL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting white solid was dissolved in MeOH and chromatographed (flash) on silica gel (300g, 230-400 mesh, 70mm OD column, packed and eluted with MeOH/CH2Cl2 (1: 9), collecting 200 mL fractions). Fractions 4-18 were combined and evaporated in vacuo to give 0.42g (44%) of T-2 (3-CO2H) as <BR> <BR> <BR> a white solid. MP: 132-136°Ci H-NMR (300MHz, DMSO-d6): 8 = 8.14 (1), 7.86-7.96 (2), 7.59 (1), 7.48 (1), 6.54 (1), 1.46 (9); IR (mull) 1703,1693,1641,1605,1585,1415,1326,1291,1270, 1260,1212,1157,975,755, and 664cm-1; MS (EI) m/z (rel. intensity): 248 (M+, 8), 193 (44), 192 (83), 191 (19), 175 (80), 174 (43), 157 (19), 130 (22), 57 (99), 56 (78), 55 (24); HRMS (EI) calcd for C14Hl6O4 248.1048, found 248.1055.

Preparation T-2-2 Scheme T, T-2, wherein 4-CO2H <BR> <BR> (E)-4- [3- (1, 1-dimethylethoxy)-3-oxo-1-propenyl] benzoic acid<BR> <BR> <BR> T-2 (Cl4Hl6O4)

To a stirring solution of the known diester 4- [3- (1,1- dimethylethoxy)-3-oxo-1-propenyl] benzoic acid methyl ester (Mjalli, A. M. M.; Cao, X.; Moran, E. J. PCT Int. Appl., 89pp.

CODEN: PIXXD2. WO 9708934 A2 970313. CAN 126: 277769) (l. OOg, 3. 81mmol) in MeOH (20mL) was added a solution of LiOH'HzO (0.40g, 9.50mmol) in H20 (5mL). After stirring for 16h at RT, the reaction mixture was evaporated in vacuo and 6N aq. HC1 was added until the pH of the mixture was ca. 1. The resulting mixture was extracted with Et20 (2X25mL). The combined organic phases were washed with saturated aq. NaCl, dried (Na2SO4), filtered, and evaporated in vacuo to afford 0.41g (43%) of the title compound T-2, (4-CO2H) as a white <BR> <BR> <BR> solid. MP: sublimesi lH-NMR (300MHz, DMSO-d6): 8 = 7.92 (2), 7.78 (2), 7.58 (1), 6.60 (1), 1.47 (9); IR (mull) 1705,1679, 1608,1426,1412,1322,1296,1256,1180,1156,1129,1113, 975,966, and 781cm-1; MS (EI): m/z (rel. intensity) 248 (M+, 11), 248 (11), 193 (49), 192 (99), 191 (39), 175 (62), 147 (52), 103 (18), 77 (15), 57 (73), 56 (19); Anal. Calcd for C14Hl604: C, 67.73; H, 6.50.

Found: C, 67.49; H, 6.76; N, 0.22.

Preparation T-4-1 Scheme T, T-4, wherein 3-substituted, R = tBu, R'= CH3 N-[[3-[(E)-3-(1,1-dimethylethoxy)-3-oxo-1- propenyl] phenyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L- phenylalanine methyl ester T-4 (C3lH30C12N206)

To a stirring suspension of the acid T-2 (3-CO2H) (0.36g, 1. 45mmol) in CH2CL2 (25mL) was added 4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (0.59g, 1.45mmol), EDC (0.28g, 1.45mmol), DMAP ( 0.05g, 0.44mmol), and HOBT (0.20g, 1.45mmol). To this mixture was added Et3N dropwise until all solids went into solution.

After stirring for 16h at RT, reaction mixture was partitioned between CH2Cl2 (50mL) and 1N aq. HCI (50mL). The organic phase was washed with sat'd aq. NaHC03 (50mL), sat'd aq. NaCl ( 50mL), dried (Na2SO<), filtered, and evaporated in vacuo. The resulting white solid was chromatographed (flash) on silica gel (400g, 230-400 mesh, 70mm OD column, packed and eluted with EtOAc/CH2C12 (1: 9), collecting 275 mL fractions).

Fractions 18-27 were combined and evaporated in vacuo to give 0.72g (83%) of T-4 (3-substituted, R = tBu, R'= CH3) as a white solid. MP: 189-193°C; IR (mull) 3347,1746,1740, <BR> <BR> <BR> <BR> 1708, 1660, 1641,1608,1549,1531,1512,1431,1330,1280,<BR> <BR> <BR> <BR> 1219, and 784cm-1 H-NMR (300MHz, DMSO-d6) : 6 = 10.66 (1), 8.90 (1), 8.15 (1), 7.83 (2), 7.43-7.60 (6), 7.26 (2), 6.61 (1), 4.69 (1), 3.64 (3), 3.01-3.20 (2), 1.47 (9); MS (FAB) m/z (rel. intensity) 597 (MH+, 19), 597 (19), 543 (21), 541 (31), 525 (21), 523 (31), 351 (22), 349 (32), 175 (99), 173 (47), 57 (38); HRMS (FAB) calcd for C31H3oCl2N206+Hl 597.1559, found 597.1541.

Preparation T-4-2 Scheme T, T-4, wherein 3-substituted, R = H, R'= CH3 N-[[3-[(E)-3-Hydroxy-3-oxo-1-propenyl]phenyl]carbonyl]-4- [(2, 6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester T-4 (C27H22Cl2N206) A solution of the diester T-4 (3-substituted, R = tBu, R'= CH3) (0.50g, 0.84mmol) in TFA (lOmL) stirred at RT for 16h.

Evaporation in vacuo gave a sticky solid which, upon trituration with Et20 afforded 0.42g (92%) of the title compound T-4 (3-substituted, R = H, R'= CH3) as a fine white solid which was collected by suction filtration and dried. MP: 170-171°C; lH-NMR (300MHz, DMSO-d6): 8 = 10.70 (1), 8.93 (1), 8.13 (1), 7.83 (2), 7.43-7.64 (6). 7.27 (2), 6.61 (1), 4.67 (1), 3.64 (3), 3.01-3.20 (2); IR (mull) 1748,1695,1665,1644,1610, 1579,1562,1550,1540,1514,1432,1415,1331,1279, and 1217cm-1. MS (FAB) m/z (rel. intensity) 541 (MH+, 93), 544 (20), 543 (65), 542 (35), 541 (93), 525 (20), 523 (31), 351 (21), 349 (41), 175 (99), 173 (32); HRMS (FAB) calcd for C27H22Cl2N206+Hl 541.0933, found 541.0938.

Example 124 Scheme T, T-4, wherein 3-substituted, R = H, R'= H N- [ [3- [ (E)-3-Hydroxy-3-oxo-1-propenyl] phenyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine T-4 (C26H2oCl2N206)

To a stirring solution of the diester T-4 (3-substituted, R = H, R'= CH3) (0.38g, 0.72mmol) in MeOH (lOmL) was added a solution of LiOHH20 (0.06g, 1.44mmol) in H20 (3mL). After stirring for 16h at RT, the reaction mixture was filtered and 6N aq. HC1 was added until the pH of the mixture was ca. 1.

The resulting precipitate was collected by suction filtration, washed with H20 and dried in the vacuum oven at 70°C for 16h to afford 0.25g (66%) of the title compound T-4 (3-substituted, R = H, R'= H) as a white, powdery solid. MP: 156-161°C; 1H- <BR> <BR> <BR> <BR> NMR (300MHz, DMSO-d6): b = 12.70 (2), 10.70 (1), 8.81 (1), 8.14 (1), 7.82 (2), (6), 7.29 (2), 6.62 (1), 4.63 (1), 2.97- 3.20 (2); IR (mull) 3261,3065,3035,1695,1641,1605,1579, 1562,1538,1517,1432,1414,1326,1271, and 1196cm-1; MS (FAB) m/z (rel. intensity): 527 (MH+, 99), 530 (23), 529 (70), 528 (40), 527 (99), 511 (42), 509 (59), 337 (22), 335 (32), 175 (90), 173 (51); HRMS (FAB) calcd for C26H20C12N206+H 527.0776, found 527.0786.

Preparation T-4-3 Scheme T, T-4, wherein 4-substituted, R = tBu, R'= CH3 N-[[4-[(E)-3-(1,1-dimethylethoxy)-3-oxo-1- propenyl] phenyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L- phenylalanine methyl ester T-4 (C3lH3oCl2N206)

To a stirring suspension of the acid T-2, (4-CO2H) (0.52g, 2.09mmol) in CH2Cl2 (30mL) was added the 4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (0.85g, 2.09mmol), EDC (0.40g, 2.09mmol), DMAP (0.08g, 0.63mmol), and HOBT (0.28g, 2.09mmol). To this mixture was added Et3N dropwise until all solids went into solution.

After stirring for 16h at RT, the resulting precipitate was collected by suction filtration, washed with H20, washed with CH2Cl2, and dried to give 0.86g (69%) of the title compound T- 4 (4-substituted, R = tBu, R'CH3) as a white solid. MP: <BR> <BR> <BR> <BR> <BR> >225°C; 1H-NMR (300MHz, DMSO-d6) : 6 = 10.66 (1), 8.92 (1), 7.76- 7.84 (4), 7.43-7.59 (6), 7.27 (2), 6.60 (1), 4.62 (1), 3.64 (3), 3.01-3.18 (2), 1.47 (9); IR (mull) 1742,1733,1708,1666,1640, 1610,1547,1513,1431,1415,1332,1320,1305,1166, and 1155cm~1; MS (FAB): m/z (rel. intensity) 597 (MH+, 1), 598 (12), 543 (14), 541 (19), 351 (9), 349 (13), 176 (11), 175 (99), 173 (31), 131 (9), 57 (31); HRMS (FAB): calcd for C31H3oCl2N206+Hl 597.1559, found 597.1547.

Preparation T-4-4 Scheme T, T-4, wherein 4-substituted, R = H, R'= CH3 N-[[4-[(E)-3-Hydroxy-3-oxo-1-propenyl]phenyl]carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester T-4 (C27H22C12N206)

A solution of the diester T-4 (4-substituted, R = tBu, R'= CH3) (0.84g, 1.40mmol) in TFA (lOmL) was stirred at RT for 16 hours. Evaporation in vacuo afforded 0.76g (100%) of the title compound T-4 (4-substituted, R = H, R'= CH3) as an off- white solid. MP: 80°C (dec.); 1H-NMR (300MHz, DMSO-d6): 5 = 10.70 (1), 8.92 (1), 7.75-7.82 (4), 7.43-7.62 (6), 7.26 (2), 6.61 (1), 4.63 (1), 3.64 (3), 2.99-3.20 (2); IR (mull) 1731,1693, 1639,1608,1562,1540,1516,1504,1433,1415,1326,1277, 1215,1195, and 1172cm-1; MS (FAB): m/z (rel. intensity) 541 (MH+, 99), 545 (14), 544 (23), 543 (72), 542 (37), 541 (99), 351 (13), 349 (27), 176 (12), 175 (99), 173 (26); HRMS (FAB) : calcd for C27H22Cl2N206+Hl 541.0933, found 541.0927.

Example 125 Scheme T, T-4, wherein 4-substituted, R = H, R'= H N- [ [4- [ (E)-3-Hydroxy-3-oxo-1-propenyl] phenyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine T-4 (C26H2oCl2N206) To a stirring solution of the ester T-4 (4-substituted, R = H, <BR> <BR> R'= CH3) (0.76g, 1.40mmol) in MeOH (lOmL) was added a solution of LiOH'HzO (0.17g, 4.20mmol) in H20 (5mL). After stirring for 16h at RT, the reaction mixture was evaporated in

vacuo. The residue was dissolved in H20 (30mL) and 6N aq. HC1 was added until the pH of the mixture was ca. l. The resulting mixture was extracted with EtOAc/THF (1: 1,50mL). The extract was dried (Na2SO4), filtered, and evaporated in vacuo to afford 0.43g (58%) of the title compound T-4 (4-substituted, R = H, R'= H) as a white solid. MP: 161-165°C; 1H-NMR (300MHz, DMSO- d6): 6 = 12.70 (1), 10.60 (1), 7.75-7.84 (4), (6), 7.28 (2), 6.61 (1), 4.58 (1), 2.95-3.20 (2); IR (mull): 3057, 1715,1693,1658,1639,1608,1562,1533,1505,1445,1431, 1415,1328,1278, and 1195cool; MS (FAB): m/z (rel. intensity) 527 (MH+, 88), 530 (19), 529 (63), 528 (33), 527 (88), 220 (21), 219 (20), 175 (99), 173 (26), 163 (18), 57 (44); HRMS (FAB): calcd for C26H2oCl2N206+Hl 527.0776, found 527.0765.

Scheme U

Preparation U-1-1 Scheme U, U-1, wherein R = CH2CH3, R'= tBu <BR> <BR> 4-Carboethoxy-1-cyclohexylideneacetic acid 1,1-dimethylethyl ester (ClsH2404) Sodium hydride (0.56g of a 60% mineral oil dispersion, 14.1mmol) was washed with hexanes (3 x lOmL), suspended in THF (lOmL), and the suspension was cooled to 0°C. To this suspension was added a solution of tert-butyl diethyl phosphonoacetate (5.0g, 19.8mmol) in THF (5mL) dropwise. The resulting solution was allowed to stir for lh at 0°C, and then a solution of ethyl-4-oxocyclohexane carboxylate (Aldrich Chemical Co., Milwaukee, WI, Catalog #32062-5) (2.0g, 11.8mmol) in THF (5mL) was added dropwise. The solution was allowed to slowly warm to RT and stirred for 16h. The reaction mixture was evaporated in vacuo. The residue was partitioned between EtOAc (lOOmL) and H20 (lOOmL), and the organic phase was washed with brine (lOOmL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting yellow oil was chromatographed on silica gel (350g, 230-400 mesh, 70mmOD column, packed and eluted with EtOAc/hexanes, 1: 9, collecting 230mL fractions) using the flash technique. Fractions 8-lS5were combined and evaporated in vacuo to afford 2.04g (64%) of the vinylogous ester U-1 (R = CH2CH3, R'= tBu) as a <BR> <BR> <BR> colorless oil. 1H-NMR (300 MHz, CDC13): 5 = 5.56 (1), 4.12 (2), 3.58 (1), 2.52 (1), 2.31 (1), 1.98-2.22 (4), 1.57-1.76 (2), 1.46 (9), 1.24 (3); IR (neat.): 2979,2939,1732,1710, 1650,1384,1368,1314,1307,1264,1249,1206,1162,1140, and 1041cm-1; MS (EI) m/z (rel. intensity): 195 (30), 194 (99), 167 (11), 139 (13), 138 (18), 121 (55), 120 (55), 93 (24), 60 (8), 57 (37); Anal. Calcd for ClsH24Ofi: C, 67.14; H, 9.01. Found: C, 67.23; H, 9.00.

Preparation U-1-2 Scheme U, U-1, wherein R = H, R'= tBu <BR> <BR> 4-Carboxy-1-cyclohexylideneacetic acid 1,1-dimethylethyl ester<BR> <BR> <BR> (C13H2009) To a stirring solution of the diester U-1 (R = CH2CH3, R'= tBu) (1. OOg, 3.73mmol) in MeOH (20mL) was added a solution of LiOH'H20 (0.78g, 18.6mmol) in H20 (5mL). The reaction mixture at RT for 16h and was then evaporated in vacuo. The residue was partitioned between H20 (lOOmL) and CHC13 (100mL), and the aqueous phase was neutralized with 1N aq. HCI. The organic phase was washed with H20 (lOOmL), brine (100mL), dried (Na2SO4), filtered, and evaporated in vacuo to afford 0.60g (67%) of the carboxylic acid U-1, (R = H, R'= tBu) as a viscous, colorless oil, which crystallized upon standing to afford a colorless solid. MP: 63-64°C; 1H-NMR (300 MHz, CDC13) : <BR> <BR> <BR> <BR> 8 5.57 (1), 3.58 (1), 2.58 (1), 2.33 (1), 2.02-2.23 (4), 1.61-1.78 (2), 1.47 (9); IR (mull) 3002,1706,1652,1434, 1317,1267,1256,1206,1197,1166,1142,1088,1011,874, and 639cm-1 ; MS (EI) m/z (rel. intensity): 184 (16), 167 (42), 166 (99), 138 (21), 121 (30), 94 (10), 93 (19), 57 (65), 56 (8), 55 (8); MS (FAB) m/z (rel. intensity): 241 (MH+, 46), 481 (1] ), 395 (7), 241 (46), 186 (9), 185 (99), 167 (62), 139 (14), 57 (67), 41 (13), 29 (13); HRMS (FAB) calcd for Cl3H2004+H, 241.1440, found 241.1434 ; Anal. Calcd for Cl3H2004: C, 64.98; H, 8.39. Found: C, 65.16; H, 8.35.

Preparation U-2-1 Scheme U, U-2, wherein R'= tBu, R"= CH3 N- [ [4- [ [ (1,1- <BR> <BR> Dimethylethoxy) carbonyl] methylene] cyclohexyl] carbonyl]-4- [(2, 6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C0H34C12N206) U-2 To a stirring solution of the carboxylic acid U-1 (R = H, R/= tBu) (0.54g, 2.25mmol) in CH2Cl2 (30mL) was added 4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (0.91g, 2.25mmol), EDC (0.43g, 2.25mmol), DMAP (0.08g, 0.67mmol), HOBT (0.30g, 2.25mmol), and diisopropyl ethylamine (3 mL). Finally, DMF (2mL) was added to facilitate dissolution. The solution stirred at RT for 16h and then was evaporated in vacuo. The residue was partitioned between 1N aq. aqueous HCl (150mL) and CH2Cl2 (150mL). The organic phase was washed with saturated NaHC03 (150mL), brine (150mL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting pale yellow solid was chromatographed on silica gel (300g, 230-400 mesh, 70mm OD column, packed and eluted with EtOAc/CH2Cl2 (1: 4), collecting 230mL fractions) using the flash technique.

Fractions 7-12 were combined and evaporated in vacuo to afford the desired product U-2 (R'= tBu, R"= CH3) as a white solid, 0.87g (66%). MP: 199-200°Ci 1H-NMR (300 MHz, DMSO-d6): # = 10.64 (1), 8.19 (1), 7.44-7. 59 (5), 7.17 (2), 5.50 (1), 4.43 (1), 3.60 (3), 3.65-3.58 (1), 3.00 (1), 2.86 (1), 1.64-2.46 (8), 1.39 (9); IR (mull) 1749,1703,1667,1649,1609,1561, 1548,1513,1432,1415,1332,1250,1197,1167, and 114ûcm~li

MS (FAB) m/z (rel. intensity): 589 (MH+, 25), 533 (31), 517 (68), 516 (36), 515 (99), 351 (37), 349 (55), 175 (42), 173 (64), 121 (45), 57 (50). HRMS (FAB) calcd for C30H34C12N206+H, 589.1872, found 589.1 846.

Preparation U-2-2 Scheme U, U-2, wherein R'= H, R"= CH3 N-[[4-(Carboxymethylene)cyclohexyl]carbonyl]-4-[(2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C26H26C12N206) U-2 A solution of the diester U-2 (R'= tBu, R"= CH3) (0.82g, 1.39mmol) in TFA (lOmL) was stirred at RT for 16h. The reaction mixture was evaporated in vacuo and the residue was dissolved in toluene and evaporated in vacuo (2xlOmL). The residue was triturated with Et20, and the resulting solid was collected by suction filtration and dried to afford 0.66g (89%) of the carboxylic acid U-2 (R'= H, R"= CH3) as powdery, white solid. MP: 140°C (dec.); 1H-NMR (300 MHz, DMSO-d6): 8 = 11.93 (1), 10.64 (1), 8.19 (1), 7.52-7.60 (4), 7.44-7.51 (1), 7.17 (1), 5.54 (1), 4.43 (1), 3.52-3.63 (4), 3.24-3.39 (1), 2.99 (1), 2.79 2.91 (1), 1.64-2.45 (6), 1.21-1.50 (2); IR (mull) 3069,1748,1652,1609,1561,1545, 1514,1432,1415,1331,1274,1250,1215,1195, and 1184 cm-1; MS (FAB) m/z (rel. intensity): 533 (MH+, 62), 535 (40), 533 (62), 517 (52), 515 (74), 351 (48), 349 (69),] 75 (63), 173 (99), 121 (55), 93 (35); HRMS (FAB) calcd for C26H26Cl2N206+Hl 533.1246, found 533.1237.

Example 126 Scheme U, U-2, wherein R'= H, R"= H N-[[4-(Carboxymethylene)cyclohexyl]carbonyl]-4-[(2,6- dichlorobenzoyl) amino]-L-phenylalanine (C25H24Cl2N206) U-2 To a stirring solution of the methyl ester U-2 (R'= H, R"= CH3) (0.60g, 1.12mmol) in CH30H (lOmL) was added a solution of LiOH'HzO (0.24g, 5.6mmol) in H20 (5mL). The solution stirred at RT for 16h and was then evaporated in vacuo. The residue was dissolved in H20 (20mL) and acidified to pH ca. 1-2 with 6N aqueous HC1. The resulting white solid was collected by suction filtration, washed with H20, and dried in a vacuum oven at 70°C for 16h. The resulting solid was crushed, washed thoroughly with H20, and dried in a vacuum oven at 100°C for 16h to afford the target diacid U-2 (R'= H, R"= H) as a white, crystalline solid, 0.45g (78%). MP: 145-148°C; 1H-NMR <BR> <BR> <BR> <BR> <BR> (300 MHz, DMSO-d6): 6 = 12.27 (1), 10.63 (1), 8.04 (1), 7.52-7.58 (4), 7.47 (1), 7.18 (2), 5.53 (1), 4.37 (1), 3.57 (1), 3.30 (1), 3.01 (1), 2.77-2.88 (1), 1.63-2.46 (6), 1.21-1.51 (2); IR (mull) 3270,3124,3070,1655,1607,1562, 1539,1517,1432,1414,1327,1269,1250,1195, and 799cm-1; MS (FAB) m/z (rel. intensity): 519 (MH+, 83), 521 (53), 519 (83), 503 (62), 501 (89), 335 (52), 175 (65), 173 (99), 139 (76), 121 (58), 91 (47); HRMS (FAB) calcd for C25H24Cl2N206+Hl 519.1089, found 519.1082.

Preparation U-1-3 Scheme U, U-1, wherein R = CH2CH3, R'= H <BR> <BR> 4-Carboethoxy-1-cyclohexylideneacetic acid (CllHl604) The diester U-1 (R = CH2CH3, R'= tBu) (0.86g, 3.20mmol) was dissolved in trifluoroacetic acid (5mL), and the solution stirred at RT for 4h. Evaporation in vacuo afforded 0.68g (100%) of the carboxylic acid U-1 (R = CH2CH3, R'= H) as a viscous oil which was used without further purification. 1H- <BR> <BR> <BR> <BR> <BR> NMR (300 MHz, CDC13): 5 = 10.96 (1), 5.68 (1), 4.14 (2), 3.58 (1), 2.57 (1), 2.40 (1), 2.16-2.30 (2), 2.01-2.13 (2), ]. 61-1.81 (2), 1.26 (3); IR (neat) 2985,2944,2872,1790, 1730,1692,1645,1449,1421,1305,1271,1252,1213,1175, and 1042cm-1 ; MS (EI) m/z (rel. intensity): 194 (99), 139 (31), 138 (40), 121 (62), 120 (93), 94 (24), 93 (64), 91 (22), 73 (23), 55 (21); MS (FAB) : m/z (rel. intensity) 213 (MH+, 5), 213 (5), 196 (12), 195 (99), 194 (6), 139 (9), 121 (12), 93 (11), 39 (4), 29 (8), 27 (6); HRMS (FAB) calcd for C1lHl604+Hl, 213.1127, found 213.1130.

Preparation U-3-1 Scheme U, U-3, wherein R = CH2CH3, R"= CH3 N- [4-Carboethoxy-l-cyclohexylideneacetyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C28H30Cl2N206) U-3 To a stirring solution of the carboxylic acid U-1 (R = CH2CH3,

R'= H) (0.70g, 3.20mmol) in CH2Cl2 (30mL) was added 4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (1.29g, 3.20mmol), EDC (0.61g, 3.20mmol), DMAP (0.12g, 0.96mmol), HOBT (0.43g, 3.20mmol) and diisopropylethylamine (4 mL). Finally, DMF (2mL) was added in order to assist dissolution. The solution stirred at RT for 16h and then was evaporated in vacuo. The residue was partitioned between 1N aqueous HC1 (150mL) and CH2Cl2 (150mL).

The organic phase was washed with saturated NaHC03 (150mL), brine (150mL), dried (Na2SO<), filtered, and evaporated in vacuo to give a white solid. Trituration with Et20 gave the desired product U-3 (R = CH2CH3, R"= CH3) as a powdery, white <BR> <BR> <BR> <BR> solid, 1.08g (60%). MP: 240°C; 1H-NMR (300 MHz, DMSO-d6): 8 = 10.65 (1), 8.22 (1), 7.52-7.60 (4), 7.47 (1), 7.18 (2), 5.64 (1), 4.52 (1), 3.98-4.08 (2), 3.61 (3), 3.46 (1), 2.94-3.04 (1), 2.78-2.90 (1), 2.47-2.58 (1), 1.78-2.19 (5), 1.30-1.55 (2), 1.12-1.18 (3); IR (mull): 3316,1746,1730,1668,1656,1634, 1611,1562,1551,1513,1434,1415,1334,1281, and 1210cm-1; MS (FAB) m/z (rel. intensity) 561 (MH+, 69), 563 (47), 562 (28), 561 (69), 195 (99), 175 (31), 173 (47), 121 (93), 105 (25), 93 (24), 91 (33); HRMS (FAB) calcd for C28H3oCl2N206+Hl 561.1559, found 561.1556.

Example 127 Scheme U, U-3, wherein R = H, R"= H N- [4-Carboxy-l-cyclohexylideneacetyl]-4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine (C25H24C12N206) U-3 To a stirring suspension of the diester U-3 (R = CH2CH3, R"=

CH3) (l. OOg, 1.78mmol) in MeOH (15mL) was added a solution of LiOH-H20 (0.37g, 8.9mmol) in H20 (5mL). H20 (lOmL) and THF (5mL) were added in an attempt to achieve a homogenous solution. The cloudy mixture stirred at RT for 16h and was then evaporated in vacuo. The residue was dissolved in H20 and 6N aqueous HCI was added dropwise until the pH was ca. 1. The resulting precipitate was collected by suction filtration, washed with H20, and dried in a vacuum oven at 80°C for 16h to afford the diacid U-3 (R = H, R"= H) as a white solid, 0.75g (81t). MP: 148-155OC'H-NMR (300 MHz, DMSO-d6): 6 = 12.27 (1), 10.64 (1), 8.06 (1), 7.52-7.59 (4), 7.47 (1), 7.19 (2), 5.64 (1), 4.40 (1), 3.41-3.54 (1), 3.30 (1), 2.96-3.06 (1), 2.75-2.87 (1), 2.35-2.45 (1), 1.78-2.19 (5), 1.30-1.54 (2); IR (mull): 3274,3064,1717,1662,1607,1562,1538,1516,1432, 1414,1327,1270,1254,1211, and 1195cm-1; MS (FAB): m/z (rel. intensity) 519 (MH+, 99), 522 (20), 521 (67), 520 (38), 519 (99), 518 (16), 335 (23), 175 (21), 173 (30), 167 (73), 121 (36); HRMS (FAB): calcd for C25H24Cl2N206+Hl, 519.1089, found 519.1104.

Scheme V

Preparation of 2-Carboethoxy-4,4-dimethylglutaric acid diethyl ester (C14H24°6) A flame dried 3-neck flask was charged with absolute ethanol (90mL), and sodium (2.53g, llOmmol) was added portionwise.

After the sodium completely dissolved, diethyl oxalate (16.3mL) and the starting diester (21.6g, lOOmmol) (Inesi, A.; Zeuli, E. J. Electroanal. Chem. Interfacial Electrochem. 1983, 149,167) were added. The resulting suspension stirred at RT for 16h, and then the ethanol was removed via distillation under reduced pressure. The residue was dissolved in H20 (500mL), and 6N aqueous HC1 was added until the pH of the mixture was ca. 1-2. The mixture was extracted with EtOAc (2 x 500mL), and the combined extracts were washed with sat'd aqueous NaHC03 (500mL), brine (50OmL), dried (Na2SO4), filtered, and evaporated in vacuo. This crude product was purified by distillation under reduced pressure to afford the triester as a clear, colorless oil, 18,1 g (63%). BP 100-110°C (O. latm); 1H-NMR (300 MHz, CDC13): b = 4.02-4.22 (6), 2.21-2.27 (2), 1.82-1.93 (1), 1.19-1.30 (9), 1.17 (6); IR (neat): 2983, 1753,1733,1477,1448,1390,1369,1302,1251,1232,1178, 1148 (s), 1114,1097, and 1030cm-1; MS (EI): m/z (rel. intensity) 288 (M+, 3), 243 (49), 215 (77), 197 (21), 173 (83), 169 (20), 160 (25), 142 (19), 141 (99), 123 (49), 95 (25).

Preparation of 4,4-Bis-carboethoxy-2,2-dimethylheptandedioic acid diethyl ester (Cl9H3208)

To sodium (0.13g, 5.80mmol) covered with Et20 (25mL) was added a solution of EtOH (2.4mL) in Et20 (45mL) dropwise. When the sodium was consumed, the triester V (8.39g, 29.1mmol) was added followed by ethyl acrylate (3.5mL, 32.0mmol). The solution was refluxed for lOh, then allowed to cool to RT. The reaction mixture was partitioned between 2% aqueous HOAc (500mL) and Et20 (500mL). The organic phase was washed with H20 (500mL), brine (500mL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting clear, colorless oil was distilled under reduced pressure (O. latm) to afford 8.61g (76%) of the target tetraester V+1 as a clear, colorless oil. <BR> <BR> <BR> <BR> <P>BP 147°C; 1H-NMR (300 MHz, CDC13): 8 = 4.00-4.24 (8), 2.35 (2), 2.06-2.31 (4), 1.17-1.30 (12), 1.16 (6); IR (neat): 2982, 2939,1735,1479,1448,1391,1368,1298,1266,1250,1180, 1143,1113,1097, and 1025cm-Anal. Calcd for Ci9HOe: C, 58.75; H, 8.30. Found: C, 58.87; H, 8.15.

Preparation of 4-Carboethoxy-2,2-dimethylheptandedioic acid diethyl ester (C 16H28°6) To a solution of the tetraester V+1 (8.55g, 22.0mmol) in DMSO (75mL) was added NaCl (2.62g, 44.0mmol) and H20 (4mL). The mixture was refluxed for 16h, then allowed to cool to RT.

Following evaporation in vacuo, the reaction mixture was partitioned between H20 (500mL) and EtOAc (500mL), and the aqueous phase was extracted with EtOAc (250mL). The combined organic phases were washed with H20 (500mL), brine (500mL),

dried (Na2SO4), filtered, and evaporated in vacuo to afford 5. Og (72%) of the desired triester V+2 as a pale yellow oil which was used without further purification. 1H-NMR (300 MHz, <BR> <BR> <BR> <BR> CDC13): 6 = 9.00-4.21 (6), 1.62-2.42 (7), 1.08-1.31 (15); IR (neat): 2981,2938,1734,1477,1465,1449,1388,1379,1304, 1256,1179,1159,1137,1097, and 028cm-1; MS (FAB) m/z (rel. intensity) 317 (MH+, 59), 318 (10), 317 (59), 272 (15), 27 (99), 243 (19), 197 (13), 169 (56), 151 (16), 95 (21), 29 (11); HRMS (FAB) calcd for C16H2806+Hl 317.1964, found 317.1969.

Preparation V-1-1 Scheme V, V-1, wherein A = C02CH2CH3, R = CH2CH3 2,4-Bis-carboethoxy-6, 6-dimethylcyclohexanone (C14H2205) V-1 Sodium hydride (0.70g of a 60% oil dispersion, 17.5mmol) was washed with hexanes (3xlOmL) and suspended in THF (25mL). To this stirring suspension was added a solution of the triester V+2 (4.95g, 15.6mmol) in THF (25mL) dropwise. The mixture was refluxed for 4h, allowed to cool to RT, and evaporated in vacuo. The resulting orange foam was partitioned between EtOAc (250mL) and H20 (250mL), and the aqueous phase was neutralized with IN aqueous HC1. The phases were separated, and the organic phase was washed with saturated aqueous NaHC03 (250mL), brine (250mL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting yellow oil was purified via Kugelrohr distillation to afford the desired cyclohexanone V-1 (A = C02CH2CH3, R = CH2CH3) diester as a clear, colorless oil, <BR> <BR> <BR> 2.73g (65%). 1H-NMR (300 MHz, CDC13): 6 = 4.05-4.24 (5), 2.62 (1), 2.39 (1), 1.84 (1), 1.66 (1), 1.05-1.35 (6), 1.17 (6); IR

(neat): 2982,2937,1734,1652,1612,1399,1375,1363,1304, 1285,1271,1255,1198,1147, and 1033cm-1; MS (EI) m/z (rel. intensity) 168 (27), 150 (28), 142 (74), 141 (34), 139 (47), 115 (31), 114 (39), 97 (99), 73 (28), 69 (90); HRMS (EI) calcd for C14H2205 270. 1467, found 270.1488.

Preparation V-1-2 Scheme V, V-1, wherein A = H, R = H 4-Carboxy-2,2-dimethylcyclohexanone (CgHl403) V-1 A mixture of the diester V-1 (A = CO2CH2CH3, R = CH2CH3) (1.90g, 7.03mmol) in 6N aqueous HC1 (25mL) was refluxed for 12h. After cooling to RT, NaHC03 was added to the reaction mixture until the pH was ca. 10. The mixture was extracted with Et20 (50mL), and the extract was discarded. 1N aqueous HC1 was added to the aqueous phase until the pH was ca. 4, and it was extracted with Et20 (50mL). The extract was washed with brine (50mL), dried (MgSO4), filtered, and evaporated in vacuo to afford the desired carboxylic acid V-1 (A = H, R = H) as a pale yellow oil which solidified upon standing, 0.85g (71%).

1H-NMR (300 MHz, CDC13): 8 = 2.94 (1), 2.60 (1), 2.38 (1), <BR> <BR> <BR> <BR> 2.34 (1), 2.03 (1), 1.76-1.93 (2), 1.22 (3), 1.09 (3); HRMS (EI) : calcd for CgHl403 170.0943, found 170.0948.

Preparation V-1-3 Scheme V, V-1, wherein A = H, R = CH3 4-Carboxymethoxy-2,2-dimethylcyclohexanone (CloHl603) V-1

To a stirring solution of the carboxylic acid V-1 (A = H, R = H) (1.20g, 7.05mmol) in CH30H (40mL) was added concentrated H2SO4 (2mL), and the mixture refluxed for 16h, then was stirred at RT for 24h. The reaction mixture was evaporated in vacuo, and the residue was partitioned between EtOAc (50mL) and sat'd aqueous NaHC03 (50mL). The organic phase was washed with brine (50mL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting yellow oil was chromatographed on silica gel (150g, 230-400 mesh, 35mm OD column, packed and eluted with EtOAc/hexanes, 15: 85, collecting 200mL fractions) using the flash technique. Fractions 9-11 were combined and evaporated in vacuo to afford the desired methyl ester V-1 (A = H, R = CH3) as a pale yellow oil, 0.65g (50%).'H-NMR (300 MHz, <BR> <BR> <BR> <BR> CDC13): 8 = 3.68 (3), 2.83-2.96 (1), 2.49-2.63 (1), 2.17-2.38 (2), 1.94-2.04 (1), 1.71-1.92 (2), 1.17 (3), 1.05 (3); IR (neat): 2966,2956,1737,1712,1463,1436,1388,1317,1297, 1275,1250,1236,1197,1166, and 1125cm1; HRMS (E1) calcd for CloHi60s 184.1099, found 184.1101; Anal. Calcd for Clou1603: C, 65.19; H, 8.75. Found: C, 64.88; H, 8.76.

Preparation V-2-1 Scheme V, V-2, wherein R = CH3, R'= tBu (E)-4-Carbomethoxy-2,2-dimethylcyclohexylideneacetic acid 1,1- dimethylethyl ester (C16H2604) Sodium hydride (0.25g of a 60% mineral oil dispersion, 6.19mmol) was washed with hexanes (3xlOmL), suspended in THF (8mL), and cooled to 0°C. To this suspension was added a solution of tert-butyl diethylphosphonoacetate (2.21g, 8.77mmol) in THF (3mL) dropwise. After stirring at 0°C for lh,

a solution of the ketone V-1 (A = H, R = CH3) (0.95g, 5.16mmol) in THF (3mL) was added dropwise. The mixture was allowed to slowly warm to RT and stirred for 16h. The reaction mixture was evaporated in vacuo, the residue was partitioned between H20 (50mL) and EtOAc (50mL), and the aqueous phase was extracted with EtOAc (50mL). The combined organic phases were washed with H20 (lOOmL), brine (lOOmL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting pale yellow oil was chromatographed on silica gel (300g, 230-400 mesh, 35mm OD column, packed and eluted with EtOAc/hexanes, 1: 9, collecting 200mL fractions) using the flash technique.

Fractions 5-7 were combined and evaporated in vacuo to afford the desired diester V-2 (R = CH3, R'= tBu) as a clear, colorless oil, 1.26g (86%).'H-NMR (300 MHz, CDC13): 8 = 5.61 (1), 3.76-3.89 (1), 3.65 (3), 2.66-2.80 (1), 2.01-2.15 (2), 1.72-1.82 (1), (1), 1.47 (9), 1.12 (6); IR (neat): 2976,2952,1738,1711,1637,1390,1378,1368,1301,1265, 1213,1197,1183,1150, and 1120cm-1; MS (EI): m/z (rel. intensity) 209 (33), 208 (99), 166 (15), 149 (34), 148 (20), <BR> <BR> <BR> <BR> 121 (25), 107 (23), 79 (14), 57 (50), 55 (11); HRMS (FAB) : calcd for C16H2604+H-283.1909, found 283.1316.

Preparation V-2-2 Scheme V, V-2, wherein R = CH3, R'= tBu (E)-4-Carbomethoxy-2,2-dimethylcyclohexylideneacetic acid (Cl2Hl804) The diester V-2 (R = CH3, R'= tBu) (0.50g, 1. 77mmol) was dissolved in trifluoroacetic acid (5mL), and the solution stirred at RT for 12h. Evaporation in vacuo gave a viscous,

pale yellow oil which crystallized upon standing to afford the carboxylic acid V-2 (R = CH3, R'= H) as a waxy white solid, 0.40g (100%). MP 126-128°C. 1H-NMR (300 MHz, CDC13): 8 = 8.32 (1), 5.76 (1), 3.79-3.89 (1), 3.68 (3), 2.71-2.85 (1), 2.05-2.24 (2), 1.78- I. 88 (1), 1.47-1.63 (2), 1.16 (6); IR (mull): 3013,2766,1735,1687,1630,1436,1416,1327,1299, 1275,1233,1193,1183,1172, and 879cm-1 ; MS (EI): m/z (rel. intensity) 315 (99), 165 (27), 105 (30), 104 (48), 85 (21), 83 (20), 71 (24), 69 (26), 57 (44), 55 (35); HRMS (FAB) calcd for C12H, 804 226.1205, found 226.1193.

Preparation V-3-1 Scheme V, V-3, wherein R = CH3, R"= CH3 N- [ (lE)-4-Carbomethoxy-2,2-dimethyl-1-cyclohexylideneacetyl]- 4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C29H32Cl2N206)V-3 To a stirring solution of the carboxylic acid V-2 (R = CH3, R' = H) (0.42g, 1.86mmol) in CH2C12 (30mL) was added 4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (0.75g, 1.86mmol), EDC (0.36g, 1.86mmol), DMAP (0.07g, 0.56mmol), HOBT (0.25g, 1.86mmol). To this suspension was added triethylamine dropwise until a solution was attained, and it was allowed to stir at RT for 16h. The solution was washed with IN aqueous HC1 (50mL), and the aqueous phase was extracted with CH2Cl2 (50mL). The combined extracts were washed with saturated aqueous NaHC03 (50mL), brine (50mL), dried (Na2SO4), filtered, and evaporated in

vacuo. The resulting off-white solid was chromatographed on silica gel (200g, 230-400 mesh, 35mm OD column, packed and eluted with MeOH/CH2Cl2 (2.5: 97.5), collecting 42mL fractions) using the flash technique. Fractions 58-82 were combined and evaporated in vacuo to afford the desired product V-3 (R = CH3, R"= CH3) as a white solid, 0.44g (41%). MP 160-163°C; 1H- NMR (300 MHz, CDC13): S-7. 57 (2), 7.28-7.39 (3), 7.13 (2), 5. 90 (1), 5.59 (1), 4.87-4.96 (1), 3.75 (3), 3.61-3.71 (4), 3.05-3.23 (2), 2.65-2.78 (1), 1.98-2.17 (2), 1.72-1.82 (1), 1.40-1.58 (2), 1.09-1.14 (6); IR 1650, 1627,1608,1546,1513,1433,1414,1327,1278,1267,1207, 1198, and 1167cm-1; MS (FAB): m/z (rel. intensity) 575 (MH+, 86), 577 (59), 576 (35), 575 (86), 351 (20), 349 (30), 209 (99), 175 (23), 173 (39), 149 (26), 107 (49); HRMS (FAB): calcd for C29H32Cl2N206+H, 575.1715, found 575.1706.

Example 128 Scheme V, V-3, wherein R = H, R"= H N- [ (lE)-4-Carboxy-2, 2-dimethyl-l-cyclohexylideneacetyl]-4- [(2, 6-dichlorobenzoyl) amino]-L-phenylalanine (C27H28C12N206) V-3 To a stirring solution of the diester V-3 (R = CH3, R"= CH3) (0.31g, 0.54mmol) in MeOH (lOmL) was added a solution of LiOH'H20 (0. 05g, 1.08mmol) in H20 (3mL). The reaction mixture stirred at RT for 16h and was then evaporated in vacuo. The residue was dissolved in H20 (20mL), and 6N aqueous HCI was added dropwise until the pH of the mixture was ca. 4. The resulting precipitate was washed with H20, and dried in the vacuum oven at 70°C for 12h to afford 0.23g (78%) of the

diacid V-3 (R = H, R"= H) as a while, crystalline solid. MP 155-162°C; 1H-NMR (300 MHz, DMSO-d6): 5 = 11.84-12.75 (1), 8.16 (1), 7.52-7.60 (4), 7.43-7.51 (1), 7.20 (2), 5.71 (1), 4.34- 4.45 (1), 3.67-3.77 (1), 2.95-3.05 (1), 2.76-2.88 (1), 2.51-2.65 (1), 1.81-2.01 (2), 1.64-1.74 (1), 1.01-1.37 (8); IR (mull): 3286,3193,3062,1717,1658,1607,1562,1539,1516, 1432,1414,1327,1271,1222, and 1196cm-1. MS (FAB): m/z (rel. intensity) 547 (MH+, 92), 561 (27), 549 (61), 548 (37), 547 (92), 335 (34), 195 (99), 175 (37), 173 (59), 149 (36), 107 (35); HRMS (FAB): calcd for C27H28Cl2N206) +H1 547.1403, found 547.1392; % Water (KF): 3.12.

Preparation V-2-3 Scheme V, V-2, wherein R = H, R'= tBu (E)-4-Carboxy-2,2-dimethylcyclohexylideneacetic acid 1,1- dimethylethyl ester (C15H2404) To a stirring solution of the diester V-2 (R = CH3, R'= tBu) (0.65g, 2.30mmol) in MeOH (8mL) was added a solution of LiOH'H20 (0.19g, 4.60mmol) in H20 (4mL). The solution stirred at RT for 16h and was then evaporated in vacuo. The residue was dissolved in H20 (25mL), and 6N aqueous HC1 was added until the pH was ca. 4. The mixture was extracted with CHCI3 (2x25mL), and the combined extracts were washed with brine (50mL), dried (MgSO4), filtered, and evaporated in vacuo to afford 0.61g (99%) of the carboxylic acid V-2 (R = H, R'= <BR> <BR> tBu) as a clear, colorless oil. 1H-NMR (300 MHz, CDC13): 6 = 5.62 (1), 3.78-3. 91 (1), 2.68-2.84 (1), 2.02-2.18 (2), 1.76-1.86 (1), 1.51-1.62 (1), 1.47 (9), 1.13 (3); IR (neat) 3006,2977,2937,2874,1709,1637,1379,1368,1303,1265,

1215,1151,1124,1117, and 758cm-1; MS (EI): m/z (rel. intensity) 195 (32), 194 (99), 166 (17), 149 (18), 138 (14), 121 (21), 107 (20), 79 (12), 57 (60), 55 (13); HRMS (FAB) calcd for C15H2404+Hl 269.1753, found 269.1755.

Preparation V-4-1 Scheme V, V-4, wherein R'= tBu, R"= CH3 N- [ [ (4E)-3,3-Dimethyl-4- [ [ (1,1- dimethylethoxy) carbonyl] methylene] cyclohexyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C32H38Cl2N206) V-4 To a stirring solution of the acid V-2 (R = H, R'= tBu) (0.44g, 1.64mmol) in CH2CI2 (30mL) was added 4- [ (2,6- dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (0.66g, 1.64mmol), EDC (0.31g, 1.64mmol), DMAP (0.06g, 0.49mmol), HOBT (0.22g, 1.64mmol), and Et3N (0.9mL, 4.92mmol). The reaction mixture was stirred at RT for 16h, then was evaporated in vacuo. The residue was dissolved in 2% MeOH/CH2Cl2 (50mL), and this solution was washed with 1N aqueous HCI (50mL), saturated aqueous NaHC03 (50mL), brine (50mL), dried (Na2SO4), filtered, and evaporated in vacuo. The resulting white solid was chromatographed on silica gel (400g, 230-400 mesh, 70mm OD column, packed and eluted with MeOH/CH2Cl2,3: 97, collecting 270mL fractions) using the flash technique. Fractions 4-6 were combined and evaporated in vacuo to afford the desired product V-4 (R'= tBu, R"= CH3) as a

white solid, 0.82g, (81%). MP 204-208°C; 1H-NMR (300 MHz, CDC13): 8 = 7.53-7.64 (3), 7.28-7.41 (3), 7.02-7.13 (2), 5.91-5.98 (1), 5.61 (1), 4.82-4.90 (1), 3.79-3.91 (1), 3.75 (3), 3.03-3.20 (2), 2.47-2.61 (1), 1.71-1.83 (2), 1.38-1.70 (12), 1.11 (6); IR (mull): 1749,1711,1672,1651,1610,1562, 1548,1514,1432,1415,1331,1278,1215,1174, and 1152cm-1 ; MS (FAB:) m/z (rel. intensity) 617 (MH+, 13), 545 (69), 544 (35), 543 (99), 351 (39), 349 (57), 175 (50), 173 (50), 149 (41), 121 (50), 57 (80); HRMS (FAB): calcd for C32H38Cl2N206+Hl 617.2185, found 617.2178.

Preparation V-4-2 Scheme V, V-4, wherein R'= H, R"= CH3 N- [ [ [ (4E)-4-Carboxymethylene-3,3- dimethyl] cyclohexyl] carbonyl]-4- [(2,[(2, 6-dichlorobenzoyl) amino]- L-phenylalanine methyl ester (C28H30C12N206) V-4 A solution of the diester V-4 (R'= tBu, R"= CH3) (0-509, <BR> <BR> <BR> 0.89mMol) in trifluoroacetic acid (5mL) was stirred at RT for 16h. The reaction mixture was evaporated in vacuo to give a pale yellow glass. Trituration with Et20 gave the desired carboxylic acid V-4 (R'= H, R"= CH3) as a white solid which was collected by suction filtration and dried, 0.38g (76%). MP 228-230°C; 1H-NMR (300 MHz, DMSO-d6) : 8-11.67-12.28 (1), 10.67 (1), 8.16-8.31 (1), 7.40-7.68 (5), 7.17 (2), 5.54 (1), 4.36 4.49 (1), 3.71 (1), 3.60 (3), 2.91-3.07 (1), 2.75 2.91

(1), 2.53-2.71 (1), 0.91-2.13 (11); IR (mull): 1750,1692, 1672,1648,1611,1553,1540,1514,1444,1432,1415,1335, 1278,1225, and 1213cm ~; MS (El) m/z (rel. intensity) 560 (M+, 1), 351 (66), 350 (19), 349 (99), 280 (20), 278 (29), 177 (16), 175 (64), 173 (99), 107 (13), 106 (17); HRMS (EI) calcd for C28H3oCl2N206 560.1481, found 560.1477.

Example 129 Scheme V, V-4, wherein R'= H, R"= H N- [ [ [ (4E)-4-Carboxymethylene-3,3- dimethyl] cyclohexyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]- L-phenylalanine (C27H28Cl2N206) V-4 To a stirring solution of the methyl ester V-4 (R'= H, R"= CH3) (0.33g, 0.59mmol) in MeOH (7mL) was added a solution of LiOH'H20 (0.05g, 1.18mmol) in H20 (3mL). The reaction mixture stirred at RT for 16h and was then evaporated in vacuo. The residue was dissolved in H20 (20mL), and 6N aqueous HCI was added dropwise until the pH of the mixture was ca. 1. The resulting gelatinous solid was collected by suction filtration and dried in a vacuum oven at 70°C for 12h. The resulting white crystalline solid was crushed, thoroughly washed with H20, and dried in the vacuum oven at 70°C for 12h to afford 0.12g (37%) of the diacid V-4 (R'= H, R"= H). MP 165-167°C; <BR> <BR> <BR> 1H-NMR (300 MHz, DMSO-d6): 6 = 11.82-12.65 (2), 10.65 (1), 8.04-8.13 (1), 7.51-7.61 (4), 7.43-7.51 (1), 7.17 (2), 5.54 (1), 4.31-4.42 (1), 3.64-3.76 (1), 2.95-3.06 (1), 2.73-2.87

(1), 2.53-2.69 (1), 0.88-2.06 (11); IR (mull) 3281,3071, 3036,1659,1608,1562,1540,1517,1432,1414,1327,1271, 1220,1196, and 1170cm-1; MS (FAB) m/z (rel. intensity) 547 (MH+, 82), 549 (54), 548 (32), 547 (82), 531 (67), 529 (99), 337 (30), 335 (45), 175 (44), 173 (70), 123 (41); HRMS (FAB) calcd for C27H28C12N206+Hl 547.1403, found 547.1417. % Water (KF): 2.51.

Scheme W

Preparation W-C-1 and W-T-1 Scheme X, W-C-1 and W-T-1, wherein R = C02tBu, R'= 5-C02Me (Z)-5-Carbomethoxy-3,4-dihydro-1 (2H)-naphthalenylideneacetic acid 1,1-dimethylethyl ester W-C-1 (Cl8H2204) and (E)-5- Carbomethoxy-3,4-dihydro-1 (2H)-naphthalenylideneacetic acid 1,1-dimethylethyl ester W-T-1 (C18H2204) To a dry, 50mL two-neck flask was added diethylphosphono t- butylacetate (Aldrich, 6.4 mL, 27.2mmol). The flask was flushed with Ar/house vac (3X) and then dry THF (lOmL) was added. The flask was immersed in an ice/water bath and, five minutes later, NaH/oil (60% NaH, l. Og., 25.0mmol) was cautiously added in portions. After stirring for 30 minutes, a solution of the known 5-carbomethoxy-2-tetralone (Gerlach, U.; Wollmann, T. Tetrahedron Lett. (4.62g., 22.6mmol) in dry THF (20mL) was added. The mixture stirred for 18 hours, warming slowly as the ice melted, then the reaction was quenched by the addition of ice (20mL) and the mixture was partitioned between water (lOOmL) and hexanes (200mL). The aqueous layer was extracted with hexanes (3X150mL) and the combined organic phases were washed with brine (lXlOOmL), dried (MgSO4), and then evaporated to dryness, giving a pale brown oil (ll. Og.). The crude product was purified by chromatography via medium pressure liquid chromatography (MPLC) and eluted with a gradient from 0 to 4% ethyl acetate/hexane. Two fractions were collected and isolated by evaporation in vacuo to give colorless oils. The first eluted (MPLC) fraction afforded 2.47g, 36% yield of the trans olefin <BR> <BR> <BR> W-T-l. lH-NMR (CDC13) 6 = 7.77 (2), 7.22 (1), 6.19 (1), 3.88 (3),

3.11 (4), 1.79 (2), 1.51 (9). MS (EI) m/z (rel. intensity) 302 (M+, 1), 247 (16), 246 (99), 229 (21), 214 (36), 186 (12), 169 (39), 142 (15), 141 (35), 115 (21), 57 (35). Anal. Calcd for Ci8H2204'0.3C3H60: C, 71.50; H, 7.33. Found: C, Found: C, 70.89; H, 7.31.. Further elution (MPLC) afforded 2.61g (38%) of the <BR> <BR> <BR> cis-olefin W-C-1 as a colorless oil. 1H NMR (CDC13) 6 = 7.85 (1), 7.65 (1), 7.18 (1), 5.75 (1), 3.87 (3), 3.17 (2), 2.44 (2), 1.94 (2), 1.42 (9). MS (EI) m/z (rel. intensity) 302 (M+, 1), 247 (16), 246 (99), 229 (20), 214 (38), 186 (13), 169 (43), 142 (17), 141 (39), 115 (25), 57 (35). Anal. Calcd for C18H2204-0.3C3H60: C, 71.50; H, 7.33. Found: C, 71.58; H, 7.19.

Preparation W-C-1 and W-T-1 Scheme X, W-C-1 and W-T-1, wherein R = CO2tBu, R'= 6-CO2Me (Z)-6-Carbomethoxy-3,4-dihydro-1 (2H)-naphthalenylideneacetic acid 1,1-dimethylethyl ester W-C-1 (C18H2204) and (E)-6- Carbomethoxy-3,4-dihydro-1 (2H)-naphthalenylideneacetic acid 1,1-dimethylethyl ester W-T-1 (C18H2204) To a dry, 50mL two-neck flask was added diethylphosphono t- butylacetate (Aldrich, 7 mL, 29.8mmol). The flask was flushed with Ar/house vac (3X) and then dry THF (lOmL) was added.

The flask was immersed in an ice/water bath and, five minutes later, NaH/oil (60% NaH, 1.15g., 28.8mmol) was cautiously added in portions. Thirty minutes later, a solution of the known 6-carbomethoxy-2-tetralone (Gerlach, U.; Wollmann, T. <BR> <BR> <BR> <P>Tetrahedron Lett. 1992,33,5499) (4.62g., 22.6mmol) (5.22g., 25.55mmol) in dry THF (20mL) was added. After two 36 hours, the mixture was quenched by addition of ice (20g) and then

partitioned between water (lOOmL) and hexanes (200mL). The aqueous layer was shaken with hexanes (3X150mL) and the combined hexanes layers washed with brine (lXlOOmL) and then evaporated to dryness, giving a pale brown oil (12.5g.).

Crystallization from hexanes (lOOmL, freezer) gave W-T-1 (6- CO2CH3) as a white solid (2.37g). The mother liquor was transferred to a medium pressure liquid chromatography apparatus and eluted with a gradient from 0 to 4% ethyl acetate/hexane. Two fractions were collected and isolated by evaporation in vacuo to give colorless solids. Band 1 (0.559g) was combined with the above hexanes crystals, with which it is spectroscopically identical, to provide a total of <BR> <BR> <BR> 2.93g (38%) of W-T-1 (6-C02CH3). 1H-NMR (CDC13): 8 = 7.71 (2), 7.56 (1), 6.22 (1), 3.81 (3), 3.07 (2), 2.71 (2), 1.75 (2); IR (mull) 2133,1935,1718,1700,1618,1438,1296,1275,1260, 1236,1201,1181,1152,1144, and 1105cm-1; MS (EI) m/z (rel. intensity) 302 (M+, 1), 246 (99), 231 (22), 229 (28), 228 (21), 187 (24), 169 (23), 142 (30), 141 (48), 115 (27), 57 (53); Anal. Calcd. for C1BH2204: C, 71.50; H, 7.33. Found: C, 71.03; H, 7.07.

Fraction 2 gave 2.50g. (32%) of W-C-1 (6-CO2CH3) as a white solid. 1H-NMR (CDC13): 5 = 7.78 (2), 7.59 (1), 5.79 (1), 3.89 (3), 2.87 (2), 2.47 (2), 1.95 (2), 1.44 (9); IR (liq.) 2951,2396, 1982,1927,1721,1437,1368,1306,1287,1266,1226,1200, 1147,1110, and 775cm-1; MS (EI) m/z (rel. intensity) 302 (M+, 1), 246 (99), 231 (19), 229 (22), 228 (20), 187 (21), 169 (17), 142 (19), 141 (29), 115 (16), 57 (29); Anal. Calcd for C18H2204: C, 71.50; H, 7.33. Found: C, 71.29; H, 7.19.

Preparation W-C-1 Scheme X, W-C-1 wherein R = C02tBu, R'= 5-C02H (Z)-5-Carboxy-3,4-dihydro-1 (2H)-naphthalenylideneacetic acid 1,1,-dimethylethyl ester W-C-1 (Cl7H2004)

Sodium thiophenoxide (5.05g, 38mmol) was added to a stirred mixture of the diester W-C-1 (2.3g, 7.6mmol) in dry THF (50mL).

The mixture was stirred for two days at room temperature and then heated for two days in a 35°C oil bath. The mixture was then evaporated to dryness in vacuo, stirred with H20 (50mL), and filtered through a sintered glass funnel, and the filter cake is rinsed with water (4X20mL). The filtrate was treated with aqueous HC1 (1.2N) to pH6 and then filtered (4X10mL H2 rinses). The filtered solid was air dried to give a white solid (1.73g) which was transferred to a medium pressure chromatography column and eluted with a gradient from 0% tc 5% CH30H/CH2Cl2. The UV absorbing band was isolated by <BR> <BR> <BR> evaporation of eluant in vacuo to give W-C-1 (R = CO2tBu, R'=<BR> <BR> <BR> <BR> 5-C02H) as a white solid (1.56g, 70%yield).H-NMR(CDCl8<BR> <BR> <BR> <BR> = 7.98 (1), 7.82 (1), 7.28 (1), 6.21 (1), 3.16 (4), 1.82 (2), 1.52 (9); MS (ESI-) for C17H2004 m/z 287.2 (M-H).

Preparation W-T-1 Scheme X, W-T-1 wherein R = CO2tBu, R'= 5-CO2H (E)-5-Carboxy-3,4-dihydro-1 (2H)-naphthalenylideneacetic acid 1,1,-dimethylethyl ester W-C-1 (Cl7H2004) Sodium thiophenoxide (5.05g, 38mmol) was added to a stirred mixture of the diester W-T-1 (R = C02tBu, R'= 5-C02CH3) (2.3g,

7.6mmol) in dry THF (50mL). The mixture was stirred for 36 hours at room temperature and then heated for 48 hours in a 35°C oil bath. The mixture was then evaporated to dryness in vacuo, stirred with H20 (50mL), and filtered through a sintered glass funnel (4X20mL H20 rinses). The filtrate was treated with aqueous HC1 (1.2N) to pH6 and then filtered (4XlOmL H20 rinses). The filtered solid was air dried to give a white solid (1.73g) which was transferred to a medium pressure chromatography column and eluted with a gradient from 0% to 5% CH30H/CH2C12. The UV absorbing band was isolated by evaporation of eluant in vacuo to give W-T-1 (R = CO2tBu, R'= 5-C02H) as a powdery, white solid (1.56g, 70% yield). 1H-NMR (CDC13): 8 = 7.98 (1), 7.82 (1), 7.28 (1), 6.21 (1), 3.16 (4), 1.82 (2), 1.52 (9); MS (ESI-) for C17H2004 m/z 287.2 (M-H).

Preparation W-T-1 Scheme X, W-T-1 wherein R = CO2tBu, R'= 6-CO2Na (E)-6-Carboxy-3,4-dihydro-1 (2H)-naphthalenylideneacetic acid 1,1,-dimethylethyl ester sodium salt W-C-1 (Cl7Hl904Na) A solution of the diester W-T-1 (R = CO2tBu, R'= 6-CO2Me) <BR> <BR> <BR> <BR> (0.94g., 3. lmmol) and sodium thiophenoxide (0.62g., 4.69mmol) in dry DMF (5mL) was stirred under Ar and heated in a 60°C oil bath. After overnight stirring, copious precipitation had occurred. The mixture was removed from the oil bath, cooled to room temperature, mixed with dry DMF (6mL), and filtered (with 4X2mL DMF rinses) through a sintered glass funnel. The filter cake was air-dried to give W-T-1 (6-CO2Na) as a white solid (0.72g., 74%). 1H-NMR (DMSO-d6): 8 = 7.52 (3), 6.21 (1), 3.03 (2), 2.73 (2), 1.72 (2), 1.44 (9); MS (ESI-) for Cl7Hl904 m/z

287 (M-Na).

Preparation W-C-2 Scheme X, W-C-2 wherein R = C02tBU, 5-substituted, R"= CH3 N- [ [ (5Z)-7,8-Dihydro-5- [ [ (1,1- dimethylethoxy) carbonyl] methylene]-1 (6H)-naphthyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C34H34Cl2N206) To a mixture of the W-C-1 (R = C02tBu, R'= 5-CO2H) (1.18g., 4.08mmol) in dry DMF (20mL) under N2 and cooled in an ice water bath was added EDC (0.86g, 4.49mmol), HOBT (0.61g, 4.51mmol), diisopropylethyl amine (3.8mL, 21.82mmol), and 4- dimethylaminopyridine (0.05g., 0.41mmol). After thirty minutes, 4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (1.8g., 4.46mmol) and more dry DMF (5mL) were added. After overnight stirring, the mixture was evaporated to dryness in vacuo, giving an oil which was dissolved in CHC13 (150mL) and washed with water (50mL), aq.

HC1 (1N, 2X50mL), water (5X50mL, to pH7) and evaporated to dryness, giving W-C-2 (R = C02tBu, 5-substituted, R"= CH3) as a pale yellow powder (2.68g., 93%). An analytical sample was recrystallized from toluene/chloroform. 1H-NMR (CDCl3): 8 = 7.59 (4), 7.27 (7), 6.20 (2), 5.08 (1), 3.80 (3), 3.31 (1), 3.13 (3), 2.73 (2), 1.74 (2), 1.51 (9); IR (mull) 1751,1700, 1433,1336,1278,1225, 1201,1153, and 1147cm-1; MS (FAB) m/z (rel. intensity) 637 (MH+, 38), 639 (28), 637 (38), 581 (25), 565 (24), 563 (35),

271 (24), 215 (99), 197 (29), 173 (35), 57 (30); Anal. Calcd for C34H34Cl2N206: C, 64.05; H, 5.38; N, 4.39. Found: C, 63.76; H, 5.41; N, 4.45.

Example 130 Scheme X, W-C-2 wherein R = CO2H, 5-substituted, R"= CH3 N- [ [ (5Z)-5-Carboxymethylene-7, 8-dihydro-1 (6H)- naphthyl] carbonyl]-4- [(2,[(2, 6-dichlorobenzoyl) amino]-L- phenylalanine methyl ester (C3oH26Cl2N206) A solution of W-C-2 (R = C02tBu, 5-substituted, R"= CH3) (0.244g., 0.38mmol) in methylene chloride was cooled in an ice water bath and then trifluoroacetic acid (l. OmL, 13mmol) was added. After 10 minutes, the cooling bath was removed. After four days, the heterogeneous mixture was filtered through a sintered glass funnel and the filter cake washed with methylene chloride (3X2mL) and air dried to give a white solid, W-C-2, R = C02H, 5-substituted, R"= CH3) (0.185g., 82%). An analytical sample was prepared by stirring the compound with saturated aq. NaHC03 to convert it to its water soluble salt followed by reversed phase chromatography (0% to 30% acetonitrile/water) and acidification. 1H-NMR (DMSO-d6) 8 = 12.21 (1), 10.69 (1), 8.74 (1), 7.51 (6), 7.25 (2), 7.12 (2), 5.80 (1), 4.69 (1), 3.68 (3), 3.15 (1), 2.89 (1), 2.41 (4), 1.71 (2); IR (mull) 3261,1743,1696,1659,1642,1610,1529,1433, 1414,1320,1265,1226,1216,1206, and 1195cm-1; MS (FAB) m/z (rel. intensity) 581 (MH+, 63), 583 (43), 582 (28), 581 (63), 565 (15), 563 (22), 349 (21), 215 (99), 197 (46), 175 (16),

173 (28); HRMS (FAB) calcd. for C3oH26Cl2N206+Hl 581.1246, found 581.1232.

Example 131 Scheme X, W-C-2 wherein R = CO2H, 5-substituted, R"= H N- [ [ (5Z)-5-Carboxymethylene-7, 8-dihydro-1 (6H)- naphthyl] carbonyl]-4- [(2,[(2, 6-dichlorobenzoyl) amino]-L- phenylalanine (C29H24Cl2N206) To W-C-2 (R = CO2H, 5-substituted, R"= CH3) (0. 9g., 1. 5mmol) in methanol (50mL) was stirred and cooled in an ice water bath. To the cooled solution was added an ice cold solution of LiOH*H20 (0.33g., 7.9mmol) in H20 (lOmL). After overnight stirring, the mixture was evaporated to dryness in vacuo, keeping the water bath temperature at or below room temperature to give a white solid. The mixture was then dissolved in water (50mL) and the pH was adjusted to approximately pH8 using 1N HC1. The solution was then filtered and the filtrate transferred to a reversed phase (C- 18) medium pressure chromatography column and eluted with a gradient from 0 to 30% acetonitrile/water. Concentration, in vacuo, of the fractions containing W-C-2 (R = C02H, 5- substituted, R"= CH3) gave 0.337g (35%) of W-C-2 (R = C02H, 5- substituted, R"= CH3) as a white solid. 1H-NMR (DMSO-d6) S 10.73 (1), 8.58 (1), 7.52 (5), 7.18 (5), 5.94 (1), 4.63 (1), 3.15 (1), 2.86 (1), 2.48-1.70 (6); IR (mull) 3257,3068,3037, 1432,1414, 1327, and 1196cm-1; MS (FAB) m/z (rel. intensity) 567 (MH+,

99), 570 (27), 569 (71), 568 (57), 567 (99), 566 (26), 216 (26), 215 (89), 175 (22), 173 (30), 169 (20); HRMS (FAB) calcd. for C29H24C12N206+H1 567. 1085, found 567.1102; % Water (KF): 3.72.; Anal. Calcd for C29H24C12N206 1. 21H20: C, 59.11; H, 4.52; N, 4.75. Found: C, 58.89; H, 4.38; N, 4.70.

Example 132 Scheme X, W-T-2 wherein R = C02tBu, 5-substituted, R"= CH3 N- [ [ (5E)-7,8-Dihydro-5- [ [ (1,1- dimethylethoxy) carbonyl] methylene]-1 (6H)-naphthyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C34H34Cl2N206) To a mixture of W-T-1 (R = CO2tBu, R'= 5-C02H) (1.18g., 4.08mmol) in dry DMF (20mL) under N2 and cooled in an ice water bath was added EDC (0.86g, 4.49mmol), HOBT (0.61g, 4.51mmol), diisopropylethyl amine (3.8mL, 21.82mmol), and 4- dimethylaminopyridine (0.05g., 0.41mmol). After thirty minutes, 4- [(2, 6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester hydrochloride (1.8g., 4.46mmol) and more dry DMF (5mL) were added. After overnight stirring, the mixture was evaporated to dryness in vacuo, giving an oil which was dissolved in CHC13 (150mL) and washed with water (50mL), aq.

HC1 (1N, 2X50mL), water (5X50mL, to pH7) and evaporated to dryness, giving W-T-2 (R = C02tBu, 5-substituted, R"= CH3) as a pale yellow powder (2.68g., 93%). An analytical sample was <BR> <BR> <BR> <BR> recrystallized from toluene/chloroform. 1H-NMR (CDCl3) 6 = 7.59 (4), 7.27 (7), 6.20 (2), 5.08 (1), 3.80 (3), 3.31 (1), 3.13 (3),

2.73 (2), 1.74 (2), 1.51 (9); IR (mull) 1751,1700,1675,1640, 1612,1555,1534,1515,1433,1336,1278,1225,1201,1153, and 1147cl 1; MS (FAB) m/z (rel. intensity) 637 (MH+, 38), 639 <BR> <BR> <BR> <BR> (28), 637 (38), 581 (25), 565 (24), 563 (35), 271 (24), 215 (99), 197 (29), 173 (35), 57 (30); Anal. Calcd. for C34H34C12N206: C, 64.05; H, 5.38; N, 4.39. Found: C, 63.76; H, 5.41; N, 4.45.

Example 133 Scheme X, W-T-2 wherein R = CO2H, 5-substituted, R"= CH3 N-[[(5E)-5-Carboxymethylene-7,8-dihydro-1(6H)- naphthyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L- phenylalanine methyl ester (C3oH26Cl2N206) To a solution of W-T-2 (R = C02tBu, 5-substituted, R"= CH3) (1.4g, 2.2mmol) in methylene chloride (20mL) under N2 was added trifluoroacetic acid (lmL, 13mmol). After overnight stirring, an additional portion of trifluoroacetic acid was added (lmL, 13mmol). After stirring for two more days, the mixture was mixed with toluene (30mL) and evaporated to dryness in vacuo to give a yellow solid. This solid was mixed with chloroform (25mL) and acetone (2mL), heated (40°C), allowed to cool to room temperature overnight and then filtered through a sintered glass funnel. The filter cake was washed with chloroform (3X3mL) and air dried to give W-T-2 (R = CO2H, 5-substituted, R"= CH3) (1.08g, 84%) as a pale yellow <BR> solid. 1H-NMR (DMSO-d6): 12.10 (1), 10.69 (1), 8.73 (1), 7.74 (1), 7.57 (5), 7.18 (4), 6.26 (1), 4.71 (1), 3.69 (3), 2.97 (4),

2.36 (2), 1.59 (2); IR (mull) 1753,1677,1644,1636,1602, 1544,1515,1443,1433,1277,1239,1220,1210,1199, and 1189cm-1; HRMS (FAB) calcd for C3oH26Cl2N206+H1 581.1246, found 581.1268.

Example 134 Scheme X, W-T-2 wherein R = CO2H, 5-substituted, R"= H N- [ [ (5E)-5-Carboxymethylene-7, 8-dihydro-1 (6H)- naphthyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L- phenylalanine (C29H24C12N206) A solution of LiOH H20 (0.3g, 7.15mmol) in H20 (5mL) was added to a solution of W-T-2 (R = CO2H, 5-substituted, R"= CH3) (0.8g, 1.3mmol) in methanol (lOmL). After overnight stirring, the mixture was evaporated to dryness in vacuo, giving a pale yellow solid which was dissolved in water (20mL) and cooled in an ice/water bath. The pH was adjusted to ca. 3 using 1N aq.

HC1. After an hour in the ice bath, the mixture was filtered through a sintered glass funnel to give a pale yellow solid which was washed with water (3X10mL) and air dried affording W-T-2 (R = C02H, 5-substituted, R"= H) (0.79g, 96%). 1H-NMR (DMSO-d6) = 12.40 (1), 10.67 (1), 8.57 (1), 7.73 (1), 7.56 (5), 7.21 (4), 6.26 (1), 4.63 (1), 2.96 (4), 2.30 (2), 1.57 (2); IR (mull) 3258,3193,3123,3066,1660,1608,1584,1562,1539, 1516,1432,1414,1327,1273, and 1195cm-1; MS (FAB) m/z (rel. intensity) 567 (MH+, 96), 570 (20), 569 (65), 568 (36), 567 (96), 551 (17), 549 (31), 215 (99), 197 (21), 175 (25), 173 (46) ; HRMS (FAB) calcd for C29H24C12N206+H1 567. 1089, found

567.1082; % Water (KF): 6.64; Anal. Calcd for C29H24Cl2N2062.24H20: C, 57.31; H, 4.72; N, 4.61. Found: C, 57.31; H, 4.43; N, 4.64.

Preparation W-T-2 Scheme X, W-T-2 wherein R = CO2tBu, 6-substituted, R"= CH3 N- [ [ (5E)-7,8-Dihydro-5- [ [ (1,1- dimethylethoxy) carbonyl] methylene]-2 (6H)-naphthyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester (C34H34C12N206) To a heterogeneous mixture of the salt W-T-1 (6-CO2Na) (0.65g., 2.1mmol) in dry DMF (20mL) under N2 and cooled in an ice water bath were added EDC (0.45g., 2.3mmol), HOBT (0. 31g., 2.3mmol), diisopropylethyl amine (2mL, 11.5mmol), and 4- dimethylaminopyridine (0.03g., 0.3mmol). After thirty minutes, 4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (l. Og., 2.48mmol) and more dry DMF (5mL) were added. After stirring for 60 hours, the mixture was evaporated to dryness in vacuo, giving an oil which was dissolved in CHC13 (150mL) and washed with water (50mL), aq.

HC1 (1N, 2X50mL), water (5X50mL, to pH7), and evaporated to dryness, giving W-T-2 (R = C02tBu, 6-substituted, R"= CH3) as <BR> <BR> <BR> <BR> a pale yellow powder (1.2g, 89%). 1H-NMR (CDCl3): 6 7.67 (1), 7.56 (4), 7.31 (4), 7.13 (2), 6.62 (1), 6.29 (1), 5.07 (1), 3.79 (3), 3.25 (2), 3.14 (2), 2.81 (2), 1.84 (2), 1.51 (9); MS

(ESI-) for C34H33Cl2N206 m/z 634.9 (M-H); IR (mull) 1748,1705, 1664,1641,1608,1561,1546,1536,1513,1441,1429,1329, 1203,1148, and 1141cm-1; Anal. Calcd for C34H34Cl2N206: C, 64.05; H, 5.38; N, 4.39. Found: C, 63.67; H, 5.39; N, 4.38.

Preparation W-T-2 Scheme X, W-T-2 wherein R = CO2tBu, 6-substituted, R"= Na N- [ [ (5E)-7,8-Dihydro-5- [ [ (1,1- dimethylethoxy) carbonyl] methylene]-2 (6H)-naphthyl] carbonyl]-4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine sodium salt (C33H3lCl2N206Na) Sodium thiophenoxide was added to a stirred solution of W-T-2 (R = C02tBu, 6-substituted, R"= CH3) (0.418g, 0.66mmol) in dry THF (20mL) under N2. After overnight stirring, the mixture was evaporated to dryness in vacuo to give a pale yellow solid which was stirred with water (50 mL) for 10 minutes and then filtered. The filtrate was transferred to a reversed phase (C-18) chromatography column and eluted with water (1L) followed by 20% acetonitrile/water. Evaporation of solvent in vacuo gave W-T-2 (R = C02tBu, 6-substituted, R"= Na) as a <BR> <BR> white solid (0.184g, 43%).'H-NMR (DMSO-d6) : 5 10-59 (1), 7.76 (2), 7.48 (7), 7.06 (2), 6.29 (1), 4.09 (1), 3.15 (1), 3.03 (3), 2.78 (2), 1.73 (2), 1.45 (9); IR (mull) 3392,3297, 1704,1664,1605,1562,1535,1517,1485,1431,1411,1402, 1393,1321, and 1145cm-1; MS (FAB) m/z (rel. intensity) 622

(MH+, 0), 669 (13), 667 (18), 647 (13), 645 (18), 331 (9), 215 (17), 179 (9), 177 (89), 57 (11), 23 (99); HRMS (FAB) calcd for C33H3lCl2N206Na+Hl 622.1637, found 645.1550.

Example 135 Scheme X, W-T-2 wherein R = C02Na, 6-substituted, R"= Na N-[[(5E)-5-Carboxymethylene-7,8-dihydro-2(6H)- naphthyl] carbonyl]-4- [(2,[(2, 6-dichlorobenzoyl) amino]-L- phenylalanine sodium salt (C29H22Cl2N206Na2) A solution of trifluoroacetic acid (4 mL) and W-T-2 (R = <BR> <BR> <BR> <BR> CO2tBu, 6-substituted, R"= Na) (0.21g,. 32mmol) was stirred overnight under N2. The reaction mixture was then mixed with toluene (50mL) and evaporated to dryness in vacuo, giving an off-white solid. This solid was then dissolved in methanol (lOmL) and stirred with saturated aqueous NaHC03 (lOmL). The mixture was then evaporated to dryness in vacuo, dissolved in water, filtered and the filtrate transferred to a reversed phase C-18 chromatography column. Elution with 0 to 10% acetonitrile/H20 gave W-T-2 (R = CO2Na, 6-substituted, R"= Na) as a white solid after evaporation of solvent in vacuo (0.14g, 70%).

1H-NMR (DMSO-d6): 7.69 (1), 7.48 (7), 6.49 (1), 4.70 (1), 3.37 (1), 3.16 (2), 2.98 (2), 2.84 (2), 1.85 (2); IR (mull) 3388, 1485,1432,1412, 1349,1328,1195, and 1114cm-l; HRMS (FAB) calcd for C29H22Cl2N2O6Na2+H1 611.0729, found 611.0755; % Water (KF): 6.40; Anal. Calcd for C33H31Cl2N206Na'2.45H20: C, 57.47; H, 5.25; N, 4.06. Found: C, 57.31; H, 5.18; N, 3.97.

Scheme X

Preparation X-1 Scheme Y, X-1 wherein R = H, R'= CH3 (Z)-5-Carbomethoxy-3,4-dihydro-1 (2H)-naphthalenylideneacetic acid X-1 (Cl4Hl4O4)

To a solution of the diester X-1 (R = tBu, R'= CH3), prepared as described in Scheme X (Preparation X-C-1 and X-T-1, R = CO2tBu, R'= 5-C02CH3) (0.77g., 2.55mmol) in methylene chloride (40mL) was added trifluoroacetic acid (2mL, 26mmol). After stirring for 16 hours an additional portion of trifluoroacetic acid (0.5mL, 6.5mmol) was added. After stirring for an additional 24 hours, the reaction mixture was diluted with toluene (50mL) and evaporated to dryness in vacuo; giving a pale yellow solid. The solid thus obtained was dissolved in ethyl acetate (150mL) and washed with water (lXlOOmL) followed by saturated aqueous sodium bicarbonate (lX30mL). The bicarbonate wash was brought to pH3 using 1N aq. HC1. The resultant heterogeneous mixture was then placed in the freezer for thirty minutes followed by filtration through a sintered glass funnel. The filtered solid was washed with water (3X30mL) and air dried to give X-1 (R = H, R'= CH3) as a white solid (0.308g., 49% yield). 1H-NMR (DMSO-d6): 6 = 12.21 (1), 7.72 (1), 7.61 (1), 7.23 (1), 5.84 (1), 3.81 (3), 3.02 (2), 2.42 (2), 1.84 (2).

Preparation X-2 Scheme Y, X-2 wherein R'= CH3, R"= CH3 N- [ (IZ)-5-Carbomethoxy-3, 4-dihydro-1 (2H)- naphthalenylideneacetyl]-4- [ (2,6-dichlorobenzoyl) amino]-L- phenylalanine methyl ester (C3lH28Cl2N206)

A mixture of the acid X-1 (Scheme Y, X-l, R = CO2H, R'= <BR> <BR> <BR> <BR> <BR> C02CH3) (0.3g., 1.22mmol) and methylene chloride (20mL) was stirred in a lOOmL round bottom flask immersed in an ice water bath. To this mixture were added EDC (0.26g., 1.36mmol), HOBT (0.19g., 1.41mmol), 4-dimethylaminopyridine (O. 05g., 0.41mmol), and diisopropylethyl amine (2mL, 11.48mmol). After thirty minutes, 4- [ (2,6-dichlorobenzoyl) amino]-L-phenylalanine methyl ester. hydrochloride (0.56g., 1.39mmol) was added. and the cold bath was removed. The mixture was allowed to stir for 36 hours then an additional portion of EDC (0.28g., 1.46mmol) and diisopropylethyl amine (lmL, 0.57mmol) were added. The mixture was stirred at room temperature for an additional 120 hours and the reaction mixture was then diluted with methylene chloride (40mL), shaken with water (2X20mL), 1N aq. HC1 (lX20mL), and water (4X20mL, to pH7). The organic layer was then evaporated to dryness in vacuo, giving X-2 (R' = CH3, R"= CH3) as a pale yellow solid (0.639g, 85%). This was ascertained (1H-NMR) to be a 1: 7.5 mixture of the respective E-and (desired) Z- isomers. 1H-NMR (DMSO-d6) # = 10.68 (1), 8.50 (1) 7.35 (9), 6.47 (0.12), 5.85 (0.88), 4.56 (1), 3.80 (3), 3.63 (3), 2.93 (6), 2.27 (0.88), 1.86 (0.88), 1.66 (0.24); IR (mull) 1513, 1433,1413,1330,1280,1246,1213, and 1197cm-1; MS (FAB) m/z (rel. intensity) 595 (MH+, 47), 598 (13), 597 (34), 596 (21), 595 (47), 349 (14), 230 (15), 229 (99), 175 (13), 173 (19),

123 (45); HRMS (FAB) calcd for C3lH28Cl2N206+Hl 595.1403, found 595.1401.

Example 136 Scheme Y, X-2 wherein R'= CH3, R"= H N- [ (IZ)-5-Carbomethoxy-3. 4-dihydro-1 (2H)- naphthalenylideneacetyl]-4- [(2,[(2, 6-dichlorobenzoyl) amino]-L- phenylalanine (C3oH26Cl2N206) A solution of X-2 (R'= CH3, R"= CH3) (0.275g, 0.46mmol) was stirred with methanol (50mL) in a flask immersed in an ice- water bath. To this cooled solution was added a solution of LiOH'H20 (O. lg, 2.4mmol) in H20 (20mL). After stirring for 16 hours, the mixture was brought to pH7 using 1N aq. HC1 and then evaporated to dryness in vacuo. The resultant solid was then dissolved in water, filtered and the filtrate transferred to a C-18 reversed phase chromatography column and eluted with a gradient from 0 to 28% acetonitrile/0.02% aq.. NaHCO3 Two UV (250nm) absorbing bands were collected and isolated by evaporation of solvent in vacuo until all of the acetonitrile was gone, followed by acidification to pH3 using 1N aq. HC1.

The resultant white precipitates were isolated by suction filtration through a sintered glass funnel. The solids were washed with H20 (3X5mL) and air dried. UV band 1 afforded X-2 (R'= CH3, R"= H, 0.16g, 60% yield) as a powdery white solid.

1H NMR (DMSO-d6) b = 12.7 (1), 10.68 (1), 8.36 (1), 7.52 (6), 7.33 (1) 7.21 (2), 7.00 (1), 5.86 (1), 4.48 (1), 3.79 (3), 2.88 (4), 2.35(2), 1.82 (2); IR (mull) 3271,1739, 1724, 1715,1696, 1680,1667,1650,1644,1612,1609,1517,1430,1255, and 1193cm-1 ; HRMS (FAB) calcd for C3oH26Cl2N206+Hl 581.1246, found 581. 1229.

Example 137 Scheme Y, X-2 wherein R'= CH3, R"= H N- [ (1Z)-5-Carboxy-3, 4-dihydro-1 (2H)-naphthalenylideneacetyl]-<BR> 4-[(2,6-dichlorobenzoyl) amino]-L-phenylalanine (C29H24Cl2N206) A solution of X-2 (R' = CH3, R" = H, 0.208g, 0.35mmol) in methanol (50mL) was stirred in a flask immersed in an ice-water bath. To this cooled solution was added a solution of LiOH'H20 (O. lg, 5.4mmol) in Hz0 (20mL). After 18 days, the pale yellow solution was diluted with water (20mL), evaporated to a volume of 30mL, acidified to pH5 using 1N aq. HC1, and filtered. The colorless filtrate was brought to pH3 using 1N aq. HC1, and the resulting precipitate was isolated by suction filtration and, after air drying, gave X-2 (R'= H, R"= H) as a white powdery solid (0.092g., 46% yield)'H-NMR (DMSO-d6): 8 12.7 (1), 8.35 (1), 7. 54 (6), 7.25 (3), 6.97 (1), 5.84 (1), 4.50 (1), 2. 91(4), 2.34 (2), 1.82 (2); IR (mull) 3263,3194,3121,3066,2941,1727,1714,1693, 1666,1647,1605,1518,1431,1412, and 1264cm-1; HRMS (FAB) calcd for C29H24CL2N206+H1 567.1089, found 567.1091. % Water (KF): 4.83;

Anal. Calcd for C29H24Cl2N206'1.6H20: C, 58.42; H, 4.70.

Found: C, 58.57; H, 4.72; N, 4.87.

Biological Assays Jurkat-Endothelial Cell Adhesion Assay: The following assay established the activity of the present compounds in inhibiting Pi-mediated cell adhesion in a representative in vitro system. This assay measures the adhesive interactions of a T-cell line, Jurkat, known to express the °64ßl integrin, to endothelial monolayers in the presence of test compounds. The test compounds were added in increasing concentrations to T-cells and then the T-cell compound mixture was added to IL-1 stimulated endothelial cell monolayers. The plates were incubated, washed and the percentage of attached cells was quantitated. The present assay directly demonstrates the cell adhesion inhibitory activity and adhesion modulatory activity of the compounds.

Human umbilical vein endothelial cells were purchased from Clonetics (San Diego, CA.) at passage number 2. The cells were grown on 0.5% porcine skin gelatin pre-coated flasks (Sigma, St. Louis MO.) in EGM-UV media (Clonetics, San Diego, CA) supplemented with 10% fetal bovine serum. Cells are refed every 2-3 days reaching confluence by day 4 to 6.

The cells are monitored for factor VIII antigen and results show that at passage 12, the cells are positive for this antigen. The endothelial cells are not used following passage 6.

The T-cell line Jurkat was obtained from American Type Tissue Culture Collection (Rockville, MD) and the cells were cultured in RPMI containing 10 % fetal calf serum. The cells were washed twice in Hank's Balanced Salt Solution (HBSS) and resuspended in Dulbecco's Minimal Eagle's Media (DMEM) containing 2.5 mg/ml Human Serum Albumin (HSA). Jurkat cells (1x106 cells/ml) were stained with 10 ng/ml BCECF-AM (Molecular Probes, Eugene, OR)) in HBSS without phenol red.

The cells were loaded with BCECF for 60 minutes in the dark at 37°C, washed 2 times, and resuspended in DMEM-HSA solution.

Confluent endothelial monolayers, grown in 96-well tissue culture plates, were stimulated for 4 hr. at 37 °C with 0.1 ng/ml (-50 U/ml) recombinant IL-1 (Amgen, Thousand Oaks, CA).

Following this incubation, the monolayers were washed twice with HBSS and 0.1 ml of DMEM-HSA solution was added. Jurkat cells (5 x 105 cells) were combined with the appropriate concentration of the test compound and 0.1 ml of the Jurkat cell-compound mixture was added to the endothelial cell monolayers. Generally, 100,20,5 and 1.25 pM compound concentrations were tested. These concentrations are adjusted downward for analogs found or thought to be more potent. The plates were placed on ice for 5 minutes to allow for Jurkat cell settling and the plates were incubated at 37 °C for 20 minutes. Following this incubation, the monolayers were washed twice with PBS containing 1 mM calcium chloride and 1 mM magnesium chloride and the plates were read using a Millipore Cytofluor 2300 (Marlboro, MA.). Fluorescence in each well was measured as Arbitrary Fluorescence Units and percent adhesion in the absence of compound was adjusted to 100% and the % adhesion in the presence of compound was calculated. Monolayers were also fixed in 3% paraformaldehyde and evaluated microscopically to verify the adhesion. This procedure is a modification of a previously published method (Cardarelli et al., J. Biol. Chem. 269: 18668-18673 (1994)).

Jurkat-CS-1 assay The CS-1 derived peptide, CLHPGEILDVPST, and the scrambled control peptide, CLHGPIELVSDPT, were synthesized on a Beckman 990 synthesizer using t-Boc methodology. The peptides were immobilized onto microtiter plates using the heterobifunctional crosslinker 3- (2-pyridyldithio) propionic acid N-hydroxysuccinimide ester (SPDP) as reported by Pierschbacher et al., Proc. Natl. Acad. USA, 80: 1224-1227 (1983). Microtiter plates were coated with 20 g/ml HSA for 2

hr. at room temperature, washed once with PBS and derivatized with 10 pg/ml SPDP for 1 hr. After washing, 100 gl of a 100 pg/ml cysteine containing peptide solution which had been recently dissolved was added to the wells and allowed to crosslink to the plates overnight at 4 °C. Unbound peptide was removed from plates by washing with PBS. To block non- reacted sites, the plates are coated with 100 1 of a 2.5 mg/ml BSA solution in PBS for 1 hr. at 37 °C. 100 ul of Jurkat cells (2.5 x 106 cells/ml) in DMEM plus BSA (2.5 mg/ml) was mixed with an appropriate concentration of the compound to be tested and the mixture was added to peptide coated dishes and incubated for 1 hr. at 37 °C. Generally 100,20,5 and 1.25 hum concentrations of the compound were tested. The concentrations of the compound were adjusted downward for compounds thought or found to be more potent.

Following this incubation the plates were washed once with PBS and the attached cells were fixed with 3% paraformaldehyde in PBS and stained with 0.5% toluidine blue in 3.7% formaldehyde. The cells were stained overnight at room temperature and the optical density at 590 nm of toluidine blue stained cells was determined using a vertical pathway spectrophotometer to quantitate attachment (VMAX Kinetic Microplate Reader, Molecular Devices, Menlo Park, CA).

This procedure is a modification of a previously published method (Cardarelli et al, J. Biol. Chem., 269: 18668-18673 (1994) and Cardarelli et al, Proc. Natl. Acad. Sci. USA, 83: 2647-2651 (1986)).

The preferred compounds are those which have low ICso values in the Jurkat EC assay or the Jurkat-CS-1 assay described above or which have at least moderate activity in both assays. All of the compounds of the present invention have an activity of less than 50uM in the Jurkat CS-1 assay or less than 500uM in the Jurkat EC assay. Compounds with activity in the Jurkat CS-1 assay preferably have ICso values of less than luM, more preferably less than 0.5uM, most preferably less than or equal to 0.08uM. Compounds with

activity in the Jurkat EC assay preferably have ICSO values of less than lOuM, more preferably less than 5uM, most preferably less than or equal to 0. 8µM.

In the Jurkat EC Assay, ICSO value ranges (uM) are depicted by A, B, and C and in the Jurkat CS-1 Assay, IC50 value ranges are depicted by D, E, and F. These ranges are as follows: Jurkat EC: 5 A < 10,0.8 < B < 5, and C S 0.8 Jurkat CS-1: 0.5 D < 1,0.08 < E < 0.5, and F < 0.08 The following chart illustrates the ICso values for selected compounds of the present invention in the Jurkat EC Assay and the Jurkat CS-1 Assay. The ranges are as described above.

IN VITRO BIOLOGICAL DATA Example Jurkat EC Jurkat CS-1 No. -4B 8 B- 9 B D -11A 12-D 14 B- -15B 16 B- -18B 19 B D 21 A- 22 B- 24 A- 25C D Example Jurkat CS-1Jurkat No. -28B E33- D34- -35- D36B D37A D38B D39- -41A D42- E44A E46B E47A E48B E49C D50A F51B F52B F53C D54- E55B E56B E57C E59B D60- E61C E62B E63C E64B Example Jurkat EC Jurkat CS-1 No. E65B E66C E67C E68C E69C E70B E71B E72C D73B E74B E75C E76B E77C E78C E79B E80B E81B E82C F83C E84C F85C F86C E87C D88A D89A -90A D91B -92B E93B Example Jurkat EC Jurkat CS-1 No. E94C D95- 96C F F97C E98C 99 B E 100 B E 101 B E E102C E103C 104 B D 105 B E 106 B E 107 B E 108B -109B 112 B E -113B E114C 115B E 116C E E117C F118C 119 F F120C -121B 123 A D 124 B D 125B F ExampleExampleJurkat EC Jurkat CS-1 No. 126B F 127 B E 128 B E 130 B D 131C F 134 C E 135 A D 137 A-

Rationale for Developing an a4fii Integrin Antagonist to Treat Inflammatory Diseases VLA-4, a member of the pi integrin family of adhesion molecules, is thought to play a critical role in several types of inflammatory disease processes by promoting leukocyte adhesion to vascular cell adhesion molecule (VCAM-1) and the CS-1 domain of fibronectin in extracellular tissue matrix (Elices MJ, Osborn L, Takada Y, Crouse C, Luhowskyj S, Hemler M, Lobb RR. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA- 4-fibronectin binding site. Cell ; 60: 577-584,1990, Humphries MJ, Akiyama SK, Komoriya A, Olden K, Yamada KM.

Identification of an alternatively-spliced site in human plasma fibronectin that mediates cell type-specific adhesion.

J Cell Biol; 103: 2637-2647,1986, Wayner EA, Garcia-Pardo A, Humphries MJ, McDonald JA, Carter WG. Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin. J Cell Biol; 109: 1321-1330,1989, Guan J-L, Hynes RO. Lymphoid cells recognize an alternatively-spliced segment of fibronectin via the integrin aß1. Celli 60: 53-61, 1990) Of the cell types expressing VLA-4, the major emphasis

has been on eosinophils, lymphocytes, and monocytes.

Validation of the role of VLA-4 has relied predominantly on the use of anti-VLA-4 antibodies which have been shown to suppress delayed-type hypersensitivity responses (Issekutz TB.

Dual inhibition of VLA-4 and LFA-1 maximally inhibits cutaneous delayed-type hypersensitivity-induced inflammation.

Am J Pathol; 143: 1286-1293,1993, Scheynius A, Camp RL, Pure E. Reduced contact sensitivity reactions in mice treated with monoclonal antibodies to leukocyte function-associated molecule-1 and intercellular adhesion molecule-1. J Immunol; 150: 655-663,1993, Ferguson TA, Kupper TS. Antigen- independent processes in antigen-specific immunity. J Immunol; 150: 1172-1182,1993, Chisholm PL, Williams CA, Lobb RR. Monoclonal antibodies to the integrin a-4 subunit inhibit the murine contact hypersensitivity response. Eur J Immunol ; 23: 682-688,1993, Elices MJ, Tamraz S, Tollefson V, Vollger LW. The integrin VLA-4 mediates leukocyte recruitment to skin inflammatory sites in vivo. Clin Exp Rheumatol ; 11 (Suppl 8) S77-80), 1993, experimental allergic encephalomyelitis (Yednock TA, Cannon C, Fritz LC, Sanchez-Madrid F, Steinman LM, Karin N. Prevention of experimental autoimmune encephalomyelitis by antibodies against jazz integrin. Nature ; 356: 63-66,1992, Canella B, Raine CS. The VCAM-1/VLA-4 pathway is involved in chronic lesion expression in multiple sclerosis (MS). J Neuropathol Exp Neurol ; 52: 311,1993), HIV-induced encephalitis (Sasseville VG, Newman W, Brodie SJ, Hesterberg P, Pauley D, Ringler DJ. Monocyte adhesion to endothelium in simian immunodeficiency virus-induced AIDS encephalitis is mediated by vascular cell adhesion molecule- 1/a4ß1 integrin reactions. Am J Pathol ; 144: 27-40,1994), pulmonary inflammation and airway hyperreactivity in asthma (Abraham WM, Sielczak MW, Ahmed A, Cortes A, Lauredo IT, Kim J. Pepinsky, B, et al. aq-integrins mediate antigen-induced

late bronchial responses and prolonged airway hyperresponsiveness in sheep. J Clin Invest; 93: 776-787, 1994, Pretolani M, Ruffie C, Roberto LapaeSilva J, Joseph D, Lobb RR, Vargaftig BB. Antibody to very late activation antigen 4 prevents antigen-induced bronchial hyperreactivity and cellular infiltration in the guinea-pig airways. J Exp Med; 180: 795-805,1994), experimental models of autoimmune- mediated diabetes (Yang X-D, Karin N, Tisch R, Steinman L, McDevitt HO. Inhibition of insulitis and prevention of diabetes in non-obese diabetic mice by blocking L-selectin and very late antigen 4 adhesion receptors. Proc Natl Acad Sci USA ; 90: 10494-10498,1993, Burkly LC, Jakubowski A, Hattori M. Protection against adoptive transfer of autoimmune diabetes medicated through very late antigen-4 integrin.

Diabetes; 43: 529-534,1994), and experimental colitis (Podolsky DK, Lobb R, King N, Benjamin CD, Pepinsky B, Sehgal P, et al. Attenuation of colitis in the cotton-top Tamarin by anti-a4 integrin monoclonal antibody. J Clin Invest; 92: 372- 380,1993). Since eosinophils represent a major component of the inflammatory cell influx in asthmatic lung tissue we developed a simple acute inflammatory model of VLA-4 integrin- dependent eosinophil infiltration which could be used to identify VLA-4 antagonists ; such compounds would be of potential value in the treatment of asthma as well as other diseases in which VLA-4 played a role.